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ABSTRACT 
 
 
Prion diseases show remarkable clinical and neuropathological heterogeneity. All reported cases 
with definite variant Creutzfeldt-Jakob disease (vCJD) were homozygous at PRNP codon 129. 
Heterozygosity at codon 219 has been shown to be protective against sporadic CJD (sCJD). Copy 
number variants (CNVs) are a novel source of genetic variability associated with susceptibility to 
neuropsychiatric disorders.  
Aims: Hypotheses tested: 
 The clinico-pathological phenotype of prion disease is modified by investigation 
findings, co-deposition of amyloid beta, tau proteins and/or candidate genetic 
variation. 
 The MRC Scale can be used for analysis of disease progression in CJD 
 Copy number variation alters the risk of prion disease in the UK and Papua New 
Guinea (PNG) 
Methods: Case reports illustrated genetic susceptibility and phenotypic heterogeneity. The MRC 
Scale was used to assess disease progression and study power in sCJD. Real-time PCR and gene 
sequencing were used to assess the role of candidate genes in clinico-pathological heterogeneity. 
GWAS were used to assess the role of CNVs as susceptibility loci to prion diseases. 
Results: Two patients with vCJD were heterozygous at codon 219. The MRC scale could be 
administered daily requiring only 90 patients to provide sufficient study power. Amyloid-β 
deposition was significantly influenced by APOE ε4 haplotype in definite sCJD. Prion protein and 
hyperphosphorylated tau deposition were influenced by MAPTH1c haplotype. CNV duplications at 
chromosome 10 and 14 were significantly enriched in cases when compared to controls. The 
finding was confirmed using real-time PCR but was not replicated in the German cohort. Analysis 
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using Penn CNV revealed a nominally significant association of CNV deletion at PARK2 gene. 
Conclusion: Heterozygosity at codon 219 is protective against sCJD but may confer susceptibility to 
vCJD. Patient stratification and assessments using MRC Scale allowed adequate study power to 
justify future therapeutic trials. MAPTH1c haplotype played a role in both prion and tau protein 
deposition. Chromosome 10 and 14 duplications and deletion at PARK2 gene may play a role in 
prion disease susceptibility.  
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I INTRODUCTION 
Prion disease is a relatively recently coined term for long-recognized transmissible disorders of humans 
and animals. The disease was initially observed in sheep and goats although it is now recognised in 
several other species. The diagnostic confirmation of a prion disease is typically based on the 
appearance of a pathological form of the prion protein in the body. Prion protein in a misfolded or 
“scrapie” form (termed PrPSc) is thought to comprise the major if not sole component of the infectious 
agent of prion diseases and induces a fatal, degenerative disease (Prusiner 1982). 
The first prion disease described was sheep scrapie. Scrapie is now recognized as one of several 
transmissible spongiform encephalopathies (TSEs), which include bovine spongiform encephalopathy 
(BSE or "mad cow disease") and chronic wasting disease of cervids (Hunter, 2007). Scrapie has been 
known since the 18th century (1732) and does not appear to be highly transmissible to humans, 
although occasional transmissions cannot be excluded (Jeffrey and Gonzalez, 2007). It is however 
demonstrably transmissible among similar animals. The affected animals compulsively scrape off their 
fleeces against rocks, trees or fences due to the itching sensation caused by the condition. Other clinical 
signs include excessive lip smacking, altered gait and convulsive collapse (Foster et al., 2001). It tends to 
persist in flocks and can also arise apparently spontaneously in flocks that have not previously suffered 
with the disease. The mechanism of transmission between animals and other aspects of the biology of 
disease are active areas of research. Recent studies suggest that prions may be spread through urine 
and persist in the environment for decades which could explain spread between flocks (Detwiler and 
Baylis, 2003). This and other phenomena are  in contrast to all other known infectious agents  such as  
bacteria, fungus or parasite which must contain nucleic acids, either DNA, RNA, or both. All known prion 
diseases affect the structure and function of the nervous system and are currently untreatable and 
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universally fatal. Epidemiological, molecular, cellular and clinico-pathological studies aim to provide 
better understanding and possible treatment and prevention of these disorders.  
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 1.1 Historical overview 
Prion diseases include kuru(Collinge et al. 2006), Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-
Scheinker (GSS) syndrome (Masters et al., 1981), fatal familial insomnia (Medori et al., 1992a;Medori et 
al., 1992b) in humans, and similar diseases in sheep, goats (WILSON et al., 1950) and mufflons (Wood et 
al., 1992), transmissible mink encephalopathy, chronic wasting disease of mule, deer and elk (Williams 
and Young, 1980;Williams and Young, 1982), bovine spongiform encephalopathy or mad cow disease 
(Bradley et al., 2006;Bradley and Liberski, 2004;Collee et al., 2006;Wells et al., 1987) and its analogues in 
several exotic species of antilopes (Cunningham et al., 1993;Fleetwood and Furley, 1990;Kirkwood et al., 
1992) and feline spongiform encephalopathy in domestic cats (Wyatt et al., 1991). The clinical features 
of scrapie, TSE in sheep and goats, have been known under different names for over 200 years. 
The first investigator who believed that scrapie was a disease caused by a ‘filterable agent’ was Besnoit 
in 1899 while the transmissible nature of scrapie was only proved in the late 1930s by the important 
experiments of Cuille and Chelle. In the follow up of these reports, Gordon (Gordon WS, 1946) 
inadvertently replicated the finding of Cuille and Chelle using a vaccine based on formalin-fixed sheep 
brains in a large group of animals which developed scrapie.  The transmission of scrapie from sheep to 
mice by Morris and Gajdusek (Morris and Gajdusek, 1963) and from goats to mice by Chandler (Chandler 
RL, 1963;Chandler, 1961) facilitated laboratory research and development of many new hypotheses on 
the aetiology and pathogenesis of the disease.  
 
The discovery of human TSEs is related to the investigation of the cause of a ‘strange encephalitis-like’ 
disease identified in 1955 in a territory of Papua New Guinea - kuru (Liberski, 2009). Gajdusek provided 
one of the first descriptions of the clinical presentation of kuru. Importantly, it was later observed that 
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the histopathology of kuru is reminiscent of scrapie. As a result, Gajdusek went on to show that kuru, 
and then Creutzfeldt-Jakob disease was transmissible, to chimpanzee (Gajdusek et al., 1966). Thereafter, 
the potential for protein-only infectious agents (Griffith, 1967) and the term “prion” and its key 
hypothesis was formulated by Stanley Prusiner (Prusiner, 1982) who co-purified prion protein (PrP) with 
infectivity. It was postulated that the scrapie agent is a proteinaceous particle, termed PrPSc. It appears 
as an abnormal fibrillar structure in scrapie, CJD and kuru-infected brains (Armstrong, 2010;Merz et al., 
1984;Merz et al., 1983) by negative stain electron microscopy. These fibrillar structures were named 
‘scrapie associated fibrils’ or ‘fillamentous virus’ and later labeled ‘prion rods’ and classified as a form of 
amyloid by Cho (Cho, 1980) and Prusiner (McKinley et al., 1983). The gene encoding PrP was cloned by 
Charles Weissmann’s group and the ablation of this gene led to complete resistance to scrapie (Bueler et 
al., 1993). A number of rare but lethal neurodegenerative diseases which affect humans share a role 
with abnormal prion protein in their pathogenesis. Possible similarities with the pathogenesis of more 
common neurodegenerative disorders and potential for outbreaks of prion diseases emphasize the 
importance of research in this field.  
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1.2 Prion protein, prion protein gene and prions: structure and function 
All known mammalian prion diseases involve PrP in their pathogenesis. The endogenous, properly 
folded, form is denoted PrPC (for Common or Cellular) while the disease-linked, misfolded form is 
denoted PrPSc (for Scrapie, after one of the diseases first linked to prions and neurodegeneration) 
(Prusiner 1982). The structure of the PrPC is shown in Figure 1. Proteins showing prion-type behavior are 
also found in some fungi, which have been useful in helping to understand mammalian prions. Fungal 
prions do not appear to cause disease in their hosts although this is controversial (Lindquist et al., 2001).  
 
Prions propagate by transmitting a misfolded protein state. When PrPSc enters a healthy organism, it 
induces normally folded protein (PrPC) to convert into the disease-associated multimeric isoform (PrPSc). 
It is hypothesised that the abnormally folded prion protein “seed” acts as a template to guide 
misfolding. The growing prion seed can fragment, these newly formed prions can then go on to convert 
more proteins and trigger a chain reaction that produces large amounts of the misfolded prion protein 
and prions (Prusiner, 1998).  
 
Propagation of prions depends on the presence of a pool of normally folded protein from which the 
prions can recruit. The altered PrPSc structures are stable and accumulate in infected tissue, causing, 
through mechanisms not well understood, tissue damage and cell death. This structural stability is linked 
to a resistance to denaturation by chemical and physical agents, making disposal and containment of 
these particles difficult.  
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Prions come in different strains, with characteristic incubation times and neuropathology, consistent in 
transmission within and even between species. It is hypothesized that strains are encoded in the 
structure of the infectious agent (Collinge and Clarke, 2007).  
Prion infections are associated with remarkably prolonged but highly consistent incubation periods in 
inbred laboratory animals followed by a rapid clinical phase. The relationship between prion 
propagation, generation of neurotoxic species and clinical onset has remained obscure. Sandberg et al 
(Sandberg et al., 2011), building on early work necessarily sparse in time points, showed that prion 
propagation in mouse brain proceeds via two distinct phases: a clinically silent exponential phase not 
determined by prion protein concentration which rapidly reaches a maximal prion titer, followed by a 
distinct switch to a plateau phase. The duration of the latter phase determines time to clinical onset in a 
manner inversely proportional to prion protein concentration. These findings are therefore consistent 
with an uncoupling of infectivity and toxicity. The authors suggest that prions themselves are not 
neurotoxic but catalyze the formation of such species from PrPC. Production of a neurotoxic species is 
triggered when prion propagation saturates, leading to a switch from autocatalytic production of 
infectivity (phase 1) to a toxic (phase 2) pathway. 
Protein misfolding and aggregation appear to be common to a larger group of neurodegenerative 
diseases. Characteristic pathological findings include brain vacuolization, astrogliosis and neuronal 
apoptosis associated with accumulation in the central nervous system of extracellular protein deposits 
that may have the properties of amyloid fibrils (Aguzzi, 2005;Aguzzi and Heikenwalder, 2006;Chesebro 
et al., 2005;Westermark, 2005). Although identical in their primary structure PrP aggregates are 
protease resistant (Leffers et al., 2005;McKinley et al., 1991;Sunde et al., 1998) and it appears that they 
are misfolded PrP species (PrPSc).  
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The human PrP gene is found on chromosome 20 and encodes a proto-protein containing 253 amino 
acids before being processed. The first 22 residues are cleaved after translation whereas the last 23 
amino acid residues are cleaved prior to addition of glycosylphosphatidylinositol anchor to serine at 
position 230.  
The human prion protein gene comprises two exons with the entire open reading frame contained 
within the larger second exon (Mead, 2006;Oesch et al., 1985). The two domains of PrP are distinct in 
terms of the corresponding genetic variation of PRNP. Figure 3 illustrates the structure of the prion 
protein gene. Codons 51-91 of the N-terminal domain encode a 5-mer repeat region consisting of a 
nonapeptide followed by four identical octapeptides. Alterations in the number of repeats are known 
polymorphisms and pathogenic mutations, but there are very few point mutations or common single 
nucleotide polymorphisms (SNPs) in this region. Point mutations causing IPD and a number of SNPs are 
found in the C-terminal domain. A common coding polymorphism at codon 129 of PRNP between 
methionine and valine (rs1799990, c.385A>G) has a critical role in susceptibility and modification of 
prion disease.  
There are three types of pathogenic PRNP mutations: point mutations leading to an amino-acid 
substitution or premature stop codon, and alteration of the octapeptide repeats (>1 deletion or >3 
insertions) (Figure 3). Over 60 different mutations have been described: some are typically associated 
with particular clinical categories of prion disease, while others are associated with a spectrum of clinical 
phenotypes, often with striking phenotypic variability. Despite the rarity of PRNP mutation, the 
protracted clinical course of some IPDs lead to a high population prevalence relative to sporadic and 
acquired prion diseases.  
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Prion protein is normally extracellular and attached to the cellular membrane by its GPI anchor.Prion 
proteins of mammals are highly conserved (although not exceptionally so compared with other human 
proteins) as indicated by human PrP sequence identity with sheep (94%), chimpanzee (99.2%) and cows 
(92.8%).  
There are a number of studies suggesting a probable function of prion protein (Figure 4). However, 
despite this a definite and consistent physiological role of PrP remains unknown (Hu et al., 2007;Steele 
et al., 2007b). Although the precise function of PrP is not yet known, it is possibly involved in the 
transport of ionic copper to cells from the surrounding environment (Brown et al., 1997). Studies have 
also proposed roles for PrP in cell signaling or in the formation of synapses (Kanaani et al., 2005), or in 
the maintenance of myelin (Bremer et al., 2010).  
Ablation of the prion protein gene (Prnp), which encodes PrP, was instrumental in an attempt to 
understand the structure and function of normal PrP. However, no obvious phenotype in PrP knock-out 
mice has been described. Studies of PrP function have often relied on intuition and serendipity. There 
are a multitude of phenotypes described in PrP deficient mice however, the critical question remains 
about the primary phenotypes associated with PrP deletion and its implication on the function of PrP.  
Many years of study of the role of PrPc in normal cell biology gives it an almost unique place within 
protein database (Figure 4). It seems that PrP has evolved (and survived) to perform a function that does 
not have a precedent amongst its GPI anchored cell-surface proteins, perhaps representing a new type 
of plasma membrane ecosystem (Westaway et al., 2011). In a context where we await a clarifying 
insight into the structure and function of PrPc, the discovery of GPI-anchored N-glycosylated Doppel 
(Dpl) and Shadoo (Sho) proteins are exciting because they have homology to the N- and C- halves of PrPc 
itself (Westaway et al., 2011) and collectively these proteins comprise a prion protein gene family. Dpl 
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and Sho may be simpler - and more "understandable" - entities that can be pursued in parallel to PrPc, 
and could contribute greatly to the understanding of the biology of mammalian prion proteins from 
fresh directions. Dpl has a profound role in successful gametogenesis that warrants close scrutiny and a 
case for deeper study can be made for Sho, a recently discovered CNS-expressed protein with many 
parallels to established aspects of PrP biochemistry.   
Transgenic mouse models have greatly contributed to our knowledge of prion pathophysiology. 
Shmerling et al (Shmerling et al., 1998) demonstrated that PrPc deficient mice are resistant to scrapie 
which is induced by mouse adapted sheep prions.  Interestingly, they demonstrated that PrP lacking 
residues 32-121 or 32-124 caused severe ataxia and neural death limited to the granular layer of the 
cerebellum as early as 1-3 months after birth. However, attempt to transfer disease of these mice did 
not succeed. Thus, PrP lacking residues 32-121 or 32-134 induced neural dysfunction (neurotoxicity) 
without infectivity.  
Early attempts to identify a function for PrP were hindered by the absence of phenotypic defects in PrP-
null mice and of conserved structural or sequence motifs (Aguzzi et al., 2008a).Despite these initial 
setbacks, subsequent studies have uncovered that PrP-null mice differ from their wild-type counterparts 
in many more subtle activities, including circadian cycles, neuroprotection, synaptic function, stem cell 
renewal and proliferation (Aguzzi et al., 2008b;Steele et al., 2007a;Wilson et al., 2009) and two recent 
studies have shown possible new roles for PrP. During zebra fish development, knockdown of either of 
the duplicated PrP genes induces loss of cell adhesion and altered localisation of E-cadherin and Fyn Tyr 
kinase, phenotypes that are suppressed by expression of murine PrP (Malaga-Trillo and Sempou, 2009). 
In adult mice, regulated proteolysis and expression of PrP on the neuronal cell surface is required for 
maintenance of myelination through a non-cell autonomous route (Bremer et al., 2010).Together, these 
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studies may suggest that PrP has a pleiotropic role in vivo, perhaps mediating its broad effects through 
an activity in cell signalling pathways (Westergard et al., 2007). 
While the absence of neurodegeneration in PrP null mice was initially considered to be incompatible 
with a loss-of-function model for prion diseases, subsequent studies have shown that expression of PrP 
fragments induces spontaneous neurodegeneration in PrP-null mice (Baumann et al., 2007;Shmerling et 
al., 1998). Based on these observations, PrP toxicity during TSE infection could be explained as a loss of 
some PrP functions but not others (Westergard et al., 2007). Consistent with this idea, PrP must be 
expressed on the surface of neurons to mediate TSE pathogenesis following infection (Brandner S et al., 
1996;Chesebro et al., 2005;Mallucci G et al., 2003) suggesting that normal localization of the protein is 
required to elicit neurotoxicity. 
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1.3 Prion toxicity and infectivity 
It is accepted that PrPSc is a refolded partially protease resistant and infectious form of the normal 
cellular isoform of PrPc encoded by the highly conserved single-copy gene PRNP (Prusiner, 1982).The 
mechanism by which PrPSc  induces brain dysfunction is not well defined. Importantly, neurotoxicity in 
prion disease cannot be explained by loss of normal functional activity of PrPc since mice lacking PrPc do 
not show signs of neurodegeneration and do not develop prion disease (Bueler et al., 1993;Mallucci G et 
al., 2002). Furthermore, in mouse models, transplant of neural tissue over-expressing PrPc into PrPc 
knock-out mice was easily infected with PrPSc but infectivity was localised within grafted tissue while 
surrounding PrPc deficient tissue was not affected. Thus, it appears that PrPc is required for PrPSc 
induced neurotoxicity (Brandner S et al., 1996). Similarly, post-natal knock down of PrP expression in a 
conditional knockout model caused no overt phenotype and allowed rescue of prion disease (Mallucci et 
al., 2003;Mallucci et al., 2002).  
 
Sandberg  et al (Sandberg et al., 2011) describe a long plateau in prion infectivity during the incubation 
time to prion disease, suggesting the uncoupling of neurotoxicity and infectivity in the mechanism of 
prion propagation. It appears therefore that PrPSc can propagate using PrPc as a substrate and then PrPSc 
may cause cell death using membrane bound PrPc although the exact mechanism of how this occurs is 
still unknown. Alternatively, there are mutliple biochemical pathways leading from PrPC with the 
generation of infection and toxicity being distinct. Recent data point to the activation of the unfolded 
protein response in the pathways associated with neurotoxicity in prion disease (Moreno et al., 2012).  
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1.4 Prion biology and disease pathogenesis  
Prion diseases are the prototypical and extensively characterized examples of protein conformation-
based phenotypic traits and can be defined by proteinaceous infectious particles (Griffith, 1967). These 
factors were originally identified as infectious entities associated with a group of transmissible 
neurodegenerative diseases in mammals— the causative agent of which is resistant to treatments that 
damage nucleic acids (Prusiner, 1998). The fact that prions could act as infectious agents despite the 
absence of a nucleic acid genome led to the formulation of the “protein-only” or prion hypothesis as a 
self-perpetuating conformer of a host prion protein (Prusiner et al., 1982). 
The infectious conformer of PrPSc was predicted to recruit and convert the normal conformer PrPc into 
the PrPSc form through contacts between specific regions of the protein, and refolding, thereby 
‘replicating’ the agent during infection. The appearance of similar conformers in mammals is typically 
associated with emergence of disease,  although subclinical infections have been described(Hill AF and 
Collinge J, 2003). Despite this clearly disadvantageous phenotype for PrP, mounting evidence suggests 
that prion-like conversions of other proteins may be a mechanism for regulating protein function and 
survival advantage (Si et al., 2003). Strong evidence supports a direct role of PrP in clinical disease. 
Depletion of PrP post-infection extends incubation times and reverses both neuropathology and 
behavioural defects induced by the infection (Mallucci G et al., 2007;White et al., 2008). 
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1.5 Prion protein strains and species barrier 
The prion hypothesis originally suggested that PrPSc catalyzed the conversion of the PrPc in the context 
of a heterodimer of the two isoforms (Griffith, 1967;Prusiner, 1982). However, subsequent studies have 
revealed that soluble PrPc binds to an oligomer of PrPSc, which stimulates remodelling upon 
incorporation into these complexes (Collinge and Clarke, 2007), see Figure 2, the “seeding” model. Such 
a mechanism will progressively increase the size of prion complexes and requires fragmentation to occur 
to generate more infectious entities. Prion proteins in both mammals and yeast can adopt a range of 
self-replicating conformers known as prion strains, which are thought to confer distinct clinico-
pathological phenotypes by assembling into aggregates with different physical properties (Collinge and 
Clarke, 2007;Legname et al., 2006;Tanaka et al., 2006). These differences are believed to be specific to 
different rates of conversion of the soluble protein and of fragmentation of prion complexes to generate 
new propagons, and thereby the efficiency of conformational self-replication, providing a molecular 
basis for the phenotypes (Angers et al., 2010;Bruce, 1993;Ghaemmaghami et al., 2009;Li et al., 
2010;Manuelidis et al., 1997). The existence of mixtures of prion strains in vivo raises the possibility that 
prion phenotypes may not simply reflect the physical properties of a single conformer but rather the 
collective and dynamic behaviour of the various forms present. 
 
Prion strains have been associated with highly variable clinical phenotypes including changes in 
incubation periods (Bessen and Marsh, 1992;Kimberlin and Walker, 1978) the efficacy of inoculation 
routes and transmission rates to other species. Similarly, prion disease pathology, duration and clinical 
symptoms in humans are altered by the coexistence of prion strains (Cali et al., 2009;Parchi et al., 2009). 
Thus, the interplay between prion strains directly affects prion phenotypes. These studies suggest that 
 
 
25 
 
 
prion strains compete for a limiting host component necessary for developing a prion infection and the 
competition between existing strains may similarly be affected by the efficiency with which each 
conformer is replicated in the tissue (Shikiya et al., 2010). 
The physical interaction between prion proteins is an essential event in conformational self-replication. 
Naturally occurring PrP polymorphisms in animals and man alter TSE characteristics and, in extreme 
cases, the susceptibility to prion disease (Morales et al., 2006). A well-characterized genetic modifier of 
prion diseases is Met/Val 129 polymorphism of the prion protein gene (Goldfarb et al., 1989;Owen et al., 
1990). Although both PrP129 homozygotes (Met/Met or Val/Val) and heterozygotes (Met/ Val) are 
susceptible to prion disease, the genotype at this position affects the pattern of PrPSc accumulation in 
the brain and the clinical symptoms, incubation period and duration of disease (Morales et al., 2006). 
Disease progression is typically more rapid in homozygotes than in heterozygotes, providing a potential 
explanation for the over-representation of homozygotes in some TSEs. Heterozygous interference 
appears to be a general phenomenon, as both animals and humans heterozygous for other PrP alleles 
show a similar overdominance (Dickinson et al., 1968;Foster and Dickinson, 1988;Goldmann et al., 
1994;Jeong et al., 2005;Westaway et al., 1987).  
In animal models of prion infectivity, the species barrier has been a well-recognised phenomenon 
(Collinge and Clarke, 2007), but increasing interest has arisen with the realization that variant CJD 
appeared in the human population following transfer of BSE from cattle (Bruce et al., 1997;Collinge and 
Clarke, 2007;Collinge et al., 1996). Studies now suggest that species barriers are the outcome of 
interactions between prion strains and sequence variants of PrP, which reflect the rate of 
conformational self-replication in the recipient (Laurent, 1998). Species barriers may manifest as a 
complete block of disease development (Kimberlin and Walker, 1978) or, alternatively, as a prolonged 
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incubation period or subclinical infection following first passage that is shortened on subsequent 
passage within the same species. In both cases, replication of the infectious species occurs during the 
asymptomatic phase (Hill AF et al., 2000;Race and Chesebro, 1998) but the toxic species apparently does 
not reach the threshold concentration required for clinical disease within the organism's natural lifespan 
(Dickinson et al., 1975). Thus, interspecies transmissibility may be operationally defined by the ability of 
the recipient protein to efficiently replicate the conformation imposed by the template. The concept of 
a conformational replication barrier to interspecies transmission also explains an early observation that 
such transitions are often accompanied by a change in prion strain (Kimberlin et al., 1989;Pattison and 
Jones, 1968).  
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1.6 Prions and the immune system 
Although prions do not induce an immune and inflammatory response typical for infection, both 
mechanisms of innate and acquired immunity play a role in prion pathogenesis and possible 
development of protection strategy. Complement has been shown to be activated early during prion 
pathogenesis by as yet undetermined mechanisms and may constitute the first active response to 
infection perhaps by binding to C1q and Factor H (Michell, 1996). This binding occurs specifically when 
prion protein is conformationally modified to represent the conversion to the disease-associated 
isoform (Blanquet-Grossard et al., 2005). The role of complement in prion pathogenesis has recently 
been subject to review (Mabbott, 2004). In brief, prion or TSE agents are opsonized by complement 
components including C1q and C3, most likely via the classical complement activation pathway, which 
may aid in their targeting of the agent to lymphoid follicles. Mice lacking in complement components 
C1qa, C2 or C3 revealed deficient peripheral prion pathogenesis (Klein et al., 2001;Mabbott et al., 2001). 
The production of complement components by mononuclear phagocytes (MNP) has been shown to alter 
their function (Hartung and Hadding, 1983).C1q enhances the receptor-mediated uptake of disease-
associated PrP by classical dendritic cells (Flores-Langarica et al., 2009). The role of complement during 
prion pathogenesis is further complicated by the observation that the interactions of the individual 
complement components with PrPSc appear to differ depending on the strain of the infectious agent 
(Hasebe et al., 2012). As with most innate immune functions within the CNS a clear 
neuroprotective/neurodegenerative dichotomy is described in the literature, indicating that 
complement activation may lead to both protective and degenerative effects dependent upon the 
context and the responsive and regulatory mechanisms involved. 
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A recent study (Michel et al., 2012) showed that mice overexpressing the cervid prion protein are 
susceptible to chronic wasting disease, but mice lacking complement acceptors C21/35 expression 
completely resist clinical disease upon peripheral infection. Mast cells have been implicated in prion 
pathogenesis due to their high expression levels of cellular prion protein (PrPC) and their ability to travel 
to the brain (Haddon et al., 2009). The role of mast cells in the brain is thought to be neuro-modulatory 
and their transport to the brain is linked to steroidal hormones and sexual activity or anxiety behaviors 
(Silver et al., 1996).The presence of mast cells in the brain and their ability to shed expressed PrP upon 
activation (Haddon et al., 2009) may have implications for prion pathogenesis within the CNS. 
Mononuclear phagocytes (MNP) may also play a role in prion pathogenesis. The expression of cellular 
prion protein in MNP has been associated with phagocytic ability and modulation of inflammatory 
responses (de Almeida et al., 2005;Nitta et al., 2009;Uraki et al., 2010). Evidence suggests that 
macrophages (generally identifiable by the markers integrin alpha M, Macrosialin or the F4/80 antigen) 
degrade the prion agent (Sassa et al., 2009). The degradative and prion clearance abilities of 
macrophages appear to be down-regulated when macrophage activation is stimulated by danger signal 
molecules (Gilch et al., 2007). Again the mechanism of degradation is unknown but represents a critical 
therapeutic target as it constitutes a natural regulatory mechanism to prion pathogenesis. Stimulating or 
enhancing this degradative ability may improve peripheral resistance to prion infection.  
An alternative hypothesis is to suggest that in prion infection with low or poor replicative ability (i.e., 
due to the factors mentioned above) the balance is switched in favor of degradation of agent, thereby 
preventing or dramatically slowing pathogenesis. This may occur both within any given cell and not 
exclusively to degradative or phagocytic cell types. In fact it is well known that there are limited in vitro 
cell infection models in the prion field due to the relevant inability to infect numerous cell types with a 
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variety of prion strains even within the same species (Neale et al., 2010) and due to the complexity of 
the host innate immune response. 
Castro-Seoane et al (Castro-Seoane et al., 2012;Klohn et al., 2013) studied the kinetics of prion 
accumulation in various splenic cell types at early phase of infection. Prions were detectable in B and T 
lymphocytes and macrophages but the highest infection titres were seen in plasmocytoid dendritic cells 
and natural killer cells. Furthermore, they showed a release of prions from infected cells via exosomes 
suggesting that intercellular dissemination may contribute to rapid prion colocalisation in the 
lymphoreticular system.  
More recently Klöhn et al (Klohn et al., 2013) reviewed the current paradigms for antigen-sharing 
pathways which may be relevant to better understand dissemination of rogue neurotoxic proteins. 
Recent evidence of a remarkably fast splenic prion accumulation after peripheral infection of mice, 
resulting in high prion titers in dendritic cells (DCs) and a release of prions from infected DCs via 
exosomes, suggest that intercellular dissemination may contribute to rapid prion colonization in the 
lymphoreticular system. Evidence from retroviral infections shows DCs and other antigen-presenting 
cells (APCs) share viral antigens by intercellular transfer to warrant immunity against viruses. Evolved to 
adapt the immune response to evading pathogens, these pathways may constitute a portal for 
unimpeded prion dissemination owing to the tolerance of the immune system against host-encoded 
prion protein. 
Antigen presenting cells have long been identified as critical to prion pathogenesis. While evidence 
exists for both cell-free and cell-mediated transport of prions to lymphoid tissues (Michel et al., 2012), 
removal of the cell-mediated trafficking severely hampers prion pathogenesis. Prion infection of ‘plt’ 
mice deficient in chemokines (CCL19/CCL21) revealed delayed pathogenesis following transcutaneous 
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infection attributable to impaired CCR7-mediated chemotaxis of DC (Levavasseur et al., 2007). Transient 
depletion of CD11c-expressing cells (a commonly used marker indicative of classical DC) revealed the 
ability to completely block or severely impair pathogenesis via oral and intraperitoneal routes (Cordier-
Dirikoc and Chabry, 2008;Raymond et al., 2007). 
Within the CNS the innate immune response is mediated by specialized MNP known as microglia. 
Following peripheral prion infection the microglia show signs of activation after neurons and astrocytes 
have responded. These findings suggest that microglia do not respond directly to presence of misfolded 
prion protein per se but may require priming by other CNS cell types. Once activated the microglial 
population expands and has been shown to upregulate various markers including Trem2, SiglecF, 
CD200R, and Fcγ receptors (Lunnon et al., 2011). 
Immunity-associated candidate genes have been identified by observational techniques e.g., following 
gene expression profiling and numerous genes have been screened for a role in prion pathogenesis via 
knockout transgenic mouse models (Tamguney et al., 2008). The majority of such studies have 
determined that knockout of an individual component does not prevent prion pathogenesis. From these 
candidates all have previously been implicated in prion pathogenesis, but interleukin-4 (Il-4), interleukin-
6 (Il-6) and interleukin-12 (Il-12) have been shown not to be required. Interleukin-10 (Il-10) knockout 
mice revealed major alterations to, but not prevention of, prion pathogenesis. 
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1.7 Genetics of prion disease 
Prion diseases are known to have powerful genetic determinants. The strongest genetic association of a 
common genotype with any disease has been observed in variant CJD (Mead et al., 2009a). All patients 
with neuropathologically proven variant CJD have been homozygous for methionine at polymorphic 
codon 129 of the prion protein gene (PRNP). Homozygous genotypes at codon 129 also strongly 
associate with sCJD (Palmer et al., 1991), iatrogenic CJD (Collinge et al., 1991), early age of onset of 
inherited prion disease (IPD) (Poulter et al., 1992) and kuru (Cervenakova et al., 1999). Although this is a 
powerful effect, about a third of the population exposed to BSE are homozygous for methionine at PRNP 
codon 129, whilst only around 220 individuals have developed vCJD to date, implicating the potential 
important role of other susceptibility loci. Another genotype, heterozygosity at codon 219, commonly 
found in several Asian populations, has been shown to be protective against sCJD (Lukic et al., 
2010;Shibuya et al., 1998).  
The prion protein gene is known to affect incubation times and disease susceptibility in humans, mice, 
and sheep (Carlson et al., 1986;Collinge et al., 1991;Hunter et al., 1994;Palmer et al., 1991;Westaway et 
al., 1994). In PRNP, a polymorphism occurs at codon 129 where either a methionine or valine may be 
encoded. Acquired and sporadic prion diseases occur mostly in homozygous individuals, and a 
protective effect of heterozygosity is also seen in some inherited cases (Baker et al., 1991;Collinge et al., 
1991;Palmer et al., 1991). Mouse quantitative trait loci (QTL) mapping studies using simple crosses have 
successfully identified many loci linked to prion disease incubation time (Lloyd et al., 2001;Lloyd et al., 
2002;Manolakou et al., 2001;Moreno et al., 2003;Stephenson et al., 2000). A new report has added to 
these data using recombinant inbred lines (Iyegbe et al., 2010). Haplotype analysis and genotyping 
representative SNPs identified Cpne8 as the most promising candidate. The role of Cpne8 in prion 
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disease has not been established but it may be implicated in PrP processing and targeting as Cpne8 is a 
member of the copine family that are Ca2+ dependent phospholipid binding proteins thought to be 
involved in membrane trafficking (Tomsig and Creutz, 2002). Furthermore, two polymorphisms in the 
murine PrP gene (Prnp) have been described where Prnpa (Leu-108, Thr-189) and Prnpb (Phe-108, Val-
189) are associated with short and long incubation times, respectively (Carlson et al., 1988;Carlson et al., 
1986;Moore et al., 1998;Westaway et al., 1987).  
Although the influence of PrP gene polymorphisms on susceptibility and incubation time is well 
established, other lines of evidence indicate that PrP amino acid differences are not the sole genetic 
influence (Hill AF et al., 1999;Owen et al., 1990;Will et al., 2000). Comparison of several inbred lines of 
laboratory mice with the same Prnp genotype reveals major differences in incubation times when 
infected by defined prion strain (varying from 100 to 500 days), suggesting that other factors including 
additional genetic loci may contribute to the observed variation (Carlson et al., 1988;Dickinson, 
1975;Kingsbury et al., 1983;Westaway et al., 1987). The identification of these loci in humans may allow 
identification of at risk individuals, allow more robust predictions of human epidemic parameters, and 
identify prion ligands and biochemical pathways that will allow a better understanding of prion 
pathogenesis and the development of rational therapeutics.  
The evidence that non-PRNP factors exist also comes from analogy with other complex traits, specific 
human observations and animal studies. Familial concurrence of sCJD has been reported in the absence 
of a causal mutation (Webb et al., 2008a). Age at onset and death is correlated between parents and 
offspring in three large UK inherited prion disease kindreds suggesting a significant heritable component 
to phenotypic variability aside from PRNP (Webb et al., 2008c). Although the human observations are 
consistent with non-PRNP factors, mouse models provide the strongest evidence: these are extremely 
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useful as they reliably recapitulate many features of the human disease as rodents are naturally 
susceptible to prion disease. It is reasonable to expect that susceptibility genes and pathways identified 
in mice will also be relevant to human prion disease.  
Lloyd et al (Lloyd et al., 2001) analysed 109 animals from an F2 intercross between 2 strains of mice 
CAST/Ei and NZW/OlaHSd, with significantly different incubation periods when challenged with scrapie 
prions. Genetic analysis showed a highly significant linkage between loci on chromosomes 2, 11 and 12 
and prion disease incubation time. In fact, multiple linked quantitative trait loci identified on these 
chromosomes explained 82% of the total variance of incubation time. Interestingly, in another study 
Lloyd et al (Lloyd et al., 2002) investigated animals from the F2 intercross between the same 2 mouse 
strains challenged with a strain of BSE passaged twice through one of the parental mouse strains. 
Genetic analysis again identified linkage with 2 highly significant regions on chromosomes 2 and 11 and 
incubation time independently of prion strains. Two additional genes have been suggested to have an 
effect on incubation time: interleukin-1 receptor (IL-1) (Marcos-Carcavilla et al., 2007) and superoxide 
dismutase-1 (SOD-1) (Akhtar et al., 2013). It had been shown that deletion of APP, IL-1 gene and 
overexpression of human SOD-1 significantly increase survival times in infected mice (Akhtar et al., 
2013). The study confirmed a highly significant association between incubation time of prion disease 
and SOD1 locus. Furthermore, the study showed that SOD1 deficiency significantly reduces incubation 
time in mice after being challenged with three different prion strains. Demonstration of mouse 
quantitative trait genes may be relevant for understanding genetics of human prion diseases as 
illustrated by the finding that HECTD2 haplotypes are a quantitative trait gene for prion disease 
incubation time in mice and are associated with susceptibility to acquired human prion diseases, vCJD 
and kuru (Lloyd et al., 2009).  
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As already discussed the PRNP locus is highly associated with prion diseases in humans and animals 
irrespective of clinical presentation of disease. Mammalian prion diseases are under strong genetic 
influence of PRNP locus and this association is driven by coding variation at codon 129 of PRNP 
(rs1799990). Genetic polymorphism encoding methionine or valine amino acid is a strong genetic factor 
or modifier of clinico-pathological phenotype (Collinge et al., 1991;Collinge, 2005;Collinge et al., 
1992;Palmer et al., 1991). As mouse study indicated the existence of several Prnp modifier genes (Lloyd 
et al., 2001;Lloyd et al., 2002;Stephenson et al., 2000) parallel studies of human genes analogous to 
mouse candidate genes have been done but they were underpowered because of the rarity of prion 
diseases. Recently Mead et al (Mead et al., 2011b) presented the first large genome wide association 
study (GWAS) that included 2000 samples from three populations of human prion diseases and relevant 
available control series. This study included samples from patients suffering from sCJD, vCJD, inherited 
prion disease, iatrogenic CJD and kuru collected in UK, Germany and Papua New Guinea. The analysis 
did not provide support for the roles of already proposed genes as potential risk factors such as RARB-
THRB locus upstream of STMN2 and in the HECTD2 and SPRN2 genes. It appears that other genetic 
factors may be weak in human prion disease although heritability has been suggested by sibling 
concurrence (Webb et al., 2008a), heritability of age of onset of inherited prion disease (Webb et al., 
2008c) and documented genetic modifiers of incubation time in mice (Lloyd et al., 2001). However, in 
comparison with other diseases, the sample size available for analysis remains modest and weak effects 
would not be detected. 
Sanchez-Juan et al (Sanchez-Juan et al., 2011) showed an association between a PRNP regulatory 
polymorhphism G310C and sCJD. After adjusting by PRNP M129V genotype, the analysis showed that 
being a C allele carrier at PRNP G310C was significantly associated with a 2.4 fold increased risk of 
developing sCJD. In addition, haplotypes carrying PRNP 310C coupled with PRNP 129M were significantly 
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overrepresented in patients compared to controls. Cases of sCJD carrying a PRNP 310C allele presented 
at a younger age (on average 8.9 years younger than those without this allele), which was of statistical 
significance. As expected, methionine and valine homozygosity at PRNP M129V increased significantly 
the risk of sCJD, alone and adjusted by PRNP G310C. The findings were in keeping with the hypothesis 
that genetic variations in the PRNP promoter may have a role in the pathogenesis of sCJD. 
Other explanations of the lack of associations in sCJD include the heterogeneity of this disease defined 
by a clinical syndrome. Several aetiologies are possible in this group including a proportion of zoonotic 
or iatrogenic diseases. Thus, PRNP genotypes were strongly associated with risk in all prion diseases and 
no other loci show a similarly strong or universal association in humans.  
A chromosomal gene encodes PrP, a member of the Prn gene family that also includes Prnd, encoding 
the Doppel protein (Moore et al., 1999), and Sprn, encoding Shadoo (Watts and Westaway, 2007), as 
previously discussed. In all known PrP genes from various species, the PrP open reading frame (ORF) is 
encoded within a single exon although the gene itself comprises two to three exons (Basler et al., 
1986;Gabriel et al., 1992;Hsiao et al., 1989;Westaway et al., 1987). The other exons contain 
untranslated sequences including the promoter and termination sites. The PrP promoter contains 
multiple copies of GC-rich repeats—a canonical binding site for the transcription factor Sp1(Saeki et al., 
1996), driving expression in many different tissues. The alignment of the translated sequences from 
more than 40 PrP genes shows substantial conservation between the mammalian sequences, suggesting 
the retention of some important function for PrP through evolution. 
Variant CJD (vCJD) due to transmission of prions from cattle to humans has gained public notoriety 
following the BSE epidemic. Whilst the incidence of vCJD has been in decline since 2001, and the 
international case load remains modest at around 220, there are several outstanding issues of relevance 
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to public health (NCJDSU, 2009). First, it is paradoxical that an estimate of the incubation time of vCJD 
(based on the duration between the BSE and vCJD epidemic peaks) is so remarkably short, at around 8 
years. Estimates of incubation times from acquired prion diseases that involve human-human 
transmission are around 12 years (for kuru, or iatrogenic CJD)(Alpers, 2008;Brown et al., 2000). Based on 
animal experiments one expects the incubation times involving transmission between species to be 
prolonged compared with intraspecies transmission. As human-human transmission incubation times 
can be over 50 years (Collinge et al., 2006), it would be incautious to conclude that vCJD is a completed 
epidemic. Secondly, there is a discrepancy between prevalence studies in the UK and the observed 
clinical cases suggesting, in congruence with animal studies, that subclinical infection may be more likely 
than clinical disease. The determinants of subclinical disease or clinical manifestation are not known. 
Thirdly, the propensity for and extent of human-human iatrogenic transmission remains poorly 
understood. Several thousand individuals in the UK have been notified that they have been exposed to 
blood or blood products derived from donors incubating vCJD. Much of the scientific basis for 
understanding these outstanding issues revolves around the susceptibility of individuals relative to their 
population. There are a number of other factors such as dose effect, PrP strain and environmental 
factors that are likely to influence the incubation time. Genetics is a tractable way to study this in order 
to inform the epidemiology and public health through estimation of risks to BSE prion-exposed 
populations. 
The purpose of research into the human genetics of prion disease is not only about addressing issues 
derived from the vCJD epidemic. Prion diseases involve the propagation of strains with distinct clinical, 
pathological and biochemical features (Collinge and Clarke, 2007). This feature is a manifestation of 
protein-based inheritance where the transmissible agent is the product of a single host gene. Aside from 
human transmissibility, other aspects of the fundamental biology may not be unique to prion diseases. 
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Several prions in yeast have now been well characterized (Wickner et al., 2007). The autocatalytic 
protein misfolding that is central to prion disease is shared with other neurodegenerative conditions 
such as Alzheimer’s and Parkinson’s diseases. The extent to which these more common disorders are 
“prion-like” and whether they also involve strains remains an important and unresolved issue. Here, the 
relevance is that the identification of non-PRNP genetic loci that control susceptibility to prion disease or 
determine strains, may allow insights into fundamental molecular pathways likely to be of wider 
relevance in neurodegeneration such as the human proteins involved in chaperoning or degrading 
misfolded protein entities; or alternatively the genes involved in determining a prion strain. 
In the European-led vCJD genome wide association study (Sanchez-Juan et al., 2012) two single 
nucleotide polymorphisms (SNPs) (rs4921542 and rs7565981) reached genome-wide significance after 
pooling discovery and replication populations. Rs4921542 (p = 1.6 × 10−8) is an intronic variant in the 
myotubulin related protein 7 gene (MTMR7), which is specifically expressed in the central nervous 
system and dephosphorylates phosphatidylinositol 3-phosphate and inositol 1,3-bisphosphate. 
Rs7565981 (p = 4.2 × 10−8) in an intergenic region upstream of the neuronal PAS (per-ARNT-sim) domain-
containing protein 2 gene (NPAS2), a regulatory gene belonging to a family of transcription factors. In 
the UK-German sCJD study, no non-PRNP loci achieved genome-wide significance. SNPs at the ZBTB38-
RASA2 locus were associated with CJD in the UK (rs295301, p = 3.13 × 10−8) but these SNPs showed no 
replication evidence of association in German sCJD or in kuru based tests. Overall, it is likely that the 
PRNP locus contains the only strong risk factors which act universally across human prion diseases. 
Whilst some genome wide significant loci have been proposed in vCJD, the low incidence of this 
condition means that there is no way at present to generate unequivocal genetic evidence at these loci. 
The collective data are consistent with the findings in other diseases, of strong effects being the 
exception but multiple risk loci of modest effects are likely to present although more difficult to confirm. 
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In prion diseases large collaborative GWAS are necessary to provide statistical power for these weak 
effects. 
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1.8 Link with genetics of other neurodegenerative diseases 
Neurodegeneration preferentially involves the cerebral cortex in Alzheimer’s disease (AD), the 
extrapyramidal system in Parkinson’s disease and the spinal cord in amyotrophic lateral sclerosis. 
Mendelian inheritance pattern has been established in inheritance of these diseases but with clinical 
presentations and pathology often indistinguishable from sporadic forms of the same disease suggesting 
the same pathophysiological mechanisms. Genome wide association studies have been used to identify 
susceptibility genes implying common single nucleotide polymorphisms. Although GWAS have 
successfully revealed numerous susceptibility genes for common disease, the odds ratio associated with 
these risk alleles are generally low and account for only a small proportion of estimated heritability 
(Hindorff et al., 2009;Manolio et al., 2009;Visscher, 2008). 
Genetic studies 
It is postulated that early onset AD is often caused by mutation in three different genes (Tsuji, 2010). 
These mutations include genes encoding amyloid-β protein precursor (APP), presenilin 1 (PSEN 1) and its 
homologue on chromosome 1 (PSEN 2). GWAS have been used to find late onset AD gene candidates 
related to disease risk, phenotype, biomarkers, imaging results and pathology. Apolipoprotein E (APOE) 
has been associated with late onset AD. The Ɛ4 allele (Arg 112/Arg 118) of the APOE gene increases AD 
risk fourfold in one copy and by greater than 10 fold two doses of allele. In contrast, Ɛ2 (Cys 112/Cys 
112) allele of APOE exert protective effect while early onset familial AD mutations are sufficient but not 
necessary to cause AD. It is believed that in AD, APOE plays a role in the clearance of amyloid-β from the 
brain.  The first genome wide significant finding was reported for GAB2, proposed to influence tau 
phosphorylation (Reiman et al., 2007) and to modulate A-β production by binding growth factor 
receptor bound protein 2 (GRB2) which binds amyloid precursor protein and presenilins (Nizzari et al., 
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2007). In addition to APOE, several other genes have been shown to have a genome wide significant 
association in AD. A study by Harold et al (Harold et al., 2009) involved over 16,000 individuals suffering 
with Alzheimer’s disease (AD), was the most powerful AD GWAS at the time. The established association 
with the apolipoprotein E (APOE) locus was replicated (most significant SNP, rs2075650, P = 1.8 x 10(-
157)) and further genome-wide significant association with SNPs at two loci were observed: at the CLU 
(also known as APOJ) gene (rs11136000, P = 1.4 x 10(-9)) and 5' to the PICALM gene (rs3851179, P = 1.9 
x 10(-8)). These associations were replicated in the second stage of the study which involved 2,023 cases 
and 2,340 controls. This finding produced compelling evidence for association with Alzheimer's disease 
in the combined dataset (rs11136000, P = 8.5 x 10(-10), odds ratio = 0.86; rs3851179, P = 1.3 x 10(-9), 
odds ratio = 0.86). 
A study by Holigworth et al (Hollingworth et al., 2011) showed new susceptibility loci for Alzheimer's 
disease through a staged association study (GERAD+) and by testing suggestive loci reported by the 
Alzheimer's Disease Genetic Consortium (ADGC) in a companion paper. A combined analysis of four 
genome-wide association datasets (stage 1) was undertaken and ten newly associated variants were 
identified with P ≤ 1 × 10(-5). These variants were then tested again for association in an independent 
sample (stage 2). The finding of three SNPs at two loci was replicated and showed evidence for 
association in a further sample set (stage 3). Meta-analyses of all data provided compelling evidence 
that ABCA7 (rs3764650, meta P = 4.5 × 10(-17); including ADGC data, meta P = 5.0 × 10(-21)) and the 
MS4A gene cluster (rs610932, meta P = 1.8 × 10(-14); including ADGC data, meta P = 1.2 × 10(-16)) are 
new AD susceptibility loci. The study also provided independent evidence for association for three loci 
reported by the ADGC, which, when combined, showed genome-wide significance: CD2AP (GERAD+, P = 
8.0 × 10(-4); including ADGC data, meta P = 8.6 × 10(-9)), CD33 (GERAD+, P = 2.2 × 10(-4); including 
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ADGC data, meta P = 1.6 × 10(-9)) and EPHA1 (GERAD+, P = 3.4 × 10(-4); including ADGC data, meta P = 
6.0 × 10(-10)). 
Amyloid-β is a proteolytic fragment generated through sequential cleavage of the amyloid precursor 
protein (APP) by β-secretase (BACE1) and γ-secretase. Cells produce Aβ peptides of variable length. A 
peptide of 40 amino acids (Aβ40) is the most prevalent species secreted by cells, whereas the longer 
Aβ42 isoform appears to be the key pathogenic species and the most abundant species deposited in the 
brain. Major support for the amyloid hypothesis is drawn from cases of early onset familial Alzheimer’s 
disease (FAD). The term FAD is confined to familial cases with an autosomal dominant inheritance 
pattern. Overall, the clinical presentation of FAD patients with APP and PSEN mutations is very similar to 
that of sporadic AD, which is supported by neuroimaging, biomarker and post-mortem neuropathology 
studies.  
APP and PSEN mutations cause FAD with autosomal dominant inheritance and early disease onset. FAD 
is clinically and neuropathologically largely indistinguishable from the sporadic forms of AD, indicating 
that amyloidosis is a driving force in the aetiology of both FAD and sporadic AD. Biochemical studies 
have shown that APP mutations either shift the generation of Aβ peptides towards the highly 
amyloidogenic Aβ42 isoform or enhance the aggregation propensity of the Aβ peptides. No evidence has 
been found that these mutations impair the physiological function of APP. PSEN mutations also drive 
amyloidosis in FAD patients through changes in the Aβ42/Aβ40 ratio. In addition, it has been proposed 
that PSEN mutations could impair other γ-secretase dependent and independent functions of PSEN. It is 
important, however, to note that none of these phenotypes have been comprehensively replicated in 
experimental models that bear relevance to the heterozygous genetic background of FAD patients with 
PSEN mutations. In the few studies that have used primary cells from FAD patients or heterozygous 
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knock-in mice, only single or a small number of PSEN mutations were investigated. It appears 
premature, therefore, to conclude that loss of function phenotypes like reduced NOTCH signalling that 
were reported in overexpression studies with FAD PSEN mutants are relevant to the clinical phenotype 
of FAD patients, or may even contribute to the pathology of sporadic AD. 
 
Clinical and neuropathological features 
While Alzheimer’s disease and prion disease differ in terms of incidence and to a lesser extent duration 
of symptoms, both processes demonstrate: (1) characteristic age of onset; (2) sporadic occurrence in the 
majority of cases; and (3) inherited disease based on mutations in an amyloidogenic protein in a 
minority of cases. Aside from kuru and rare iatrogenic cases, prion disease tends to present in middle 
age and in older patients (Parchi et al., 1999a). Therefore, it is not surprising that age-related 
pathological processes such as oxidative stress, protein cross-links, and adduct formation that are 
widespread early findings in Alzheimer’s disease (Sayre et al., 1999), also occur in prion disease (Choi et 
al., 2004;Guentchev et al., 2000;Kim et al., 2001). 85% of human prion disease cases are sporadic, i.e., 
there is no exposure to contaminated material and no detectable mutation leading to disease. The lack 
of clusters of CJD throughout the world aside from kindreds with familial CJD (e.g., E200K mutation) is 
also consistent with the sporadic disease concept and suggests that prion disease is primarily a 
neurodegenerative process. In the last few years, a striking number of epidemiological, 
neuropathological, and biochemical similarities between prion diseases and Alzheimer’s disease have 
been identified, in particular the fact that there are interactions between the two proteins (Jucker and 
Walker, 2011;Jucker and Walker, 2013) and between the signalling pathways involving both proteins. 
Epidemiologically and clinically, both disorders are dementing illnesses that mainly occur sporadically, 
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but can also be inherited. Histopathologically, both are characterised by the deposition of an 
extracellular amyloid that is produced by neurones. In both diseases, there is formation of amyloid 
oligomers and ultimately also of solid amyloid aggregates in the brain: both amyloid proteins can 
accumulate diffusely, or they can exhibit prominent and widespread deposition of dense amyloid 
plaques with a diameter of more than 200 µm, and both elicit a considerable astrocyte and microglial 
reaction (Jucker and Walker, 2013). 
 
Transmission studies 
A study by Eisele et al (Eisele et al., 2009) demonstrated the induction of cerebral β-amyloidosis in 
different brain areas of APP23 transgenic mice through the injection of dilute amyloid-β containing brain 
extracts. Once the amyloidogenic process has been exogenously induced, the nature of the induced 
amyloid-β deposition was determined by the brain region of the host. The authors further tested the 
transmission of cerebral β-amyloidosis to APP23 transgenic mice through the contaminated steel wires 
which were only prevented by plasma sterilization, but not boiling of the wires before implantation. The 
study suggested that very small amounts of amyloid-β containing brain tissue in direct contact with the 
CNS can induce cerebral beta-amyloidosis. The observation is reminiscent of prion-like mechanisms 
including the propagation of pathology suggesting common pathways in the pathogenesis of the two 
conditions.  
The concept of prion-like induction and spreading of pathogenic proteins has recently been expanded to 
include aggregates of tau, α-synuclein, huntingtin, superoxide dismutase-1, and TDP-43, which 
characterize such human neurodegenerative disorders as frontotemporal lobar degeneration, 
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Parkinson/Lewy body disease, Huntington disease, and amyotrophic lateral sclerosis. A recent finding by 
Jucker et al (Jucker and Walker, 2011) showing that the most effective amyloid-β seeds are small and 
soluble intensifies the search in bodily fluids for misfolded protein seeds that play a role in the 
proteopathic cascade, and could serve as predictive diagnostics and the targets of early, mechanism-
based interventions.  
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1.9 Genome wide association studies - copy number variants 
Variation is the currency of human genetics. These differences between individuals can take many forms 
including: single nucleotide polymorphisms (SNPs), tandem repeats, small insertions and deletions or 
larger variants involving thousands-millions of nucleotides due to deletions, insertions and duplications 
referred to as copy number variants (CNVs). There are also other chromosomal rearrangements such as 
inversions and translocations (also known as copy neutral variations) and copy neutral loss of 
heterozygosity (LOH). Insight into human DNA variation has been facilitated by two major projects: the 
Human Genome Project (Collins and McKusick, 2001) which sequenced the human genome and the 
HapMap project (2003) which identified and annotated the sequence location of over one million SNPs 
and their associations with nearby variants in key populations.  
The annotation of SNPs to their location within the human DNA sequence facilitated the development of 
arrays containing hundreds of thousands of SNPs and CNV probes used as markers for genotyping. 
Utilizing these technologies, the frequency of alleles and CNVs in cases versus controls is made possible, 
forming the basis for the now routine genome-wide association (GWAS) case-control study. Platforms 
developed for high-throughput genotyping allow hundreds of thousands of DNA samples to be 
genotyped with high accuracy for up to around a million SNPs and CNV probes simultaneously in a single 
procedure. 
Despite their overall success, standard genome-wide association studies have limitations, they generally 
test for associations of single nucleotide polymorphisms with a relatively high minor allele frequency 
(MAF) (typically >1%). The strategy of focusing on common SNPs in genetic association studies 
effectively considers the “common-disease-common-variant (CDCV)” hypothesis, i.e. risks for common 
diseases are conferred by multiple common variants albeit of variable strength of effect. GWAS based 
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on a quarter of a million to one million common SNPs rely on linkage disequilibrium (LD) mapping, the 
non-random association of alleles of adjacent loci on a chromosome (Li and Leal, 2008). A set of 
common SNPs (chosen either randomly, for technological reasons or selected to optimize the capture of 
other SNPs by LD) provided by the existing high-throughput genotyping platforms can cover the genome 
well enough to capture a large proportion of all the common variants at unmeasured loci. The “rare 
variants hypothesis” proposes that a significant proportion of inherited susceptibility may be due to the 
combination of the effects of a series of rare or low frequency variants of a number of different genes, 
each conferring a moderate-strong increase in relative risk. Such rare variants are more likely to be 
private to populations or families because of founder effects and genetic drift which makes these SNPs 
less well understood and harder to comprehensively incorporate in off-the-shelf genotyping 
technologies. The debate about the importance of common or rare variants is relevant to study design, 
but inevitably rather pointless as it has already been established that variants of all population 
frequencies may be significant risk factors in complex traits. 
GWAS is based on a case–control association design to determine if one or more alleles are more 
frequent in cases, reflecting the genetic region of a risk variant. It is important to understand that a 
region identified may contain multiple genes or non-gene factors that have effects at a distance. 
Generalities in recent case–control association studies are that risk is usually conferred by multiple 
genetic factors each contributing only modest effects, and that variants are rarely associated with 
coding changes in proteins, rather, presumably acting by altering expression of a gene in the broadest 
sense. Because of the large number of hypotheses tested, there is great potential for false-positive 
associations. To overcome these issues a statistical correction is applied, conventionally the Bonferonni 
correction which requires a p value of less than around 5×10−8 for a locus to be considered to have 
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evidence for genome-wide association and to have a high chance of being replicated (Petretto et al., 
2007).  
A typical genome wide association study with about 2,000 cases and controls has the power to detect 
only moderate effects with an MAF of 5% at the stringent genome-wide significance level (5×10−8). To 
overcome this constraint, a very large discovery sample size is usually required which may not always be 
possible, particularly in case of rare diseases such as prion disease and certainly for vCJD. Replication in 
an independent sample is necessary to solidify evidence for association and rule out biases such as 
genotyping error or population stratification. Replication should be conducted in a similar population 
with a sample size adequate to detect a similar magnitude of effect and significance using the same 
genetic model.  
Genome wide association studies have allowed the analysis of structural genetic variation (McCarthy et 
al., 2008). CNVs have recently gained considerable interest as a source of genetic diversity with well-
known examples causing neurodegenerative diseases (Blauw et al., 2010;Nuytemans et al., 2009). 
Several large-scale studies have reported the presence of extensive copy number variation in humans, 
suggesting that CNVs may account for a significant proportion of human phenotypic variability, including 
disease susceptibility (Feuk et al., 2006). They represent the most dynamic form of human genetic 
variation from one generation to the next, peppered throughout the genome and recently associated 
with conditions such as schizophrenia, autism and mental retardation. Several theories have been 
proposed to explain the widespread occurrence of CNVs in the human genome such as non-allelic 
homologous recombination and non-homologous end joining (Frazer et al., 2009).  
A widely used whole-genome SNP genotyping platform, the Illumina Human Hap 550 BeadChip 
(Gunderson et al., 2005), assays more than half a million SNPs in parallel (median SNP distance ~3 kb), 
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permitting kilobase-resolution detection of CNVs. The assay combines specific hybridization of genomic 
DNA to arrayed probes with allele-specific primer extension and signal amplification, thus achieving a 
high signal-to-noise ratio in genotype calling (Gunderson et al., 2005). The assay does not require PCR-
based amplification, thus detected signals are less susceptible to biases caused by differential 
amplification of given chromosomal regions. In addition to the total fluorescent intensity signals from 
both sets of probes/alleles at each SNP (referred to as ‘log R ratio’), the Illumina platform also allows 
inference of the relative ratio of the fluorescent signals between 2 probes/alleles at each SNP (referred 
to as ‘B allele frequency’). Furthermore, data normalization at each SNP on the Infinium platform is 
performed by comparison of signals from a set of reference samples (eg. HapMap samples) leading to 
less signal variation between SNPs.  Conventional methods for CNV identification on the Illumina 
platform involve examination of intensity signals (implemented in the LOH-plus module of the 
BeadStudio software), which identifies copy number changes by calculating the mode of B Allele 
Frequency for SNPs in a sliding window along the chromosome. While simple to implement, the sliding 
window approach has limited and relatively coarse boundary resolution for detected CNVs. A recently 
described algorithm, QuantiSNP, incorporates the log R Ratio and B Allele Frequency simultaneously in a 
hidden Markov model (HMM) framework (Colella et al., 2007). As demonstrated by simulations and by 
studies on individuals with known large aberrations, QuantiSNP significantly improves the resolution of 
CNV detection. The development of algorithms that both accurately model the signal measures and 
integrate more available data (e.g., genotype frequency, family relationship) can potentially lead to 
further improvement of CNV detection. 
CNV Partition plug-in algorithm is supported by Genome Studio and has been optimised for speed and 
accuracy using log R and B allele frequency in combination to identify chromosomal aberrations, 
estimate copy number value and calculate per-region confidence scores. It is fast to analyse and report 
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(~1min per sample) and detects CNV regions and estimates CNV values with high accuracy (Winchester 
et al., 2009). It identifies small CNV regions (<100 kb) and provides confidence score for each locus. 
CNVs account for a significant proportion of genetic diversity, with consequences in term of evolution 
and disease susceptibility (Conrad and Hurles, 2007). Consequently, their detection and association with 
quantitative traits and clinical phenotype constitute an important step towards a better understanding 
of disease etiology. However, accurate detection of copy number variants remains challenging. There 
are numerous factors in the data generation and computational analyses that can lead to spurious 
associations. The sheer amount of data that can be generated for a single subject imposes challenges in 
terms of data interpretation. Several large- scale aberrations (Dowjat and Wlodarska, 1981;Nister et al., 
1987;Pepler et al., 1968)were identified before the development of higher resolution techniques. 
Fluorescence in situ hybridization (FISH) has increased this resolution, enabling the detection of sub-
microscopic CNVs that could not be detected with karyotyping. Today, the most widely used techniques 
can be classified as amplification-based polymerase chain reaction (PCR), hybridization-based (FISH, 
comparative genome hybridization, and SNP arrays) or sequencing-based. These techniques differ in 
precision, throughput, and resolution.  
A combination of rare and disruptive variants of large effect can contribute to different phenotypic 
outcomes, such as intellectual disability, epilepsy, autism and schizophrenia. Primary mutations sensitize 
individuals to disease from secondary mutational events, which compound at the molecular level to 
modify the outcome and severity. The mode of inheritance for both primary and secondary mutations, 
as well as the size and gene content of copy-number variants, is a critical determinant in distinguishing 
syndromic disorders from mutations with phenotypic variation.  The overall burden of genes that are 
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affected by large variants may eventually be of prognostic significance, allowing clinicians to better 
anticipate long-term outcomes when the variants are discovered in affected persons. 
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1.10 Neuropathology of prion diseases 
The classical triad of spongiform change, neuronal loss, and gliosis (astro- and microglia) is the 
neuropathological hallmark of prion diseases (Reiniger et al., 2011). Neuronal loss and gliosis may be 
present in many other conditions of the CNS, for example, Krabbe disease, caused by a deficiency of the 
enzyme galactosylceramidase. Progressive Spongiform Leukoencephalopathy (PSL) -- which is a 
spongiform encephalopathy—is not a prion disease, although the etiological factor which causes it 
among heroin smokers has not yet been identified (Kriegstein et al., 1999). Prion to PrP 
immunohistology, the crucial feature was spongiform change accompanied by neuronal loss and gliosis. 
This spongiform change is characterized by diffuse or focally clustered small round or oval vacuoles in 
the neuropil of the deep cortical layers, cerebellar cortex or subcortical grey matter, which might 
become confluent. Spongiform change should not be confused with non-specific spongiosis. This 
includes status spongiosus (“spongiform state”), comprising irregular cavities in gliotic neuropil following 
extensive neuronal loss (including also lesions of “burnt-out” CJD), “spongy” changes in brain oedema 
and metabolic encephalopathies, and artifacts such as superficial cortical, perineuronal, or perivascular 
vacuolation; focal changes indistinguishable from spongiform change may occur in some cases of 
Alzheimer's and diffuse Lewy body diseases. Very rare cases might not be diagnosed by these criteria. 
Then confirmation must be sought by additional techniques such as PrP immunoblotting, molecular 
biologic studies, or experimental transmission (Budka et al., 1995). 
The spongiform change may be mild, moderate or severe (illustrated in Figure 5) and is characterised by 
diffuse or focally clustered, small, round or oval vacuoles in the neuropil of the deep cortical layers, 
cerebellar cortex or subcortical grey matter, which might become confluent. Presence and distribution 
of spongiform change vary greatly between cases and disease subtypes. An almost constant location in 
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sCJD is the head of the caudate nucleus. On the contrary, spongiform changes are rarely present in the 
brainstem and spinal cord, although PrP accumulation can be demonstrated at these sites. Extensive 
sampling from various brain areas (including frontal, temporal, and occipital lobes, basal ganglia, and 
cerebellum) is normally done in every suspected case. However, one block of tissue with typical 
histological changes and/or unambiguous PrPScimmunoreactivity is sufficient for a definite diagnosis. 
Brain biopsy has been found to have a diagnostic sensitivity of 95% of sporadic CJD cases in which the 
disease has been confirmed at autopsy or by experimental transmission. This procedure is however, 
usually restricted to rare instances where a treatable alternative diagnosis is suggested by clinical or 
investigation findings. In sCJD, the regional distribution of spongiform change in distinct patterns was 
shown to depend upon PrPSc  fragment sizes and glycotypes, and codon 129 genotype of PRNP (Budka, 
2000). However, some prion diseases have equivocal, little, or no spongiform change, such as inherited 
prion diseases due to D178N mutation that is specifically characterised by prominent thalamic atrophy 
with profound astrogliosis.  
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Figure 5. Spongiform change and PrP deposition in sCJD: spongiosis (a–c) and patchy confluent vacuolisation (d–f). 
Patterns and intensities of commonly observed prion protein deposits: (g–i) coarse granular deposits of prion 
protein, which may form confluent aggregates.( j–l) Synaptic PrP, ranging from mild to severe, and (m–o), 
formation of plaques in sCJD. (Images obtained from ‘Reiniger L, Lukic A, Linehan J, Rudge P, Collinge J, Mead S, 
Brandner S.Tau, prions and Aβ: the triad of neurodegeneration’, Acta Neuropathol. 2011 Jan;121(1):5-20). 
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1.11 Clinico-pathological characteristics of human prion diseases 
Traditionally, the human prion diseases have been classified into clinic-pathological syndromes: CJD, 
Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia and kuru, an epidemic prion disease of 
the Fore linguistic group of Papua New Guinea. Alternatively, they can be grouped by aetiology, as 
inherited, acquired, or sporadic (unknown) cause. sCJD occurs with a seemingly random case 
distribution and an annual incidence of around one per million per year. Around 10-15% of human prion 
disease is inherited; almost all cases of familial prion disease have been associated with coding 
mutations in the prion protein gene (PRNP), of which more than 60 mutations are described (Mead, 
2006), see Figure 3. The acquired prion diseases include iatrogenic CJD, kuru and variant CJD, and arise 
from accidental exposure to human prions through medical and surgical procedures (especially acquired 
dura mater transplantation or cadaver-derived growth hormone therapy), participation in 
endocannibalism in the case of kuru, and exposure to BSE infected meat. Most types of prion disease 
are highly heterogeneous in terms of clinical presentation, incubation time (in acquired types) and age 
of onset.   
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1.11.1 Sporadic CJD 
The annual mortality rate of sCJD is roughly 1-2 per million per year and is broadly similar worldwide and 
between sexes. It peaks in the seventh decade and then appears to decline with advancing age 
(www.cjd.ed.ac.uk/documents/report22.pdf). There have been occasional reports in young adults aged 
<40 years.  The core clinical feature is a rapidly progressive cognitive decline which may be preceded by 
a change in personality, psychiatric features or sleep disturbance. It may only be a matter of weeks 
between presentation and death. Definitive diagnosis is by autopsy and is characterized by spongiform 
change, neuronal loss, astrocytosis and prion protein deposition. 
During life, patients can be diagnosed with possible or probable sCJD according to established WHO 
criteria (www.cjd.ed.ac.uk, Table 1). A study by Tschampa proposes the introduction of brain MRI for 
diagnosis of CJD (Tschampa et al., 2005). The data confirm that basal ganglia and cortical 
hyperintensities represent the most frequent MRI findings in sCJD and are present in most cases. The 
authors suggested modifying the diagnostic criteria to include detection of either hyperintensity in the 
basal ganglia (both caudate nucleus and putamen) or in at least two cortical regions (from either the 
temporal, parietal or occipital cerebral cortices).  Characteristic brain MRI lesion patterns are helpful in 
establishing a diagnosis of sCJD and may help to identify atypical sporadic disease forms. Atypical cases 
may have a protracted clinical course or present with unusual clinical features. Such cases are more 
frequently associated with a valine homozygous genotype at codon 129. The diagnosis of sCJD should be 
questioned if there is a history of dementia longer than 2 years, if the typical neurological signs are 
absent, or if there is evidence of inflammation. Periodic sharp waves are not seen in a third of EEGs in 
definite CJD cases and MRI shows high signal on T2 weighted scans in the caudate and putamen in about 
 
 
56 
 
 
two-thirds of definite CJD (Tschampa et al., 2005). Proposed diagnostic criteria according to Tschampa et 
al (Tschampa et al., 2005) for sCJD are presented in Table 1. 
The differential diagnosis of sCJD includes: Alzheimer’s disease and other dementias (usually in older 
patients), cerebral vasculopathies, chronic encephalitis (including Hashimoto’s encephalitis), 
encephalopathy (due to anoxic brain damage or a paraneoplastic cause) and white matter diseases such 
as multiple sclerosis.  
 
Table 1 shows the proposed diagnostic criteria according to Tschampa et al (Tschampa et al., 2005) for sCJD 
patients to include the characteristic MRI changes associated with sCJD. For the diagnosis of probable sCJD, two 
out of the listed clinical signs and at least one of the listed tests is necessary. For a diagnosis of possible sCJD two 
out of the listed clinical signs and disease duration of less than 2 years is required. 
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1.11.2 Inherited prion disease 
The incidence of inherited prion disease (IPD) is around 10-15% of the total. All cases so far have been 
associated with pathogenic mutations in the open reading frame (ORF) or prion protein gene and are 
dominantly inherited.  A proportion of IPD cases have been reported without a positive family history of 
the disease, and many cases do not share clinical features with classical CJD, hence the term inherited or 
genetic prion disease is used by many in preference to ‘familial CJD’. Many cases of IPD have relatively 
slowly progressive phenotypes, such as Gerstmann–Sträussler–Scheinker syndrome (GSS), fatal familial 
insomnia (FFI) and inherited prion disease due to Y163X mutation in the prion protein gene (termed PrP 
systemic amyloidosis). There are three types of mutation, point mutation, altering an amino acid, point 
mutation generating premature stop codon, and alteration of the number of octapeptide repeats by 
insertion or >1 deletion (OPRI). There is much variation in the penetrance of different mutations as 
evidenced by considerable intra-familial and intra-generational phenotypic variability. For this reason in 
some cases the disease is not reported in the first degree relatives. Inherited prion disease can be 
diagnosed by PRNP analysis, a method which has allowed recognition of a wider phenotypic spectrum of 
human prion disease to include atypical dementias and fatal familial insomnia (FFI). No such pathogenic 
mutations are present in sporadic and acquired prion disease. Inherited prion disease is generally 
associated with an early age at onset and a longer duration of illness than sCJD.  However, the 
phenotype is remarkably variable, ranging from an aggressive disease indistinguishable from sCJD to a 
prolonged slowly progressive dementia over more than 20 years.  The frequency of mutations differs 
worldwide; however, geographical or ethnic clusters of IPD cases with mutations E200K, V210I, D178N, 
and V180I have been reported from Slovakia, Israel, Spain, Italy, Chile, and Japan(Gambetti et al., 
2010;Nozaki et al., 2010). Multiple strains, although yet remain unidentified, may be involved in the 
pathogenesis of the disease.   Clinical phenotypes related to most mutations overlap with those of sCJD 
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(Gambetti et al., 2010;Nitrini et al., 1997). The exception is the phenotype carrying  T183A- 129M 
haplotype which is characterised by fronto-temporal features such as aggressive behaviour, 
hyperorality, verbal stereotypes and often parkinsonian signs although there are not enough cases to 
consider this a distinctive phenotype (Anghinah et al., 2006).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
1.11.3 Gerstmann-Sträussler-Scheinker (GSS) disease 
GSS is an autosomal dominant prion disease associated with point mutations in the prion protein gene, 
defined by the classical neuropathological changes. Most typically they show a slowly progressive ataxic 
syndrome. The most frequent mutation associated with GSS involves a proline-to-leucine substitution 
within the unstructured N-terminal region of the PrP at codon 102 (P102L), segregating with methionine 
at codon 129 on the mutant allele(Hsiao et al., 1989). Other mutations have been described either at the 
N-terminal or at the C-terminal PrP region. The genetic heterogeneity of GSS partly explains the 
variability in age of onset, disease duration, and the ample number of clinical variants. However, 
phenotypic heterogeneity is also observed both within and between pedigrees with the same mutation, 
especially in P102L GSS cases (Barbanti et al., 1996;Hainfellner et al., 1995;Webb et al., 2008b). 
Accordingly, while in some P102L patients progressive gait disturbances, truncal ataxia, lower limb 
hyporeflexia and dysarthria are the presenting clinical features, followed over years by dementia and 
pyramidal signs, in other cases a rapidly evolving dementia, indistinguishable from sCJD, is observed. As 
yet, the molecular basis for such clinical variability remains to be fully explained. Neuropathological 
examination in GSS P102L shows marked variation in the degree and brain regional distribution of 
spongiform changes, which largely correlates with the biochemical detection of proteinase K (PK)- 
resistant PrPSc with a core fragment of 21 kDa (Ghetti et al., 1996;Parchi et al., 1998;Piccardo et al., 
1998). As opposed to the variable topographical distribution of spongiform degeneration, typical multi-
centric plaques are widely distributed throughout cerebral and cerebellar cortical and subcortical 
regions, and appear to be constituted by an abnormal PrP isoform that upon PK-digestion generates an 
internal 8 kDa fragment (PrP8), overall spanning from residues 74–90 to 146– 153; this fragment is 
natively present in brain extract of GSS P102L, although is enriched after PK treatment. Experimental 
 
 
60 
 
 
transmission in mice of GSS P102L brain tissues with only PrP8 induces PrP-amyloid deposition, but not 
spongiform encephalopathy (Piccardo et al., 2007). 
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1.11.4 Fatal Familial Insomnia (FFI) 
FFI due to D178N mutation presents between 20 and 72 years (average, 49 years) and is characterised 
with insomnia and stuporous episodes with hallucinations and confusion, autonomic dysfunction, and 
often myoclonus, spasticity and seizures (Medori et al., 1992b). Some of the signs differ between 
129MM and 129MV subjects. Insomnia, myoclonus and autonomic malfunction are often more severe in 
129MM subjects, while in 129MV subjects ataxia, dysarthria and seizures often predominate. Insomnia 
has not been reported in CJDD178N–129VV. Routine electroencephalography (EEG) activity is generally 
slowed and may demonstrate periodic sharp wave complexes (PSWC) associated with myoclonus in 
patients with long disease duration. Polysomnography is an invaluable diagnostic tool in FFI as it shows 
markedly shortened sleep time and disorderly transition between sleep stages (Sforza et al., 1995). 
These changes are less severe in the 129MV patients. PET scanning that demonstrates hypometabolism 
in the thalamus and cingulate cortex, more widespread in 129MV patients than in 129MM patients. 
Neuropathological changes are the defining features of FFI. It is characterised by loss of neurons and 
astrogliosis in the thalamus in all cases and in the inferior olives in most cases (Medori et al., 
1992b;Tabernero et al., 2000). PrP deposits are usually absent, but may be detected in the molecular 
layer of the cerebellum with a stripe-like pattern and in the subiculum-entorhinal region (Almer et al., 
1999).  
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1.11.5 Inherited prion disease associated with octapeptide repeat insertional mutations 
Prion disease is associated with 4–12 extra 24-bp repeats in the PRNP gene (Mead, 2006). As in other 
inherited prion diseases, the amino acid at codon 129 may influence the phenotypic effects of the 
repeat-expansion mutations. The clinico-pathological phenotype is highly variable (Capellari et al., 
1997;Collinge et al., 1996) and tends to become less pronounced when cases are grouped according to 
the number of repeats. 
A study by Kaski et al. (Kaski et al., 2011) on patients with 4-OPRI mutations showed that the risk of 
clinical disease is increased by a combination of the mutation and a susceptibility haplotype on the wild-
type chromosome. The predominant clinical syndrome is a progressive cortical dementia with pyramidal 
signs, myoclonus and cerebellar abnormalities that closely resemble sCJD. Autopsy showed 
perpendicular deposits of prion protein in the molecular layer of the cerebellum. PRNP genotyping 
showed that all patients were homozygous for methionine at polymorphic codon 129. In addition, at a 
single nucleotide polymorphism upstream of PRNP thought to confer susceptibility to sCJD (rs1029273), 
all patients were homozygous for the risk allele (combined p = 5.9x10-5). These findings may provide a 
precedent for understanding apparently sporadic neurodegenerative diseases caused by rare high-risk 
mutations. 
In contrast, the mean age at onset in patients with 5 or more extra repeats is 32 years (range, 21–61 
years). The vast majority of these patients present with a slowly progressive syndrome characterised by 
mental deterioration, cerebellar and extra-pyramidal signs often lacking the PSW complexes on EEG 
examination. 
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Histopathologically, the cases with 4 or fewer extra repeats are indistinguishable from classical CJD, 
whereas the cases with 5–7 extra repeats are heterogeneous and may show either CJD-like change, GSS-
like features, or may be difficult to classify either as GSS or CJD changes.  
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1.11.6 E200K mutation 
E200K is particularly prevalent in Jews of Libyan and Tunisian origin and Slovakians with an incidence of 
CJD about 100 times higher than the world-wide average (Lee et al., 1999). Patients with CJD due to 
E200K–129M haplotype usually have a mean age at onset of 58 years (range, 33–84 years) and a mean 
illness duration of 6 months (range, 2–41 months)(Kahana and Zilber, 1991;Simon et al., 2000). The 
presentation includes cognitive abnormalities, cerebellar signs, visual signs and myoclonus (Kahana and 
Zilber, 1991). Patients also present with signs of motor and sensory peripheral neuropathy found rarely 
in sCJD patients. The EEG shows slowing in all patients while about 75% display PSW complexes (Brown 
et al., 1991). Brain atrophy is detected in about one-third of patients (Chapman et al., 1993). The CSF 14-
3-3 protein is elevated in almost all CJD cases with E200K mutation (Rosenmann et al., 1997).  
The E200K–129V haplotype has been reported in five subjects from apparently unrelated families, and 
all have type 2 PrPSc. In contrast to those of E200K–129M, the phenotypes of the E200K–129V haplotype 
are similar to those of sCJDVV2 (Parchi et al., 1999b), presenting as ataxia at onset followed by 
myoclonus and PSW complexes on EEG examination. PrPSc accumulates predominantly in the cerebellum 
where it forms plaque-like structures. Spongiform degeneration, astrogliosis and neuronal loss in various 
combinations of severity are invariably present. They are generally severe and widespread in the 
cerebral cortex and milder in the striatum, diencephalon, and cerebellum. The extent of astrogliosis and 
neuronal loss appears to be related to disease duration. PrP immunohistochemistry is consistently 
positive throughout the brain with a punctate or 'synaptic’ pattern apparently correlated to the 
histological lesions.  
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1.11.7 Variant CJD (vCJD) 
The first 10 patients of new variant or simply of variant CJD (vCJD) were reported in April 1996 in UK 
(Will et al., 1996).Over 220 vCJD cases have been reported hitherto from 8 European and 4 non-
European countries (USA, Canada, Saudi Arabia, and Japan). Figure 6 shows the incidence of BSE and 
vCJD in the period from 1987 to 2012. The incidence of vCJD peaked following the BSE epidemic and 
continued to decline from 2000 (Figure 6). Reported rate of sCJD has been increasing possibly because 
the condition is now better recognised. The age range of disease onset in vCJD is between 16 and 74 
years and they manifest a predominance of psychiatric symptoms later advancing to cerebellar ataxia 
and/or progressive dementia. This is in contrast to sCJD where the average age of disease onset is 65 
years (Brown, 1996) and disease duration is usually much shorter than in vCJD. 
The majority of vCJD cases have been reported from the UK alone (Beekes, 2010). Psychiatric and 
behavioural symptoms of vCJD may include agitation, aggression, depression, anxiety, apathy, emotional 
lability, insomnia, poor concentration, paranoid delusions, recklessness, or withdrawal; a combination of 
two or more of these symptoms appear in most of the patients (Spencer et al., 2002). Some patients 
may also show signs of sensory disturbance such as pain, paresthesia and dysesthesia. The neurologic 
symptoms occur at least 6 months after the onset of psychiatric symptoms and include cerebellar ataxia, 
cognitive impairment, involuntary movements which may be dystonic, choreiform or myoclonic. 
Incontinence of urine, progressive immobility, and akinetic mutism are the late onset signs. Death often 
occurs because of intercurrent infections. The mean age at onset of symptoms is 29 years, and the 
progression or total duration of the disease spans 18 months in average, which is similar to that 
reported for kuru and iCJD linked to treatment with hGH (Belay, 1999). The observation of posterior 
thalamic high signals characterized by ‘pulvinar’ or ‘hockey stick’ signs on T2 diffusion or FLAIR MR 
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imaging and the detection of PrPSc in tonsillar biopsy are important for the specific diagnosis of vCJD. 
The neuropathological hallmark of vCJD is the presence of kuru-type amyloid plaques surrounded by 
spongiform lesions “the florid plaques” which also have been seen in scrapie but never in other human 
prion diseases (Will, 2003). Spongiform changes occur most evidently in the basal ganglia and thalamus 
with sparse distribution throughout the cerebral cortex. The florid plaques and misfolded PrP 
immunohistochemical staining have occurred predominantly in the cerebellum and cerebrum. However, 
sufficient amounts of abnormal PrP are detected in the lymphoreticular system of vCJD patients (Will, 
2003). The detection of misfolded PrP in the lymphoreticular system has confidently been used for the 
diagnosis of vCJD (Ironside et al., 2006). To date, all definite vCJD patients have been 129 MM 
homozygotes (Bishop et al., 2009), with one possible case of MV vCJD reported in 2009 (Kaski et al., 
2009). Very soon after the report on 10 vCJD cases, epidemiological studies, experimental transmission 
of the disease to cynomologous macaques and mice (wild as well as transgenic) and biochemical strain 
typing linked the etiology of vCJD to infection from BSE prions. The same or diverse phenotypes may 
develop on primary and secondary transmission of vCJD and BSE to mice expressing human PrP, 
depending on the source of inoculum and the PrP sequence of the recipient, and the 129 MV 
heterozygotes may be less resistant to vCJD transmission as compared to BSE transmission (Wadsworth 
et al., 2004). Moreover, at least 4 pathologically confirmed cases including 1 with subclinical or 
potentially preclinical infection have been associated with the secondary vCJD transmission via blood 
transfusion (Wroe et al., 2006). These reports of secondary iatrogenic transmission and the possibility of 
vCJD occurrence with long incubation periods in individuals with 129 MV and 129 VV PrP genotypes 
have raised serious public health concerns (Ironside et al., 2006). Some cases of kuru and iatrogenic CJD 
(iCJD) have occurred after incubating the disease for almost 50 and 30 years, respectively (Collinge et al., 
2006). 
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Edgeworth et al (Edgeworth et al., 2011)  developed a solid-state binding matrix to capture and 
concentrate disease-associated prion proteins and coupled this method to direct immunodetection of 
surface-bound material. Quantitative assay sensitivity was assessed with a serial dilution series of 10⁻⁷ 
to 10⁻¹⁰ of vCJD prion-infected brain homogenate into whole human blood, with a baseline control of 
normal human brain homogenate in whole blood (10⁻⁶). The test allowed detection of a 10⁻¹⁰ dilution of 
exogenous vCJD prion-infected brain from a 10⁻⁶ dilution of normal brain, an assay sensitivity that was 
orders of magnitude higher than any previously reported. All 15 samples which scored positive in this 
study were from patients with vCJD, showing an assay sensitivity for vCJD of 71·4% and a specificity of 
100%. These initial studies provide a prototype blood test for diagnosis of vCJD in symptomatic 
individuals, which could allow development of large-scale screening tests for asymptomatic vCJD prion 
infection although the validation of such a test may prove to be challenging.  
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1.11.8 Iatrogenic CJD (iCJD) 
Duffy et al described a case of iatrogenic CJD in a person who received cadaveric corneal transplant from 
a patient of CJD (Duffy et al., 1974). Several cases of human prion disease, since then, have been 
associated with iatrogenic transmission of CJD by the use of stereotactic intracerebral EEG needles or 
neurosurgical instruments, cadaveric dura mater grafts and intramuscular injections of contaminated 
cadaveric pituitary-derived human growth hormone (hGH) and gonadotrophin hormone. The highest 
proportion of iCJD cases is attributed to treatment with hGH and dura mater grafts. Most of CJD cases 
linked to treatment with hGH have occurred in France, while those linked to treatment with dura mater 
grafts have mainly occurred in Japan (Nozaki et al., 2010). Between the late 1950s and 1985, about 
30,000 children were treated with hGH worldwide, and the overall proportion of CJD cases from the 
treated population has been estimated to be about 1/100. It is believed that the likely PrPSc 
contamination of pituitary-derived hGH and dura mater grafts resulted from the practice of batch 
processing. Before the production of recombinant hGH, it was a pharmaceutical practice to process 
5,000-20,000 cadaveric pituitary glands in a single batch for the extraction of the hormone. The 
presence in the batch of a few pituitary glands from unknown CJD cases may be responsible for 
contamination. With the availability of recombinant hGH and the initiation of separated processing of 
individual dura mater grafts since 1987, the probability of occurring future iCJD cases appears to be very 
low. A peak in the incidence of iCJD cases seems to have passed, however those with long incubation 
periods may still occur (Collinge et al., 1991;Rudge et al., 2015). The clinicopathological features of CJD 
linked to treatment with hGH resemble those of kuru. The majority of UK cases were 129 VV, while 
codon 129 MM was thought to be a risk factor in other countries. The incubation periods may be in the 
range of 4.5 to over 25 years with a mean of 12 years  (Collinge et al., 1991). In contrast, the 
clinicopathological features of CJD linked to neurografting of dura mater or the use of neurosurgical 
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instruments resemble those of sCJD. The mean duration of illness is 18 months and the incubation 
periods may be in the range of 1.5-18 years with a mean of about 6 years. In Japan, the minimum risk of 
developing iCJD has been estimated to be approximately 1/3000 graft recipients (Will, 2003). 
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1.11.9 Kuru 
Kuru is the first human prion disease that was shown to be transmissible to chimpanzees by 
intracerebral introduction of brain homogenates from kuru patients (Gajdusek et al., 1966). Kuru has 
occurred exclusively in the Fore linguistic group of Papua New Guinea Eastern Highlands and the 
neighbouring peoples with whom they intermarried. There was a practice among these groups to 
consume the dead bodies of their relatives as a mark of respect and mourning (ritualistic cannibalism). 
Women and young children of both sexes were more exposed to the risk material such as brain and 
viscera than adult men who usually had preferentially to consume muscles. The kuru epidemic killed 1-
2% of the population per annum at its peak. Some villages became even devoid of adult women. With a 
ban on ritualistic cannibalism in the mid-1950s imposed by Australian authorities, the incidence of the 
disease started to decline steadily. Kuru was introduced to Western medicine in late 1950s, although the 
first case of kuru was observed around 1920.  The Western scientists were very soon able to prove 
ritualistic cannibalism as the etiology of the disease. The older kuru patients who experienced an 
exposure to the infection before the ban can still be seen. The incubation periods of kuru in such 
patients would be more than 50 years (Collinge et al., 2006;Liberski and Brown, 2008). Kuru has imposed 
strong selection pressure in the affected Fore groups on PRNP especially at codons 127 and 129. 
Heterozygosity at these PRNP codons is a resistance factor for kuru and can be seen with marked 
prevalence among survivors of the kuru epidemic (Mead et al., 2009b). Kuru has 3 clinical stages namely 
ambulant (still can walk), sedentary (only can sit up), and terminal (unable to sit up independently). An 
ill-defined prodromal period characterized by headache and pain usually in the joints of legs may 
precede these stages. Cerebellar ataxia, tremors, choreiform and athetoid movements are distinctive 
and prominent clinical signs. Shivering amplifiable by cold was the symptom on the basis of which the 
disease was named “kuru”. The most prominent clinical feature of sCJD, the dementing illness can also 
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occur in some cases but it happens during the final disease stages only (Collinge et al., 2008). 
Neuropathological features such as spongiosis, neuronal loss, and astrocytic microgliosis can variably be 
observed in CNS usually in the grey matter. 
The PrPSc deposition is observed in CNS only (Brandner et al., 2008). The neuropathological property 
which distinguishes kuru from sCJD is the presence of numerous kuru plaques, spherical bodies with a 
rim of radiating filaments. Kuru is believed to be caused by the consumption of prion infected brain 
tissue and experimental transmission studies have shown similarity between the molecular and 
pathobiological properties of prions causing kuru, sCJD and iCJD (Wadsworth et al., 2008a). Similar 
studies have also revealed differences in transmission dynamics, peripheral pathogenesis and the 
neuropathology properties of kuru and vCJD prions (Wadsworth et al., 2008a). As both kuru and vCJD 
are caused by infection via oral route, these differences can be attributed to the strain type or dose 
effect rather than the route of infection (Brandner et al., 2008).  
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1.12 Phenotypic variation in prion disease 
Prion diseases show a remarkable extent of phenotypic heterogeneity (Gao et al., 2011). These 
variations, observed as differences in age at presentation, disease duration, clinical features, 
investigation findings and pathological phenotype may be genetically determined, associated with a 
particular prion protein strain or with specific environmental factors. A better understanding of these 
mechanisms may lead to classification of prion diseases based on the causes rather than the effects of 
this heterogeneity. Such classification is likely to be more accurate and may result in a wider detection 
and more precise diagnosis of prion diseases.   
A recent study by Gao et al (Gao et al., 2011) investigated clinical heterogeneity in 259 Han Chinese 
patients with sCJD. 163 patients with probable sCJD and 96 patients with possible sCJD were included in 
the study.  Progressive dementia was the most common presenting symptom. Psychiatric features were 
present in a large number of patients, followed by pyramidal or extrapyramidal disturbance, cerebellar 
syndrome, slowly progressive dementia and the least common was presence of visual disturbance. The 
proportion of patients with slowly progressive dementia (persistent longer than one year) in the group 
of possible sCJD were slightly higher than that of probable sCJD, but the difference was not statistically 
significant. Almost all probable and possible sCJD patients had progressive dementia in their clinical 
courses. Except for dementia, the presence of four other clinical manifestations were included in the 
diagnostic criteria; visual or cerebellar disturbance, pyramidal or extrapyramidal dysfunction and 
akinetic mutism, were compared between two groups. Pyramidal or extrapyramidal dysfunction was the 
most commonly observed sign in both probable and possible patients, which accounted for 77.9% and 
79.2%, respectively. Visual or cerebellar disturbances were noted comparably in probable (57.1%) and 
possible (58.3%) sCJD patients. Akinetic mutism appeared in 38.0% of probable and 30.2% of possible 
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sCJD patients. Myoclonus was more frequently observed in the group of probable sCJD, showing 
statistically significant differences (Gao et al., 2011).  As an important diagnostic marker for sCJD, the 
data for CSF 14-3-3 protein detected using Western blot and EEG recordings were collected through the 
NCJDSU surveillance network. Two patients with relatively long clinical course (more than 500 days) 
were CSF 14-3-3 positive, but had negative EEG findings. Although probable sCJD patients show high 
ratios of both positive CSF 14-3-3 protein and presence of PSWC on EEG, only approximately 45% of 
patients who have undergone those two examinations were positive for both. It emphasizes again the 
important role of CSF 14-3-3 protein and EEG findings in the diagnosis of sCJD. In addition, the data 
show that the presence of myoclonus is associated with the presence of PSWC on EEG.  
Phenotypic heterogeneity is also observed in patients with inherited prion disease. Studies of 
heterogeneity in patients with IPD provides a unique opportunity to characterize this diversity and 
examine possible modifying factors amongst individuals in whom prion disease has been initiated by the 
same defined genetic mutation. As the inherited prion diseases comprise a significant proportion of 
early-onset dementia, an appreciation of their wide range of clinical presentation is important for 
differential diagnosis. 
A study by Mead et al (Mead S et al., 2006) was done on patients from southeast England with inherited 
prion disease caused by a prion protein octapeptide repeat insertion mutation. Genealogical and clinical 
record review, together with the characterization of the mutation-linked single nucleotide 
polymorphism and microsatellite haplotype, suggested a single founder for both this large kindred and a 
smaller family. The study investigated the phenotype of 86 affected individuals and another 84 
individuals known to be at risk of inheriting the disease. Clinical onset, typically with cognitive 
impairment, can be strikingly early when compared with other inherited or sporadic prion diseases. The 
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study investigated the effect of PrP genotype, candidate genes and prion strain type on clinical, 
neuroradiological and neuropathological phenotype. The transmission characteristics of prions from 
affected individuals resembled those of classical sporadic Creutzfeldt-Jakob disease. One surprising 
finding was a strong inverse correlation between age of onset and disease duration. The PrP gene 
polymorphic codon 129 was found to confer 41% of the variance in age of onset but interestingly this 
polymorphism had no effect on disease duration suggesting different molecular mechanisms involved in 
determining disease onset and rate of clinical progression. 
Zarranz et al (Zarranz et al., 2005) investigated the phenotypic heterogeneity in patients with fatal 
familial insomnia (FFI). FFI is associated with D178N mutation when the mutant allele encodes 
methionine in the polymorphism of codon 129, whereas the encoding of valine by the mutant allele 
would produce the CJD phenotype (Goldfarb et al., 1992). Around 30 FFI families have been reported 
world-wide so far (Kovacs et al., 2002;Montagna et al., 2003;Spacey et al., 2004). Although insomnia is 
the most characteristic early symptom of the D178N-129M mutation, only three patients complained of 
insomnia as the first symptom. Seven patients presented with gait ataxia. Ill-defined psychological 
changes or cognitive decline were the first symptoms in another seven patients, a finding already 
pointed out in the literature (Almer et al., 1999). However, it may happen that in the absence of a 
spontaneous subjective complaint, abnormal nocturnal sleep pattern is under recognised. 
Homozygosity at codon 129 of the prion protein gene increases susceptibility to all forms of prion 
diseases. This polymorphism plays an important role in modulating the clinico-pathological phenotype. 
Padovani et al (Padovani et al., 1998) compared several variables such as age of onset, disease duration, 
histopathological findings, and abnormal PrP deposits between patients homozygous and heterozygous 
at codon 129. They concluded that despite certain significant differences, there was considerable 
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overlap between both groups with regards to age of onset and disease duration. However, in some 
studies, duration of illness is significantly shorter in patients homozygous for methionine than in either 
codon 129 MV or VV patients.  
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1.13 Clinical trials 
The possibility to induce prion diseases in experimental animals that accurately reproduce the main 
clinical and histopathological features of human disease provided an opportunity to evaluate a range of 
experimental therapeutics including small molecules and monoclonal antibodies. Prion diseases are 
particularly tractable for drug development, as animals are naturally susceptible, leading to the 
discovery of prion immunotherapeutics (White et al., 2003), and small molecule therapeutics (Silber et 
al., 2013;Wagner et al., 2013), which suppress prion replication and delay or prevent disease 
progression in mice. There is however no effective therapeutic that modifies the course of the human 
disease.  
There is a need to evaluate the effects of compounds showing effectiveness in laboratory rodents in 
human disease given the pressing unmet need and the fact that prion diseases comprise a clinically 
heterogenous group of syndromes with genetic, acquired or sporadic aetiologies. Development of 
clinical trial methodology is a major challenge. The main obstacles include the fact that the disease is 
rare, clinical phenotype is highly variable and there is difficulty to allocate placebo therapy to patients. 
Collinge et al (Collinge J et al., 2009) provided PRION-1 study design based on patient preference in 
order to evaluate the effect of quinacrine in prion disease. Patients were offered a choice between 
taking the drug, not taking the drug or being randomized to immediate quinacrine or delayed therapy 
(24 weeks).  Patients were assessed at baseline (enrollment) with follow-up at 1, 2, 4 and 6 months and 
then 3-monthly including a standardized clinical examination, the Glasgow Coma Scale (GCS)(Teasdale 
and Jennett, 1974), mini-mental state examination (MMSE) (Folstein et al., 1975), cognitive component 
of the Alzheimer’s Disease Assessment Scale (ADAS-cog)(Rosen et al., 1984), Brief Psychiatric Rating 
Scale (BPRS) (Overall and Gorham, 1962), Clinical Dementia Rating Scale sum of Boxes (CDR-SB)(Morris, 
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1993), Global Impression of Change (GIC)(Schneider et al., 1997), Rankin scale (Rankin J., 1957) and the 
Barthel Activities of Daily Living Index(Mahoney F and Barthel D., 1965). Other prion disease clinical 
trials have also used survival as the primary endpoint (Geschwind et al., 2013;Haik et al., 2014;Otto et 
al., 2004) .  
Quinacrine had no beneficial effect on any of the 8 parameters. However, the Barthel and Clinician 
Dementia Rating Scales were the most valued and powerful scales in a simulated clinical trial of an 
effective therapeutic (Collinge J et al., 2009). A combination of selected subcomponents from these 2 
scales may help to more accurately detect clinically relevant effects in future trials. Based on these 
experiments the Prion Clinic proposed the Medical Research Council (MRC) Prion Disease Rating Scale 
(Thompson et al., 2013). This Scale was applied in our National Prion Monitoring Cohort (NPMC) study. 
NPMC study is a longitudinal, observational study based on detailed clinical assessment of patients, EEG 
recordings, neuropathological analysis, comprehensive neuropsychological assessments and 
quantitative brain imaging at regular intervals to help with the diagnosis and assess disease progression. 
In addition, a number of rating scales were used to assess cognitive function, mobility, self-care, 
continence, feeding, speech and other functions affected by the disease including the new MRC Prion 
Unit rating scale that can be administered over the telephone. The rating scales allow accurate 
monitoring of disease progression that can also serve as a baseline for patient assessments in future 
therapeutic trials. The aim of the cohort study was to allow a unique analysis of the natural history of 
prion disease in ~400 patients and provide a standard for future prion disease trials. 
The information collected during NPMC study has been combined with the PRION-1 trial, an open-label 
patient-preference study carried out to assess the efficacy of quinacrine treatment. In PRION-1 trial 
patients were assessed at baseline and regular follow-up intervals. Neurological assessments and 
 
 
78 
 
 
functional scales were used to objectively assess disease progression. These included standardized 
neurological examination, cognitive assessment - MMSE, ADAS-cog, GCS, CDR, the clinician-interview-
based impression of change plus carer input (CIBIC-P-plus), BPRS, Rankin scale and Barthel activities of 
daily living index. 
Approximately 90-120 people are diagnosed with prion disease annually in the UK(NCJDSU, 2009) with 
sporadic Creutzfeldt-Jakob disease (sCJD) being the most common form of human prion disease (~85%) 
and the most obvious target for clinical trials. As already discussed sCJD typically manifests as a rapidly 
progressive dementia with myoclonus and other neurological signs. Median clinical duration is ~4 
months although forms with short (few weeks) and long durations (>2 years) are well recognised 
(Pocchiari et al., 2004).  
Chen et al (Chen et al., 2013) analysed the survival time and possible influencing factors in patients with 
prion diseases in China. The analysis was based on the surveillance data from Chinese Creutzfeldt-Jakob 
disease (CJD) surveillance network from January 2008 to December 2011. A retrospective follow-up 
survey was performed. Median survival time of 121 deceased patients was 7.1 months, while those for 
sporadic CJD, familial CJD and fatal familial insomnia cases were 6.1, 3.1 and 8.2 months, respectively. 
74.0% of sCJD patients, 100% of fCJD cases and 91.7% of FFI died within one year. The general socio-
demographic factors and clinical findings did not significantly influence the survival times of Chinese 
prion patients.The survival time was comparable with that of many Western countries, but was shorter 
than that of Japan. Patients with acute onset and rapid progression had significantly shorter survival 
times. 
Surveillance data for Creutzfeldt-Jakob disease in China showed that Chinese patients had similar 
epidemiological and clinical characteristics as prion disease patients worldwide. A study by Shi et al (Shi 
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et al., 2008) included 12 Chinese provinces in CJD surveillance system. A total of 192 suspected CJD and 
5 IPD cases were reported; 51 probable and 30 possible sCJD cases were diagnosed. The collected sCJD 
cases distributed sporadically without geographical clustering or seasonal relativity and the highest 
incidences in both probable and possible sCJD cases appeared in the age group of 60-69. The most 
common symptoms were progressive dementia, cerebellar and psychiatric features. The probable sCJD 
patients with both typical EEG abnormalities and positive CSF 14-3-3 protein had more characteristic 
clinical syndromes than those with only one positive test. The polymorphisms at codon 129 of all tested 
reported cases showed typical patterns of Han Chinese as previously reported, with MM homozygosity 
being predominant and MV heterozygosity relatively rare. These data confirmed that Chinese CJD 
patients have similar epidemiological and clinical characteristics compared to CJD patients worldwide. 
In response to the challenges faced during MRC PRION-1(Collinge J et al., 2009) and other human 
trials(Haik et al., 2014) (Geschwind et al., 2013), including the lack of a validated outcome measure, we 
studied UK patients with prion disease to optimise clinical trial methodology and develop a resource for 
open-label studies. In preparation for clinical trials in sCJD, we used item-response modelling to develop 
a functionally-orientated rating scale (MRC Prion Disease Rating Scale, or MRC Scale) with favourable 
statistical properties and weighted the items to represent the most impactful domains reported by 
patients and carers (Thompson et al., 2013).  A combination of disease aetiology, severity, and genetic 
stratification with codon 129, proved to be an extremely powerful approach in our trial model, resulting 
in estimated sample sizes for adequately powered and meaningful clinical trials which are substantially 
smaller than those required in other more common neurodegenerative diseases. 
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II AIMS 
1. To describe extreme examples of phenotypic heterogeneity using case studies and 
reports  
2. To investgate/describe phenotypic heterogeneity using an heuristic clinical scoring 
scheme and the MRC Rating Scale 
3. To establish a semi-quantitative histopathological rating scheme in prion diseases 
4. To test several hypotheses, based on candidate genes, that gene variants may 
determine the clinico-pathological phenotype of definite sporadic CJD 
5. To test a hypothesis that large copy number variants confer susceptibility to prion 
diseases using genome wide association studies 
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III MATERIAL AND METHODS 
2.1 Subjects 
2.1.1 Patient Selection 
Prion disease samples were obtained from patients seen at the NHS National Prion Clinic, St Mary’s 
Hospital and the National Hospital for Neurology and Neurosurgery, University College London NHS 
Foundation Trust, London and collaborating Institutions in Scotland, Germany and Papua New Guinea 
(PNG). The clinical and laboratory studies were approved by the local research ethics committee of 
University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery 
and by Scotland A Research Ethics Committee (Cohort study) or the Eastern Research Ethics Committee 
(PRION-1 study), and relevant bodies in Germany and acting for the Government of PNG. Full 
participation of the PNG communities was established and maintained through discussions with village 
leaders, communities, families and individuals. For the Cohort study and PRION-1 trial informed consent 
was obtained directly from study participants or from relatives, carers or Independent Mental Capacity 
Advocates as appropriate.  The samples and patient details were obtained by the NPC team led by 
Professors John Collinge and Simon Mead. Patients were diagnosed according to the WHO criteria as 
outlined below (http://www.cjd.ed.ac.uk/)(Zerr et al., 2009). 
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a. Sporadic CJD 
Definite: 
A diagnosis of definite sCJD was made by standard neuropathological techniques; and/or 
immunocytochemical analysis; and/or Western blot confirming protease-resistant PrP; and/or presence 
of scrapie-associated fibrils. 
Probable: 
Probable CJD is characterised by a rapidly progressive dementia; and at least two out of the following 
four clinical features: 
i. Myoclonus  
ii. Visual or cerebellar signs  
iii. Pyramidal/extrapyramidal signs  
iv. Akinetic mutism 
AND a positive result on at least one of the following laboratory tests: 
a. a typical EEG (periodic sharp wave complexes) during an illness of any duration; and/or  
b. a positive 14-3-3 cerebrospinal fluid (CSF) assay in patients with a disease duration of less than 
2 years  
c. Magnetic resonance imaging (MRI) high signal abnormalities in caudate nucleus and/or 
putamen on diffusion-weighted imaging (DWI) or fluid attenuated inversion recovery (FLAIR) 
and/or high signal change (“cortical ribbon”) in two cortical areas not known to be liable to 
false positive results 
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AND without routine investigations to indicate an alternative diagnosis. 
Possible: 
Possible CJD is characterised by progressive dementia; and at least two out of the following four clinical 
features: 
i. Myoclonus  
ii. Visual or cerebellar signs  
iii. Pyramidal/extrapyramidal signs  
iv. Akinetic mutism 
AND the absence of a positive result for any of the three laboratory tests that would classify a case as 
“probable” (see tests a-c above) 
AND duration of illness less than two years 
AND without routine investigations indicating an alternative diagnosis 
 
b. Variant CJD (vCJD) 
Variant CJD was first described in the United Kingdom in 1996 (Will et al., 1996) and has been linked 
with exposure to a transmissible spongiform encephalopathy of cattle called Bovine Spongiform 
Encephalopathy (BSE). All patients with vCJD were thought to have acquired the disease in the UK. 
Clinically, vCJD is characterised by early psychiatric or sensory symptoms, which often take the form of 
depression, apathy or anxiety, and occasionally unusual persistent and painful sensory symptoms. 
Neurological signs, including unsteadiness, difficulty walking and involuntary movements, develop as the 
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illness progresses and, by the time of death, patients are completely immobile and mute. The current 
WHO criteria for variant CJD are summarised below: 
 
Diagnostic Criteria for vCJD 
IA Progressive neuropsychiatric disorder 
B Duration of illness >6 months 
C Routine investigations do not suggest an alternative diagnosis 
D No history of potential iatrogenic exposure 
E No evidence of a familial form of TSE 
IIA Early psychiatric features - depression, anxiety, apathy, withdrawal and delusions 
B Persistent painful sensory symptoms 
C Ataxia 
D Myoclonus or chorea or dystonia 
E Dementia 
IIIA EEG does not show the typical appearance of sCJD in the early stages of illness 
B Bilateral pulvinar high signal on MRI scan 
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IVA Positive tonsil biopsy 
A diagnosis of definite vCJD is made by inclusion of IA and neuropathological confirmation of vCJD 
(spongiform change and extensive prion protein deposition with florid plaques throughout the cerebrum 
and cerebellum).  Diagnosis of probable vCJD is made following inclusion of I and 4/5 of II and IIIA and 
IIIB, or I and IVA. Possible diagnosis of vCJD requires I and 4/5 of II and IIIA.  
 
c. Iatrogenic CJD 
Iatrogenic CJD is characterised by a progressive cerebellar syndrome in a recipient of human cadaveric-
derived pituitary hormone; or clinical features typical of sCJD with a recognized exposure risk such as 
antecedent neurosurgery with dura mater implantation. 
 
d. Inherited prion disease 
Inherited prion disease is characterised by definite or probable CJD plus definite or probable CJD in a 
first degree relative; and/or neuropsychiatric disorder plus disease-specific PrP gene mutation. 
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e. Kuru 
The samples from this group were collected by the Kuru Surveillance Team led by Professor Michael 
Alpers and Dr Jerome Whitfield in Papua New Guinea, at the Institute for Medical Research and in the 
villages of Waisa and South Fore. This group also included elderly recent kuru cases with long incubation 
time. Kuru surveillance was conducted by many different investigators prior to 1987 (Gajdusek, Zigas, 
Alpers, Hornabrook and others) and in the period from 1987 to 1995 it was solely led by the Kuru 
Surveillance Team of the PNG Institute of Medical Research. From 1996, the surveillance was reinforced 
with a basic laboratory for sample processing and storage which was established in the village of Waisa 
in the South Fore. The kuru collection comprised young children, adolescents and adults from around 
the peak of the epidemic and elderly recent kuru cases with long incubation times. Samples obtained in 
the 1950s were stored at the NIH, c/o Joe Gibbs, Storey Landis, Carleton Gajdusek and colleagues.  
 
f. Elderly women resistant to kuru 
This group specifically comprised elderly women aged over 50 years at sampling from a region known to 
be exposed to the kuru epidemic. These women were asymptomatic at the time of sampling but were 
thought to have been exposed to multiple cannibalistic feasts by their own recollection. If these women 
have not been resistant to kuru their incubation time would have exceeded 40 years.  
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2.1.2 Healthy Controls 
Publically available data from the Welcome Trust Case Control Consortium, (WTCCC) and Collaborative 
Health Research in the Region of Augsburg (KORA) were used for the analysis. WTCCC is a collaboration 
of over 50 research groups from the UK investigating the genetics of common human diseases, such as 
bipolar disorder, coronary artery disease, Crohn’s disease, hypertension, rheumatoid arthritis, type 1 
diabetes mellitus, and type 2 diabetes mellitus. The WTCCC data were provided following use of quality 
control criteria similar to those often applied as standard in genome wide association studies (GWAS). 
KORA (Collaborative Health Research in the Region of Augsburg) is a research platform based on a 
population-based cohort study of 18,000 adults from Southern Germany. Recruitment started in 
1984/85 and was performed in 4 surveys, followed by repeated investigations at regular intervals. 
Phenotyping was broad, with a focus on cardiovascular and metabolic diseases. KORA biobank has been 
used in more than hundred national and international collaborations.  
As control samples for kuru and elderly women resistant to kuru, the young Fore and neighbouring 
linguistic groups healthy population unexposed to kuru were used. When identified either by 
genealogical data or microsatellite analysis first degree relatives were excluded from the analysis.  
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2.2 Phenotypic heterogeneity – National Prion Monitoring Cohort (NPMC) 
From 2004 UK neurologists were asked by the Chief Medical Officer to refer all patients with suspected 
prion disease jointly to the National CJD Research and Surveillance Unit (NCJDRSU) and to the NHS 
National Prion Clinic (NPC). Communication between both Units several times per week ensured 
exchange of patient details referred to one of the Units. 85% of patients were visited by the NPC within 
five days of referral or NCJDRSU visit. Details of enrolment into the PRION-1 trial and Cohort Study have 
been published (Collinge J et al., 2009;Thompson et al., 2013).  
The National Prion Monitoring Cohort (NPMC) involves comprehensive assessment of all suspected and 
diagnosed prion disease patients in the UK. These include all patients with probable or definite sporadic 
Creutzfeldt-Jakob disease, variant CJD, iatrogenic CJD, and inherited prion disease, according to updated 
diagnostic criteria as discussed above (Zerr et al., 2009). In addition patients thought to have prion 
disease but not meeting formal criteria could be enrolled following review by an expert panel. Patients 
were enrolled at home, hospitals and other healthcare settings around the UK from 2008 onwards 
(Figure 9). 
Together with a specialist nurse I travelled within the UK to assess patients suspected to have prion 
disease following a telephone discussion with the local hospital teams. I met with patients and their 
families, reviewed the clinical notes, took clinical history and performed full neurological examination. 
Where this was possible, I performed a detailed cognitive assessment using short cognitive examination, 
clinical dementia rating, brief psychiatric rating scale and Barthel index of daily living. These data were 
later used to design MRC Prion Disease Rating Scale.   
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I also discussed the possibility of familial CJD and counselled the patient and their relatives for genetic 
studies. I took blood samples for genetic testing and research with the agreement of the patient and 
their family. I reviewed the MRI scan and collected a copy to be reviewed by our neuroradiologist, Dr 
Hyare at the National Prion Clinic. I discussed the neuropathological studies as the only way of obtaining 
definitive diagnosis and obtained written consent if the family wished to proceed with this. I discussed 
the patients with the rest of the team during our weekly clinical meetings.  
Where this was possible, I did a follow-up visit to assess disease progression and advice on the 
symptomatic management. Between the visits I was in regular contact with the local teams and patient 
relatives to advice on symptomatic management and disease progression.  
I enrolled over 100 patients to the National Prion Monitoring Cohort Study and performed follow up 
visits where this was possible. A total number of referrals and eligible patients enrolled is summarized in 
Figure 9.  
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Figure 9 Flowchart of enrolment and selection of patient subset for the main study to develop a clinical trial model 
in sporadic CJD. Figure shows the number of patients recruited in PRION-1 trial and the NPMC study until June 
2014. About a third of patients also had post-mortem studies which allowed a definitive diagnosis to be made.  
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Participants were stratified at enrolment to the Cohort study according to their likely rate of disease 
progression based on diagnosis:  
(I) symptomatic patients with sporadic CJD, variant CJD, iatrogenic CJD and forms of inherited prion 
disease likely to have rapid clinical progression (in the Cohort study, due to 4-octapeptide repeat 
insertion, E200K, D178N, E196Q, E211Q or V210I mutations) 
(II) symptomatic inherited prion disease patients likely to have slow progression (in the Cohort study, 
those with 5 and 6-octapeptide repeat insertion, P102L, P105L, Q212P, A117V or Y163X mutations), and  
(III) at-risk and healthy control individuals.  
Patients in stratum (I) had face-to-face follow-up assessments initially every 6 to 8 weeks.  Several 
outcome measures and rating scales were recorded along with a systematic history and examination. 
The analysis was focussed on the MRC Scale (Thompson et al., 2013). If clinical progression measured by 
the MRC Scale proved to be slower than the expected significant deterioration over this interval (ie 
there was minimal or no change as determined by an overall clinical impression over 6-8 weeks), study 
physicians could decide to reduce follow-up frequency for subsequent assessments (up to a maximum 
interval of 24 weeks).  Patients in strata (II) and (III) had follow-up assessments every 6 to 12 months. 
From May 2010 patients in stratum (I) also had telephone assessments of the MRC Scale up to every 2 
weeks between follow-up assessments.  These were discontinued if there was minimal change between 
consecutive assessments (at worst possible score) (Figure 9). During the visits patients were assessed by 
one clinician and one specialist nurse from the National Prion Clinic team. The initial assessment 
included cognitive analysis, clinical examination and a blood test to look for a possible genetic cause of 
prion disease and take samples for research. Further follow up visits were made to repeat these 
assessments and document accurately disease progression as already discussed. The initial 
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investigations were usually performed at the local hospitals where the patient first presented. Results of 
the blood tests, CSF analysis, brain imaging and EEG recordings were then forwarded to the NPC team. A 
subset of patients was investigated at the National Hospital for Neurology and Neurosurgery (NHNN) 
where they were looked after by the NPC team. They had a clinical assessment by one of the doctors, 
full neuropsychological analysis, MRI using the 3T scanner which allows more detailed imaging and 
EEG/neurophysiology testing. 
The clinical parameters investigated were demographics, presenting clinical features, cognitive deficit on 
presentation, presence of visual symptoms, severity of cerebellar signs, pyramidal features, involuntary 
limb movements and sensory disturbance. The consensus opinion of two study physicians was used to 
allocate each patient to one of seven empirically-recognised clinical subtypes of CJD, based on the 
earliest clinical features which impaired function (not simply the first symptoms as these are often non-
specific and irrelevant to subsequent course). Patients with sCJD were sub-classified into Heidenhain 
variant if visual disturbances such as cortical blindness, oculomotor impairment, and/or visual 
hallucinations were documented as the first presenting symptom (Appleby et al., 2009). The 
Oppenheimer-Brownell variant of sCJD included patients who presented with ataxia in the absence of 
cognitive and visual impairment. Cases presenting with dementia, memory impairment, executive 
dysfunction, language impairment, and/or confusion in the absence of visual, cerebellar, and mood 
symptoms within the first week of illness were classified as the pure cognitive variant. Patients with 
cognitive symptoms and ataxia, without visual impairments and affective symptoms during the initial 
illness phase, were classified as having classic CJD. Patients who were reported to have symptoms of 
depression, mood lability, mania, hypomania, and/or anxiety within the first week of illness were 
classified as having the affective variant if they did not meet inclusion criteria for the Heidenhain group.  
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Thus categories defined were: 
1. visual or Heidenhain subtype associated with cortical blindness, double vision, hemianopia 
2. ataxic subtype 
3. pure cognitive subtype eg. isolated frontal, parietal, speech output or amnestic syndrome or 
combination of these 
4. psychiatric subtype associated with mood disorder, delusional state, marked agitation in the absence 
of ataxia, motor or movement disorder 
5. thalamic subtype in which the key feature was insomnia 
6. stroke-like subtype with abrupt or subacute onset hemiplegia and  
7. classical CJD subtype which does not fit into the above categories, typically a combination of rapidly 
progressive multi-focal dementia, with ataxia and myoclonus.  
 
Data were recorded on paper forms and returned to a central database at the NPC. 
Demographic features and the presenting clinical symptoms coding scheme are summarised in Table 2. 
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Table 2 shows demographic data such as disease duration, age of onset, gender and disease category to include 
sCJD, inherited prion disease, iatrogenic CJD and variant CJD. Disease duration and age of onset were expressed as 
quantitative trait while gender was labelled as categorical value, male or female. Also included were molecular 
genetic data, for example, PRNP codon 129 polymorphism included homozygosity for methionine or valine and 
heterozygosity for methionine/valine labelled as MM, VV or MV. Presenting symptoms at disease onset included 
visual symptoms, ataxia, pure cognitive problems, psychiatric, thalamic, stroke-like symptoms and classical CJD. 
These were categorical values depending on whether they were absent (0) or present (1) at disease onset. 
 
Different clinical features characteristically associated with prion disease were noted during the first 
visit by the National Prion Clinic team. The first visit was prioritised for classification as this was thought 
to be the most informative, particularly for patients suffering with sCJD who deteriorate rapidly and 
often become mute and bed-bound by the second clinical assessment, thus detailed clinical examination 
was difficult to perform. If it was inclear form the history obtained by the family or relative we often 
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referred back to the clinical notes or contacted GP surgeries to check what the patient initially 
complained of.  
Cognitive function was assessed by performing a MMSE and GCS in more severely affected patients. The 
scores were documented as 0-30 and 0-15 respectively. Presence and absence of visual symptoms to 
include cortical blindness, oculomotor impairment and visual distortions were documented as binary 
values. Involuntary limb movements categorised as tremor, myoclonus or chorea were also documented 
as absent or present. Presence or absence of sensory abnormalities particularly important in patients 
with variant CJD was documented as present or absent. Frontal release signs were generated as a single 
figure by adding different components such as glabellar tap, pout reflex, grasp reflex and rooting to 
create a single number from 0-4. Severity of cerebellar signs assessed by examining different systems 
such as gait, limb coordination and eye movements were expressed as a single value 0-17. Severity of 
pyramidal features was assessed by grading the severity of increased tone and reflex abnormalities. A 
value generated by adding these components was thought to be a more accurate representation of the 
severity of each system involvement in prion disease.  
With informed consent, Sanger sequencing of the prion protein gene (PRNP) was done to identify 
mutations that cause inherited prion disease and polymorphic genetic variants (Figure 3) (Wadsworth et 
al., 2008b). With informed consent, autopsy was done in 60% at The National Hospital for Neurology 
and Neurosurgery, Queen Square or other hospitals in the UK; all were reviewed by Professor Sebastian 
Brandner. For the purposes of this study, autopsy results were used to confirm the diagnosis of human 
prion disease and provide tissue for molecular studies. PrPSc type was determined by Western blotting of 
frontal lobe tissue as previously described and according to the London Classification system 
(Wadsworth et al., 2008b). 
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Magnetic resonance brain imaging (MRI) was performed at The National Hospital for Neurology and 
Neurosurgery, Queen Square, or obtained from local hospitals where the patient was initially 
investigated. The basal ganglia, cerebral cortex and thalamus were reviewed by a consultant 
neuroradiologist and each region was independently documented as clinically normal/abnormal for high 
signal change on T2, FLAIR or diffusion weighted imaging. The MRI study was not blinded to diagnosis. 
CSF analysis was done at NCJDRSU or The National Hospital for Neurology and Neurosurgery, Queen 
Square. The 14-3-3 protein was documented as normal/abnormal; S100b protein was recorded in ng/ml 
(normal range <0.55 or <0.61). Electroencephalogram investigation reports from hospitals were 
obtained and recorded as normal/abnormal for background, and whether periodic sharp wave 
complexes were observed. The difficulty with this was that the reports were subjective as reported by a 
Neurophysiologist at the local hospital.  
MRC Scale measurements (see below) were transformed to the underlying Rasch scale used in their 
development using RUMM2030 (Humphry and Andrich, 2008) all subsequent analyses were done on 
this scale which runs from 100 (best possible score) to 0 (worst possible score). 
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2.3 DNA extraction from blood 
DNA extraction from blood was performed using NucleonTM(BACC3 Kit, Nucleon BACC Genomic DNA 
Extraction Kit, GE healthcare, Life Sciences, Amersham, UK). The following protocol was used: 10 ml of 
Reagent A  as part of the ‘Illustra’ DNA extraction kit) was added to a 50 ml polypropylene tube followed 
by 30ml of 18.2MΩ deionised water and then 3-10ml of whole blood.  The mix was centrifuged at 1300G 
for 5 minutes and the supernatant was removed.  2 ml of reagent B was added and the pellet was re-
suspended.  Re-suspended pellet and solution were transferred to a 15 ml polypropylene tube.  500µl of 
sodium perchlorate was added and mixed and the tube was incubated at 650C for 25mins. 2 ml of 
chloroform stored at -200C was added to the tubes and mixed thoroughly. 300µl of Nucleon resin was 
added and centrifuged at 1300G for 3 min. The upper phase was carefully transferred to a fresh 15ml 
tube. 1-2X volumes of 100% ethanol (EtOH) stored at -200C was added and the tubes inverted several 
times to allow DNA precipitation. DNA was spooled out using the glass pipette and allowed to air dry for 
approximately 2 minutes.   DNA was subsequently transferred to TE in a labelled tube and placed at 37oC 
for one hour to assist with re-dissolving. DNA was quantified using a Nanodrop spectrophotometer and 
the concentration was noted. 
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2.4 Allelic discrimination using real time Polymerase Chain Reaction 
All genotyping assays were undertaken on the 7500 Fast Real Time PCR (Applied Biosystems, UK) using 
pre-prepared 96 well plates. DNA plates containing 20ng/µl were used as reservoirs for genotyping 
assays. All reactions contained a total volume of 5 µl mix. 1 µl (20ng) of the reaction volume was added 
as the final addition by multi-channel pipette from the DNA plate. 
Custom Primers and Minor Groove Binder (MGB) (Applied Biosystems, UK) probes were diluted to 90µM 
and 20µM respectively, to represent 100X concentrations, prior to storage. Each well contained the 
equivalent of: 2.5 µl of ABI 2X Genotyping Mix, 0.05 µl forward primer 1 (900nM), 0.05 µl reverse primer 
1 (900nM), 0.05 µl Probe 1 (Probe labelled Vic was assigned to allele 1) (200nM), 0.05 µl Probe 2 (Probe 
labelled Fam was assigned to allele 2), (200nM) and 1.3µl of deionised water and 1µl of DNA. 
Pre-designed probes for the allelic discrimination assays were supplied as a mix at either 20X or 40X 
concentrations (40X mixes were diluted by half following the addition of deionised water). Each well 
contained the equivalent of: 2.5 µl  ABI 2X Genotyping Mix, 0.25 µl of allelic discrimination assay at 20X 
concentration, 1.25 µl of deionised water and 1µl (20ng/µl) DNA. All additions other than DNA were 
made as a cocktail for the number of wells plus 15%.  
Plates were transferred onto SDS7500 Fast Machine for allelic discrimination using standard cycling 
conditions to include pre-read for baseline estimation, amplification run and a post-read. Fam probe 
was assigned to SNP 1 and Vic probe was assigned to SNP 2. Figure 11 shows variation in clustering due 
to the genotype of the target allele. For example in case of codon 129 polymorphism, there are three 
clearly distinguishable clusters representing the three possible genotypes at that locus (the MM, VV 
homozygote and the MV heterozygote polymorphism). 
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2.5 Gene sequencing 
SPRN 
2.5.1 PCR reaction 
MegaMix Blue (containing Taq DNA polymerase, dNTP’s, MgCl2, reaction buffer and an enzyme 
stabiliser, Microzone, UK) was prepared containing primers at 0.5μM sufficient for 25µl reactions on a 
96 well plate.  The primers used are detailed below:  
 
 
 
24μl of premix (containing primers at 0.5µM) was pipetted into each relevant well of a 96-well plate and 
1µl DNA was added to each well from a 96 well DNA storage plate using a multi-channel pipette. The 
plate was sealed and spun down. It was then transferred to a PCR machine (Bio-Rad DNA Engine Tetrad 
2) for DNA amplification using the following cycling conditions: 1) 94C for 5mins, b) 94C for 30secs, c) 
63C for 40secs for 650/1 primers and 65C for 644/5 primers, d) 72C for 45secs, e) steps b)-d) were 
then repeated 34 times and e) 72C for 5mins. PCR products were assessed using electrophoresis of 5µl 
product on a 2% agarose gel stained with ethidium bromide.  5μl of HyperLadder (Bioline Reagents, Ltd, 
UK) was loaded and the gel viewed using the Bioradtransilluminator (Biorad, UK) and Quantity One 
software (BioRad Corporation, USA). 
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2.5.2 PCR product clean-up   
An equal volume of Microclean (Microzone) was added to the PCR product, mixed by vortexing and left 
at room temperature for 5 minutes. Plate was spun at 3000G at room temperature for 40 minutes, 
inverted onto tissue paper and spun again at 40G for 30 seconds to remove fluid. Pellets were 
resuspended by adding 50µl 18MΩ H2O, vortexed and left to stand for 5 min. The plate was vortexed 
again and spun down. 
 
2.5.3 Sequencing Reactions 
For each sequencing reaction a premix was prepared to include 1µl of BigDye (Applied Biosystems), 5µl 
Better Buffer (Microzone), 3μl betaine (5M, Sigma) and 4.25μl 18MΩ ddH20.  13.25μl of the mix was 
pipetted into each well of a 96 well plate. 0.75μl of the sequencing primer (as detailed above) was 
pipetted into their respective wells and 1μl of PCR product was added to each well. Plate was covered, 
spun down and placed on a PCR machine with the following cycling conditions: 1) 96C for 1 minute, 2) 
96C for 10 seconds, 3) 50C for 5 seconds, 4) 60C for 4 minutes, steps 2)-4) were then repeated 24 
times. 
 
2.5.4 Sequencing Product Clean-up 
3.75µl of 0.125M EDTA (Sigma-Aldrich) was added to each sequencing reaction. 45µl 100% ethanol was 
added to each reaction, mixed by pipetting and left at room temperature for 15 minutes. Plate was spun 
at 3000G for 30 minutes at 4C, inverted and spun again up to 185G. 60µl 70% ethanol was added and 
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the plate was spun at 1650G for 15 minutes at 4C. Plate was inverted and spun at 185g for 1 minute. It 
was then placed on a PCR block, uncovered, at 37C for 5 minutes to remove final traces of ethanol. 
 
2.5.5 Capillary electrophoresis of Sequencing Products 
10µl Hi-Di (Applied Biosystems) formamide loading solution was added to each well. Plate was covered, 
spun down and samples denatured by placing on PCR block held at 95C for 2 minutes, and transferred 
to ice/4C PCR block immediately for 2 minutes. Plates were transferred onto the sequencing machine 
(Applied Biosystems 3730XL) and run using standard protocol (Big Dye 1.1). Both raw and analyzed data 
were viewed using the Sequence Analysis Software Seqscape (Life Technologies, UK). Signal strength of 
over 8000 relative fluorescence units (RFU) did not produce adequate data and these samples were re-
injected with a shorter injection time.  Where the signal strength was too low, the base-line was too 
noisy and the samples were re-injected with a longer injection time. 
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2.6 Genome-wide association analysis (GWAS) 
2.6.1. DNA sample selection 
DNA for genome wide association analysis was obtained from patients with prion disease diagnosed 
according to the above criteria (see section 2.1.1) (Lukic et al., 2011;Zerr et al., 2009). Most patients 
were of white British ethnic origin and all patients of known non-white ethnic origin were excluded. This 
information was based on names and geographical location for some samples. The rest of the samples 
were checked using principal component analysis (as discussed below, Quality control 2.5.3) and all the 
ethnic outliers were excluded. Study also included patients with kuru and women resistant to kuru.        
A cohort of German patients who all had neuropathologically confirmed sCJD was used in our replication 
study. These patients all had a classical presentation of sCJD. Genomic DNA was extracted from 
peripheral blood and brain tissue was used as a source of genomic DNA for patients where blood was 
not available using the methods discussed. Amplified DNA was used for a small number of samples. 
Samples were checked for degradation and amplified as discussed. 
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2.6.2 Genotyping 
Cases included 680 German definite sCJD samples, 579 UK sCJD, 133 UK vCJD (and 5 non-UK vCJD), 165 
kuru samples, 125 kuru resistant women and 286 geographically matched control individuals. All cases 
were genotyped on an Illumina 660K platform. Publicly available KORA controls were genotyped on 
550K Illumina arrays and 5667 WTCCC2 controls on the Illumina1.2M Custom Duo array. There was no 
discrepancy between reported and genetic gender in the cases. Prior to analysis, samples were removed 
from the WTCCC2 data set by their prescribed criteria. The WTCCC2 chose criteria to be similar to those 
often applied as standard in GWA studies. Individuals were excluded if they displayed a disproportionate 
number of heterozygous or missing calls. Related individuals were excluded according to identity by 
descent (IBD) (as discussed below). Individuals were excluded on the basis of ancestry if they differed 
from the majority of the collection according to a principle component analysis of HapMap individuals. 
Following quality control, a total of 467 WTCCC2 individuals were removed leaving 5200 samples which 
comprised of 2630 males and 2570 females. 
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2.6.3 Quality control 
Confounding can be a major source of bias in population-based case-control studies and is caused by 
underlying differences between the case and control groups other than those directly under 
investigation. In the case of genotype distribution, the main source of confounding is population 
stratification, in which genotypic differences between cases and controls are generated because of 
different population origins rather than any effect on disease risk (Cardon and Palmer, 2003). Efforts 
were made to remove or reduce the effect of population stratification through the removal of 
individuals of divergent ancestry. Principal components analysis (PCA) was used to identify and 
subsequently remove individuals with large-scale differences in ancestry (Patterson et al., 2006;Price et 
al., 2006). PCA is a multivariate statistical method used to produce a number of uncorrelated variables 
or principal components from a data matrix containing observations across a number of potentially 
correlated variables. The principal components were calculated so that the first principal component 
accounts for as much variation in the data as possible in a single component, followed then by the 
second component and so on. When using PCA to detect ancestry the observations were the individuals 
and the potentially correlated variables were the markers.  
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2.7 Copy Number Variants (CNV) analysis 
2.7.1 CNV analysis in Genome Studio 
The CNV Partition (Bead Studio, Illumina Infinium) plug-in algorithm is supported by Genome Studio. It 
uses a recursive partitioning approach to provide copy number estimates, as well as copy number 
bookmarks. It identifies regions of the genome that are aberrant in copy number using two Infinium® 
Assay outputs: the log R ratio (LRR) and B allele frequency (BAF). Since LRR is the logged ratio of 
observed probe intensity to expected intensity, any deviations from zero in this metric are evidence for 
copy number change. BAF is the proportion of hybridized sample that carries the B allele as designated 
by the Infinium Assay. In a normal sample, discrete BAFs of 0.0, 0.5, and 1.0 are expected for each locus 
representing AA, AB, and BB. It is fast to analyse and report (~1min per sample) and detects CNV regions 
and estimates CNV values with high accuracy. It identifies small CNV regions (<100 kb) and provides 
confidence score for each locus. 
There are 2 further softwares that allow CNV detection, Quanti SNP and Penn CNV. Each algorithm has 
different advantages and disadvantages such as speed, accuracy of CNV detection and ability to detect 
small versus large deletions and duplications. In order to select the most appropriate algorithm we 
analysed a 10 sample project using all three softwares. The project was created in Genome Studio using 
a unique sample sheet. The performance and accuracy of 3 different CNV softwares was initially 
assessed. Following CNV analysis, PLINK, a genome wide analysis tool was used to estimate type, 
genomic location and frequency of CNV deletions and duplications. It allowed estimation of genome-
wide CNV burden as well as specific association analyses. The primary analysis was a chi2 test with the 
use of empirical p values. Three different algorithms were used to detect copy number value, 
confidence score, chromosomal location and copy number size. A preliminary CNV analysis was 
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performed with a 10 sample project using 3 different algorithms: CNV Partition, Penn CNV and Quanti 
SNP. It showed the total number of CNV deletions/duplications detected as well as the lowest and 
highest confidence value. CNV Partition detected the highest number of CNVs of even small CNV 
deletions and duplication with a high CNV confidence value suggesting good dependability and was 
therefore used for further analysis of the complete sample set. 
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2.7.2 Quality Control 
Prior to analysis, samples were removed from the data sets by their prescribed criteria: 
1. If there were fewer than 20 SNPs/CNV markers and if they had a low SNP density (>15kb per 
marker).  
2.  CNVs were excluded if > 50% of their length overlapped regions of segmental duplications, as 
defined by the ‘Segmental Dups’ track in UCSC. 
3. We joined any CNVs that appeared to be artificially split by the algorithm if the length of the 
sequence between two CNVs was <50% of the length of the larger CNV. Consistent with previous 
CNV studies in a closely related disorder (Chapman et al., 2013), we analyzed only rare CNVs (<1%) 
due to the problems of reliably calling more common CNVs with standard SNP arrays. We filtered 
out the common CNVs present in >1% of each sample using PLINK and performed association tests.  
4. All of these CNVs were found at <1% frequency in the control population and included more than 20 
markers 
5. The CNVs were separated according to size as: >100kb, >500kb and >1MB and quality score of >50 
was used.  
6. Of the total 27 >1000kb duplications seen in European case samples (from Germany, France and 
UK), 3 overlap in a region of chromosome 16 (NCBI build 36, 15,387,380-16,197,033) comprising 7 
genes, although this same region was involved in 6 large duplications in control samples. Due to 
differences related to platform and filtering we have not directly compared these frequencies with 
other studies.  
7. In PNG sample analysis a 1% filter was applied as the control population was small, and the 
population genetics of the Eastern Highland region has not been studied in detail.   
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Individuals were excluded if they displayed a disproportionate number of heterozygous or missing 
calls. Related individuals were excluded according to identity by descent (IBD). Individuals were 
excluded on the basis of ancestry if they differed from the majority of the collection according to a 
principle component analysis of HapMap individuals. Gender discrepancy between the supplier and 
the inferred gender also led to sample removal. Individuals were excluded if the mean of their A and 
B allele intensities were outliers when compared with the sample at large. Samples were excluded 
from the Genome Studio project if they had a low average SNP genotyping call rate (<98%). For CNV 
Partition project cases (670K array) and controls (1.2M Custom Duo) were merged using a unique 
sample sheet. Only probes common to both projects were used and chromosome X was excluded 
from the analysis to avoid false positive associations created by the software due to the absence of 
2nd chromosome X in males. 
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2.7.3 CNV analysis in UK patients 
A total of 708 UK samples (509 sCJD, 123 vCJD and 76 inherited prion disease samples) were analysed 
and compared to 902 Welcome Trust controls. Patient samples were analysed on Illumina Human-Hap 
670 array and the publicly available WTCCC2 controls on 1.2M Custom Duo array. The data was 
imported into Genome Studio and the 2 projects were analysed using CNV Partition. When more case 
and control samples became available the analysis was repeated using Penn CNV.  
 
2.7.4 Real time PCR in UK sporadic CJD 
In order to validate the findings following genome wide CNV analysis, real time PCR was used for 
validation. All genotyping assays were undertaken on the 7500 Fast Real Time PCR machine (Applied 
Biosystems) using pre-prepared 96 well plates containing DNA at 20ng/ml. 1 µl of DNA was added to 
reaction premix as the final addition. Each well contained: Applied Biosystems 2.5 µl 2X Genotyping Mix, 
0.25 µl of 20X allelic discrimination assay mix, deionised water 1.25 µl and DNA 1.0 µl (20ng/µl). Plates 
were transferred onto the SDS7500 Fast Machine for allelic discrimination using standard cycling 
conditions to include pre-read for baseline estimation, amplification run and a post-read. 
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2.7.5 CNV analysis in German sporadic CJD 
In order to replicate findings detected in UK patients CNV analysis was performed in German definite 
sCJD patients. A total number of 635 German sCJD cases and 822 control samples were analysed. The 
cases were analysed on 670K Illumina Genome Studio platform and controls on an older 550K Illumina 
platform. The 2 projects were merged using a unique sample sheet. CNV analysis was performed in 
Genome Studio using CNV Partition and PLINK for case/control association analysis.  
 
2.7.6 Validation using real time PCR 
In order to confirm the findings following genome wide CNV analysis, real time PCR was used for 
validation. All genotyping assays were undertaken on the 7500 Fast Real Time PCR machine (Applied 
Biosystems) using pre-prepared 96 well plates containing DNA at 20ng/ml. 1 µl of DNA was added to 
reaction premix as the final addition. Each well contained: Applied Biosystems 2.5 µl 2X Genotyping Mix, 
0.25 µl of 20X allelic discrimination assay mix, deionised water 1.25 µl and DNA 1.0 µl (20ng/µl). Plates 
were transferred onto the SDS7500 Fast Machine for allelic discrimination using standard cycling 
conditions to include pre-read for baseline estimation, amplification run and a post-read. 
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2.7.7 Statistical analysis 
Data management and statistical analysis were performed using PLINK (Renteria et al., 2013). PLINK is 
an open-source whole genome association analysis toolset, designed to perform a range of basic, large-
scale analyses in a computationally efficient manner. In our study PLINK was used for 
genotype/phenotype data analysis that has already been called from raw intensity data.  
Cohorts of CJD patients were compared with relevant controls using allelic and genotypic models. Age at 
death (or sampling) was used as a quantitative trait in analysis of kuru patients. Age at clinical onset 
expressed as deviation from the mean expected onset for each IPD mutation was used as a quantitative 
trait in the IPD cohort. Meta-analyses were done using PLINK. Imputation was done using IMPUTE2 
using data provided by the WTCCC and 1000 genomes project. IMPUTE2 uses a fine-scale recombination 
map and a densely genotyped reference panel to "fill in" missing genotypes in a study dataset, which 
might consist of cases and controls typed on a commercial SNP chip. By estimating the genotypes of 
SNPs that were not in the original study data, imputation allows a much larger set of SNPs to be tested 
for association. This can increase both the power to detect association signals and the signal resolution 
near a causal or associated variant. 
Conditional analyses were done at the PRNP locus using rs1799990 in additive and genotypic models. 
Stratified analyses were done using all three genotypes at rs1799990. Age of clinical onset in UK sCJD 
was used either as a quantitative trait or as a threshold for stratification (include only sCJD age at onset, 
60 years). 
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Case–control labels were permuted within each of the four CJD cohorts, and a genome-wide meta-
analysis was performed on the permuted data set using the same analysis as for the observed data set. 
This was repeated 500 times generating crude estimates for the significance of this statistic.  
The statistical case/control analysis for a given quantitative trait was analysed using PLINK commands 
based on Wald parametric statistical test. The quantitative phenotypes analysed were: 
1. Cognitive function 
2. Visual symptoms 
3. Involuntary limb movements 
4. Sensory abnormalities 
5. Frontal release signs 
6. Cerebellar features 
7.    Pyramidal features 
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2.8 Neuropathological analysis in prion disease 
Ethics approval for these studies was obtained from the Local Research Ethics Committee of UCL 
Institute of Neurology, National Hospital for Neurology and Neurosurgery. Informed consent was 
obtained from relatives to use tissue for research. Clinical data, disease history, PRNP mutation and 
polymorphism at codon 129 were available for majority of cases analysed.  
Autopsies were carried out by Professor Brandner and Dr Reiniger laboratory in a post-mortem room 
designed for high risk autopsies. Brain tissue was stored in buffered formalin. The frontal, temporal, 
parietal, occipital lobes and cerebellum were sampled and immersed in a 10% buffered formalin for up 
to one week, immersed into 98% formic acid for one hour and post fixed for 24 hr in 10% buffered 
formalin. Tissues were then processed through graded alcohols and embedded in paraffin wax.  
 
2.8.1 Antibodies, immunohistochemistry and electron microscopy 
Antibody staining and immunohistochemistry was performed by the neuropathology team using anti-
PrP ICSM35 D-Gen Ltd, London, UK raised in Prnp0/0 mice against recombinant human PrP (Isaacs et al., 
2008) and anti-PrP KG9 TSE resource Centre, Roslin Institute University of Edinburgh (Bell et al., 1997). 
ICSM35 recognises residues 93-102 and KG9 binds to residues 140-180 of human PrP. 
Immunofluorescence and preparation for transmission electron microscopy was performed by the 
neuropathology team using thin tissue blocks. Resin sections were stained with Toluidine blue and 
suitable regions selected for tissue EM. Images were recorded on a 4Megapixel SIS Megaview digital 
camera.  
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2.8.2 Examination and quantification 
Gross inspection of the whole brain in sporadic Creutzfeldt-Jakob disease often did not reveal obvious 
abnormalities. More commonly, there was some degree of cerebral atrophy, which was diffuse or focal. 
Based on the preferential involvement of specific regions the analysis involved assessment of frontal, 
parietal, temporal, occipital and cerebellar lobes. Each of the lobes was investigated for the presence 
and distribution of spongiform degeneration and prion protein deposition. In order to investigate a 
possible multiple protein pathology and neuropathological similarities with other neurodegenerative 
conditions we looked at the presence of amyloid-β and phosphorylated tau in brains from prion disease 
patients. Similarly, we investigated the association of neuropathological abnormalities in sCJD, inherited 
prion disease, iatrogenic and variant CJD with polymorphism at codon 129 of the prion protein gene, age 
at disease onset and disease duration. 
I was initially taught by Professor Brandner and Dr Reiniger on how to recognise characteristic 
pathological CJD changes and grade them according to the devised criteria. Together with Dr Reiniger I 
performed of spongiform chage, prion protein, amyloid-β and tau protein distribution and deposition in 
prion disease patients. I performed scoring of a subgroup of slides. The aim of our study was to ascertain 
the extent to which misfolded proteins associated with other neurodegenerative diseases are found at 
autopsy examination of human prion diseases. 
Table 5 summarises key features we observed in the neuropathological analysis. Prion protein 
accumulates to form granular, synaptic, plaque deposits and peri-neuronal net. The deposits vary in 
severity and were graded from mild, moderate to severe. In our study the grading was based on the 
appearance according to an example image (Figure 5, introduction). A more detailed description of 
spongiform change, PrP, amyloid-β and tau deposits is summarised in Table 5. 
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Table 5. describes typical changes associated with prion protein, amyloid-β and phosphorylated tau deposition. 
The changes are scored from 1-3 to indicate mild, moderate and severe deposition. In some cases where tau 
deposion was very high a score of 4 was used. This was rare and was only used to score occasional very heavy tau 
deposits (The table shows only grading from 1-3 for each of the proteins).  
 
Neuropathological changes in prion disease such as neuronal loss and gliosis accompany many other 
conditions of the central nervous system, whereas spongiform change is moderately specific to prion 
diseases. Spongiform change is characterised by diffuse or focally clustered, small, round or oval 
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vacuoles in the neuropil of the deep cortical layers, cerebellar cortex or subcortical grey matter, which 
might become confluent (Figure 5, Introduction). The semi-quantitative analysis was performed based 
on the typical pathological appearance. The deposits were graded from mild to severe using scores 0-3. 
In some cases where tau deposion was very high a score of 4 was used. This was rare and was only used 
to score occasional very heavy tau deposits. (The table shows only grading from 1-3 for each of the 
proteins). The severity of the abnormal appearance was subjective and established by two different 
observers performing analysis together (AL was one of the two). One slide for each of the areas frontal, 
parietal, temporal, occipital lobe and cerebellum were analysed and the final score taken as an average 
of the above areas.  The examination was performed on a LEICA DM2500 with a 40X Pan Apochromat 
objective. The typical pathological features that were looked for when the scoring was performed are 
illustrated in Figure 5 in Introduction. 
In addition to prion protein deposits, β-amyloid and hyperphosphorylated tau were investigated in the 
brains of patients with prion disease. These were scored according to intensity but also the typical 
distribution of deposits. Table 6 shows how a single score was obtained to illustrate both distribution 
and intensity of each of the three proteins. For prion protein a single score was generated depending on 
whether the deposits were plaques or synaptic. They were associated with a score from 1-3 to indicate 
severity of the deposition (for example score S2 would indicate moderate synaptic prion protein 
deposition). Amyloid-β deposits were labelled as P or A depending on whether they formed diffuse or 
dense deposits and were associated with a score from 1-3 depending on the severity of deposition (eg. 
score A2 would indicate moderate diffuse amyloid-β deposition). Tau deposits usually occurred as 
threads or stubs and were graded from 1-4 depending on the severity of deposition. 
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Table 6 shows combined score generated to demonstrate both the quality and intensity of prion protein 
hyperphosphorylated tau and amyloid-β deposition. Where the 2 scores were different the highest score was used 
to generate the combined score that best describes the protein deposits.  
 
Amyloid-β forms diffuse and plaque deposits, whereas tau phosphorylation usually accumulates in the 
vicinity of amyloid-β and prion protein. Tau protein can however, be present independently in which 
case it has a slightly different appearance.  
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Due to its varied aetiology and appearance quantitative assessment of hyperphosphorylated tau 
deposits was done using a heat map (Figure 12) to enable counting of the number of tau rods and 
granules in a high power field. The heat map displays the counts of hyperphosphorylated tau inclusions 
in a data matrix. Larger values are represented by dark red or black squares (pixels) and smaller values 
by lighter squares. A parallel tissue section was also produced and stained for prion protein to assess the 
PrP deposition in the same area that corresponds to the heat map. Figure 12 shows the count and 
colour coded representation (heat map). The tau inclusions were counted in different areas for each of 
the lobes as illustrated in the figure. The corresponding prion protein deposition is also demonstrated. 
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Figure 12.The heat map illustrates quantitative assessment of hyperphosphorylated tau deposits. Figure shows the 
count and colour coded representation. Middle column shows a parallel tissue section, stained for abnormal PrP 
showing deposits corresponding to the tau heat map. Right column shows high power magnification of the areas 
indicated by a blue square in the heat map and in the overview of the PrP labelled section (corresponding to 
roughly 25% of the blue square). (Figure copied and adapted from Tau, prions and Aβ: the triad of 
neurodegeneration. Reiniger L, Lukic A, Linehan J, Rudge P, Collinge J, Mead S, Brandner S. Acta Neuropathol. 2011 
Jan;121 (1):5-20.)  
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III  RESULTS 
3.1 Phenotypical heterogeneity and susceptibility locus in variant CJD- clinical case reports 
Prion diseases show marked phenotypic heterogeneity in terms of disease duration, age at onset, 
clinical, investigation and neuropathological features. These differences may be genetically determined, 
associated with a particular prion protein strain or specific environmental factors. In order to illustrate 
this heterogeneity we provide clinical and investigation findings of 2 patients with clinical presentation 
typical of sCJD who were subsequently diagnosed with vCJD following neuropathological analysis, 
confounding expectations. 
We also present 2 cases with an unexpected polymorphism at codon 219. All neuropathologically 
proven vCJD patients were homozygous for methionine at codon 129. In this study we describe 2 
patients with diagnosis of vCJD and a rare polymorphism at codon 219. Heterozygosity at codon 219 
(E219K) is known to have a protective effect in Japanese patients with sCJD (Shibuya et al., 1998). This 
finding is intriguing as the polymorphism appears to be neutral or may even confer increased 
susceptibility to vCJD. We also wished to test the hypothesis that the prion protein coding sequence is a 
crucial determinant of clinical phenotype. 
 
 
 
 
 
 
121 
 
 
3.1.1 Atypical clinical presentation in two patients with variant CJD, correctly diagnosed following 
neuropathological analysis. 
 As already discussed variant CJD (vCJD) has been causally linked to BSE and typically affects young 
individuals in contrast to sCJD (Will et al., 1996). It is associated with a rapid cognitive decline, 
psychiatric and sensory disturbance. In patients with vCJD, the PrPSc is deposited in the lymphoreticular 
system and has a characteristic appearance following partial protease digestion and Western blotting 
(Wadsworth et al., 2001). MRI typically shows high signal intensity in the pulvinar nucleus on T2 
weighted images (Will et al., 2000). Pre-mortem diagnosis can be assisted by tonsillar biopsy (Hill AF et 
al., 1999). Accurate pre-mortem diagnosis is important for patients and their families, in terms of a 
differential diagnosis including treatable causes, prognosis and choices about experimental therapeutics.  
Phenotypic variability due to atypical clinical presentation in vCJD can lead to misdiagnosis and have 
implications regarding potential experimental therapeutics (Allroggen et al., 2000). We describe clinical 
and investigation features in 2 patients prompting a diagnosis of sCJD by the updated WHO criteria 
(http://www.cjd.ed.ac.uk/documents/criteria.pdf). The correct diagnosis of vCJD was made at autopsy 
in both cases. Both patients had MRI findings typical of sCJD with greater signal hyperintensity in the 
caudate and putamen than the pulvinar nuclei which was further confirmed with quantitative analysis. 
The age at presentation in the first patient was unusually late at 54.  
CASE 1 
A 54 years old lady presented with a 7 month history of episodic memory abnormalities, depression, 
occasional paranoid delusions, somnolence and vivid dreams. She subsequently developed in-
coordination and intermittent upper limb twitching and her daughter noticed a breathing abnormality 
characterized by heavy breathing and ‘humming’. Her gait became unsteady and she required assistance 
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for walking. She developed an obvious short-term and topographic memory deficit. On admission to 
hospital her MMSE was 11/30 and she had a broad-based, ataxic gait. During a six week admission she 
continued to deteriorate in terms of mobility, speech and swallow. When examined by the NPC she was 
drowsy, disoriented in time and place and responded verbally with a few appropriate words. On cranial 
nerve examination there was vertical gaze palsy, improved by doll’s head movements, implicating a 
supranuclear component and a prominent pout reflex. In the upper limbs there was an alien limb 
phenomenon and cogwheel rigidity which was more pronounced on the left. In the lower limbs there 
was bilateral spasticity. The tendon reflexes were brisk throughout with extensor plantar responses. She 
had great difficulty in standing due to a combination of ataxia and apraxia and was doubly incontinent. 
She continued to deteriorate becoming bed-bound and mute and died 11 months into the illness. The 
MRI showed abnormal high signal in the caudate and basal ganglia which was greater than in the 
thalamus as shown by quantitative studies (Figure 13). The CSF analysis was unremarkable apart from 
being positive for 14-3-3 protein. The EEG revealed generalized slow wave activity. Extensive 
investigations to exclude an autoimmune, inflammatory and a para-neoplastic disorder were negative. 
PRNP gene analysis revealed no mutations and the codon 129 genotype was methionine homozygous. 
The post-mortem examination was diagnostic of vCJD.  A detailed neuropathological examination of the 
brain tissue revealed multiple 'florid' plaques in the cerebral and cerebellar cortex, severe spongiform 
change,  severe thalamic gliosis and marked accumulation of the disease-associated prion protein in 
diffuse and pericellular deposits in the cerebrum and cerebellum (Figure 14). 
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Figure 13. Diffusion Weighted Imaging (DWI) at two levels demonstrate hyperintensity in the basal ganglia 
bilaterally. The signal intensity ratios of the deep grey nuclei compared to white matter performed are: caudate 
234.7/48.6; putamen 220.6/48.6 and pulvinar 195.1/48.6. High signal in the basal ganglia was greater than in the 
thalamus, thus the pulvinar sign was not present as expected in vCJD. The FLAIR images were degraded by 
movement artifact and were therefore undiagnostic although the high signal in the basal ganglia appeared greater 
than that in the thalamus (Images kindly provided by Dr Hyare). 
 
Figure 14. There is a severe spongiform change accompanied by gliosis in the cortex with striking depositions of 
florid plaques which often appear in clusters and are typically seen in vCJD (H&E stain, 40x) (Images kindly 
provided by Prof Brandner and Dr Reiniger). 
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CASE 2 
A 24 years old patient complained of pain in the right leg attributed to heavy manual work which 
spontaneously resolved within 2 weeks.  Two months later he became unsteady, speech was slurred and 
his personality changed in that he became socially withdrawn and apathetic. He had several falls and 
intermittent episodes of incontinence which did not appear to cause him any concern. He was admitted 
to the hospital and his behaviour continued to deteriorate with aggressive outbursts and increasing 
withdrawal. There was a suggestion of pre-morbid personality change as during the previous 2 years at 
school his academic achievement had declined and he had subsequently dropped out of a course in 
graphic design. On admission the examination revealed moderately severe cognitive impairment with a 
MMSE of 12/30.  He performed poorly on frontal executive tasks, had some language impairment and 
dyscalculia with intact visuo-perceptual functions. There was a moderate dysarthria. Muscle tone was 
increased in both upper and lower limbs and reflexes were symmetrically brisk with extensor plantar 
responses. He had a markedly ataxic gait requiring assistance of two to walk. He continued to 
deteriorate and when re-examined by NPC he could only utter occasional words, had moderate 
dysphagia, bilateral grasp reflexes and occasional myoclonic jerks. Myoclonus became more severe with 
intermittent choreiform movements in the arms. He subsequently became essentially mute, 
deteriorated in terms of mobility and swallow and died 9 months into the illness. The MRI of the brain 
showed abnormal signal return from the basal ganglia and dorso-medial thalamus and the frontal 
cortical grey matter especially on the left on T2, FLAIR and DWI sequences (Figure 15).  The EEG showed 
diffuse slow wave abnormality. The CSF examination was unremarkable apart from a greatly elevated 
tau protein (14-3-3 protein was negative). Extensive investigation failed to reveal an alternative auto-
immune, paraneoplastic or inflammatory cause for the illness. PRNP gene analysis showed no mutations 
and the codon 129 genotype was methionine homozygous. 
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Figure 15. MRI image demonstrates hyperintensity in the caudate and putamen which is greater than in the 
thalamus on DWI. The signal intensity ratios for the deep grey nuclei compared to white matter performed on 
image are: caudate 201.2/137.4; putamen 181.7/137.4 and pulvinar 165.7/137.4. Therefore, the pulvinar sign was 
not present as expected in vCJD. The appearance on FLAIR images also supported these findings (Images kindly 
provided by Dr Hyare). 
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Figure 16. Immunohistochemistry for abnormal prion protein demonstrates frequent formation of small to 
medium sized plaques which frequently form confluent aggregates. In addition, there is intracellular deposition of 
prion protein forming stellate deposition (ICSM35 antibody, 40x). The findings are consistent with vCJD. (Images 
kindly provided by Prof Brandner and Dr Reiniger). 
 
Phenotypic variability as demonstrated by an unusually old age at disease onset and sporadic-like MRI 
appearance is not commonly reported in vCJD. One of the challenges faced by clinicians is dealing with 
the variability of clinical symptoms, signs and investigation findings in prion disease, which may pose a 
serious diagnostic challenge as evidenced by the cases described. It may result in a delayed diagnosis 
and delayed inclusion in therapeutic trials when relatives/patients desire to do so. In our experience of 
60 biopsies, by far the largest series worldwide, tonsillar biopsy has 100% sensitivity and specificity, at 
any stage of the disease (Lukic et al., 2011). Prion protein deposition in the tonsil can be patchy, and at 
least 20 germinal centers need to be examined (Ironside et al., 2000).  A recent study shows that 
detection of disease-associated prion proteins in blood is possible and may allow a rapid, non-invasive 
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screening of individuals with suspected vCJD (Edgeworth et al., 2011;Jackson et al., 2014) although the 
test has been positive in sCJD samples. This may be of particular importance for the diagnosis of atypical 
cases in the evolution of vCJD outbreak associated with an altered clinical phenotype, investigation 
findings and genetic analysis. The challenge remains in ascertainment of genetic loci that may be 
associated with the phenotypic variation by altering the pathway of protein misfolding or by their 
involvement in the mechanism of chaperoning or degrading misfolded proteins or alternatively the 
genes involved in determining a prion strain. A better understanding of these genes may allow an insight 
into the pathogenesis of prion protein misfolding and allow stratification to help clinical trials or improve 
recognition of diagnostic markers in prion disease.  
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3.1.2 PRNP codon 219 may represent a susceptibility polymorphism to variant CJD 
As already discussed, variant Creutzfeldt-Jakob disease (vCJD), an acquired prion disease transmitted by 
exposure to bovine spongiform encephalopathy prions, was first recognized in the mid-1990s (Knight, 
2006;Will et al., 1996). More than 200 cases have been identified worldwide, most in the United 
Kingdom. In neuropathologically confirmed vCJD (or probable vCJD according to WHO criteria), every 
patient who has undergone genotyping to date has been homozygous for methionine at a common 
polymorphism of the prion protein gene (PRNP) at codon 129. This genetic variant has profound 
susceptibility effects across all categories of prion disease (Collinge, 2005). However, two thirds of the 
population carries this genotype whereas only around 220 patients developed clinical vCJD in a 
population widely exposed to BSE implicating the potential importance of other genetic loci in 
susceptibility to disease.  A further genetic polymorphism has been reported at codon 219 in which 
guanine (G) is replaced by adenine (A) in the first position of codon 219, resulting in substitution from 
glutamic acid (E) to lysine (K). This polymorphism is common in east Asians, with an allele frequency of 
0.06 in the healthy population. It has not been reported in patients with sCJD in the Korean and 
Japanese populations and is, therefore, considered strongly (perhaps completely) protective against this 
disease (Jeong et al., 2005;Shibuya et al., 1998). Eleven patients and controls with E219K all had Asian 
ethnicity or ancestry based on a heterogenous diagnostic referral series totaling more than 1800 
samples at the MRC Prion Unit (Beck et al., 2010) We detected this polymorphism in 2 patients with 
clinical and investigation findings consistent with vCJD suggesting its possible role in susceptibility to this 
form of prion disease. We investigated the possibility that PRNP variants are determinants of clinical 
phenotype in variant CJD. 
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CASE 1 
A 34-year-old British man presented in 2004 with a few months’ history of personality change and mild 
episodic memory impairment. He became obsessive, socially withdrawn, and apathetic, and he began to 
experience difficulty with managing finances. Several months later his gait was noted to be unsteady, 
and he was intermittently incontinent of urine. Subsequently, he developed clumsiness in the upper 
limbs and difficulty manipulating fine objects, and he could no longer use a knife and fork. His gait 
became increasingly unsteady, and he started to fall. His mood deteriorated significantly, and he began 
to demonstrate suicidal ideation. He was soon unable to perform his usual daily activities. He 
subsequently became doubly incontinent, started to experience choreiform movements in the upper 
limbs, and he spoke less. He seemed to respond to visual hallucinations and experienced a disordered 
sleep-wake cycle. Physical examination revealed a bilateral grasp reflex. Involuntary choreiform limb 
movements were present, in addition to purposeful rubbing of his chest and hair. Spontaneous 
myoclonus of the lower limbs was present. His speech was hypophonic, mumbling, and monosyllabic. 
His gait was ataxic, with reduced arm swing, and he was unsteady on turning. There was increased tone 
and preserved power in all 4 limbs. His reflexes were symmetrically brisk, and the plantar responses 
were extensor bilaterally. His Mini-Mental State Examination score was 12 of 30 at the time of 
investigation, 12 months after symptom onset. Investigation findings were positive for cerebrospinal 
fluid 14-3-3 protein and a raised S-100B protein level of 1.36 ng/mL (reference range <0.38 ng/mL), with 
a cerebrospinal fluid protein concentration of 0.07 g/dL (reference range, 0.02-0.05 g/dL) and otherwise 
normal cerebrospinal fluid constituents and no oligoclonal bands. Electroencephalography revealed 
nonspecific slow wave activity. Diffusion weighted magnetic resonance imaging showed increased 
thalamic signal bilaterally, consistent with the pulvinar sign, with an additional increase in the left 
occipital cortex, and was thought to be most compatible with vCJD. Findings from autoimmune, 
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inflammatory and para-neoplastic screening were negative. Results of treponemal and human 
immunodeficiency virus serologic analyses were negative. Results of screening tests for Wilson disease 
were also negative. Mitochondrial DNA analysis showed no evidence of the MELAS (mitochondrial, 
encephalopathy, lactic acidosis, and stroke-like episodes) 3243 mutation. DNA analysis showed both 
Huntington gene alleles to be within the reference range for CAG repeats. A diagnosis of probable vCJD 
was made. PRNP Sanger sequencing was performed and showed a methionine homozygous codon 129 
genotype and an E219K polymorphism. Twelve months after the illness began, the patient deteriorated 
further in terms of speech, swallowing, mobility, and cognitive function. He became bed bound and 
mute; he died 3 months later. Neither diagnostic tonsil biopsy (Hill AF et al., 1999) nor autopsy was 
performed. 
CASE 2 
A 31 year old British woman of Afro-Caribbean descent presented in 2001 with episodic memory 
impairment which was initially noticed by her husband. She was 34 weeks pregnant when the symptoms 
started. Her son was born at 36 weeks by Cesarean delivery owing to antepartum hemorrhage. She had 
no problems caring for him initially, but she subsequently started to experience short-term memory 
problems and low mood, so the husband became more involved with caring for their baby. The patient 
became increasingly apathetic, and when she tried to return to work 6 months later she was unable to 
function at her previously high level. She developed gait ataxia and an involuntary choreiform 
movement disorder. Her husband described her as having difficulty with speech and language. At this 
stage, she was noted to have myoclonic jerks of both upper and lower limbs. Physical examination 
revealed a Mini-Mental State Examination score of 16 out of 30. Her gait was broad-based and 
unsteady, and her speech was slurred. She had a positive grasp reflex bilaterally and brisk finger jerks. 
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The patient had abnormal movements of her upper and lower limbs and a rocking movement of the 
body, which were suppressible only for a short period. Tone and power were normal. Her reflexes were 
symmetrical, and the plantar responses were flexor bilaterally. She was disorientated in time and place. 
There was evidence of fronto-temporal and parietal lobe cognitive dysfunction demonstrated by 
dyspraxia with difficulty miming, substitution of body parts as tools, and problems with motor 
sequencing. Investigation findings were positive for cerebrospinal fluid 14-3-3 protein. Magnetic 
resonance imaging showed bilateral pulvinar high signal. Electroencephalography was unremarkable. A 
tonsillar biopsy demonstrated abnormal prion protein (PrP) typical of vCJD on Western blotting (type  4t 
PrPSc using the London classification) (Hill AF et al., 1999;Wadsworth et al., 2001). PRNP sequencing 
revealed a methionine homozygous codon 129 genotype and an E219K polymorphism. The patient 
deteriorated further and became bed-bound and mute. She died 16 months after the onset of 
symptoms. An autopsy was not performed.  
 CASES CONTROLS 
E219K DETECTED 2 9 
E219K NOT DETECTED 117 1683 
Summary table of E219K polymorphism in variant CJD cases and controls.  Heterozygosity at codon 219 was 
detected in 2 patients with diagnosis of probable and definite variant CJD in our large referral MRC series totalling 
1800 patients.   
 
Heterozygosity at codon 219 is a common polymorphism in the healthy Japanese population and in 
populations in Oceania, South Asia, and the Middle East, but it has not been detected in Africans or 
Europeans (Beck et al., 2010;Mead et al., 2003;Soldevila et al., 2003). 11 out of 1800 patients and 
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controls in our heterogenous referral series at the MRC (Medical Research Council) Prion Unit had E219K 
heterozygosity at codon 219. All 11 individuals were of Asian ethnicity or ancestry. The potential role for 
codon 219 in susceptibility and phenotype modification of vCJD is discussed further in section 4.1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
133 
 
 
3.2 Clinical heterogeneity - National Prion Monitoring Cohort 
Broad enrolment criteria were selected to ensure the Cohort study was representative of prion disease 
in the UK (see Methods). Patients enrolled in the PRION-1 trial and the Cohort study until June 2014, 
were included in these analyses. 96% of eligible patients were recruited by the NPMC team and only 
<1% withdrew consent prior to death. A total of 2681 assessments were done over 470 patient-years of 
study. 94% of recruited patients met the criteria for probable human prion disease indicating good 
diagnostic accuracy. Neuropathological analysis was done in 60% which confirmed prion disease in all 
cases. A molecular diagnosis by genetic testing or biopsy was achieved in 22%, resulting in 70% of 
patients with a definite diagnosis of prion disease (some had a genetic and autopsy diagnosis). Clinical 
deterioration was measured using the MRC Scale. Rapid decline over weeks or a few months was seen 
mostly in sCJD patients, but also some acquired prion disease and specific inherited prion disease 
mutations. Slow decline over years includes almost exclusively patients with inherited prion disease 
typically associated with the GSS and related phenotypes and a small proportion of patients with rapid 
decline followed by prolonged survival at high levels of neurodisability, essentially a comatose state 
(MRC Scale <3), which may be in part due to exceptional supportive care. Variant CJD patients who were 
heterozygous at codon 219 of the prion protein gene did not show distinct clinical phenotypes however, 
it is difficult to make this conclusion with confidence due to a small number of patients.  
The purpose of this analysis was to investigate the determinants of heterogeneity, which could help 
optimise clinical trials. As sCJD is the most common category of prion disease, and given the varied 
timescales over which functional decline occurred in stratum I and II (see Methods and Table 4), further 
analysis was focused only on the rapidly progressive forms of prion disease. The other patients were 
excluded from the analysis. In stratum I, rates of functional decline were significantly slower for 
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acquired prion disease versus sCJD (P<0.001). As incidence of acquired disease is currently very low this 
group of patients was also excluded from further analyses. Since rapidly progressive forms of IPD 
(clinically mimicking sCJD) may not be diagnosed for several weeks after prion disease itself is first 
identified, these patients were included, as it would not be feasible to completely exclude them from a 
prospective clinical trial. Finally, as many patients are diagnosed with CJD at advanced stages of 
neurodisability, when irreversible neuronal death has already occurred, patients with severe disease at 
presentation (MRC Scale <5) were also excluded from the analysis. 
The rapidly progressive group was further subdivided according to the codon 129 polymorhpism and the 
rate of decline mesured using the MRC Scale. In the best-fitting linear mixed model in 154 rapidly 
progressing human prion disease patients (sCJD and fast progressing IPD), baseline MRC scale depended 
only on age, being 4.1 Rasch units lower for every 10 years older (p<0.008, Table 7).  
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Table 7 Model for MRC scale decline in trial-relevant population. Model includes 824 measurements from 154 
sCJD and fast IPD patients in stratum I with MRC Scale score >=5 at enrolment. Reference category aged 65 years 
and was codon 129 MM. For the statistical analysis the 20-point MRC Scale was converted to the continuous Rasch 
score used in its development. This allowed for the more reliable imputation of rare missing questions in the MRC 
Scale.  
 
 
 
 
 
 
 
136 
 
 
Functional decline of patients with rapidly progressive CJD depended strongly on codon 129 genotype 
(interaction p<0.0001). Predicted declines from the best possible Rasch score of 100 (equivalent to 
20/20 on the MRC Scale are shown in Figures 17 and 18. Patients who were homozygous for methionine 
at codon 129 suffered with the fastest disease progression while the patients who were heterozygous at 
the polymorphic codon 129 had the slowest functional decline in this disease group.  
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Figure 17. Trellis plots illustrate model-predicted slopes of decline in function in individual patients matched to 
their MRC Scale observations (as converted to a Rasch score, see text). Black cross indicates proxy Rasch score of 0 
at date of death. Different genotypes at polymorphic codon 129 are shown by line colour (red = MM, blue = VV, 
green = MV). This montage illustrates the 40 most rapidly progressive patients from a Cohort of 154. These were 
the most challenging from the point of view of model fitting. 
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Figure 18 Predicted neurological declines from best possible score by codon 129 subtype. The figure shows 
model-predicted mean declines (lines) and 95% confidence intervals (coloured bands) in Stratum 1 patients with 
three different codon 129 genotypes at PRNP. The most rapid decline was observed in patients with codon 129 
MM polymorphism, followed by patient with codon 129 VV polymorphism. The slowest decline was observed in 
patients who were codon 129 MV heterozygous. The Rasch score approximates to 5x MRC Scale score. 
 
Patients with sCJD/fast IPD and polymorphic codon 129 genotypes MM, VV and MV lost 10% of their 
function measured by the MRC Scale in 5.3 (4.2-6.9), 13.2 (10.9-16.6) and 27.8 (21.9-37.8) days. There 
was no evidence that codon 129 genotype significantly affected the MRC scale measurement at 
enrolment (in the final modelled sample, p=0.11). However, in addition to these population-level 
differences in the mean declines, codon 129 genotype also significantly affected how variable individual 
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patients were around these means (differential random effects and residual errors, p=0.0001). Although 
enrolment scores varied similarly between MM and non-MM genotype patients, subsequent declines 
varied significantly more in MM than non-MM, and residual errors (variability not explained by the 
underlying trajectories) was also significantly greater (Table 7).  
Once the main model had been constructed and the potential effects of enrolment function, age, 
gender, disease category, and codon 129 had been considered, we further investigated whether the 
following additional investigation factors had important effects on baseline or decline in MRC scale:  
1. clinical phenotype as assessed by the visiting physician (7 types, sCJD only; see Methods) 
2. the presence or not of signal change in the basal ganglia, cortex or thalamus on MRI brain (see 
Methods for scoring) 
3. the type of PrPSc assessed by partial protease digestion and Western blotting (types 1-3 London 
classification)  
4. the presence of periodic sharp wave complexes or background abnormalities on routine EEG 
recordings 
5. the presence or not of 14-3-3 protein in routine CSF analysis, or the concentration of CSF S100b 
(Table 3) 
Four of these factors affected decline in MRC scale when considered alone: clinical category (n=159, 
p<0.0001), strain type (n=53, p=0.025), presence of periodic sharp wave complexes (n=147, p=0.009) (as 
noted in the EEG reports from NHNN and local hospitals) and CSF S100b (n=124, p=0.046)), but either 
these effects disappeared after adjusting for the impact of codon 129 subtype on decline (periodic sharp 
wave complexes, adjusted p=0.33), or effects weakened with the effect of codon 129 subtype remaining 
similar to Table 7 and which were much stronger in magnitude. In the multivariate analysis, higher levels 
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of CSF S100b, a quantitative measurement of a glial protein routinely used to assist diagnosis of CJD, 
were associated with more rapid decline (p=0.005) although not at a statistical level beyond which might 
be expected as a result of performing tests of multiple hypotheses. Therefore the PrP gene sequence 
appears to be a profoundly important predictor of decline relative to other demographic or investigation 
factors. We note that a small proportion of rapidly progressive sCJD patients had a PrPSc type at data 
freeze, which may have impacted the power to detect an effect of PrPSc type beyond codon 129 
genotype. 
 
Power calculations using the MRC Scale 
Furthermore, we used the observed enrolment frequency of codon 129 subtypes (33% MM, 43% MV, 
24% VV), distribution of ages (mean 65.1 years, standard deviation 9.4), population and individual rates 
of decline as estimated in Table 7 to simulate cohorts of patients who might be enrolled into clinical 
trials of an investigational agent which reduced the rate of decline by (proportionately) 0%, 25% or 50%. 
We assumed a fixed percentage reduction in decline given the large absolute differences in decline 
observed (Table 7). We therefore estimated the impact of the intervention using a test for the 
percentage reduction (see supplementary materials for details).  We compared the power of different 
sized trials to detect effects based on estimating the impact of an intervention on the MRC scale, and 
survival based on this. 
First we considered a randomised trial which could be either placebo-controlled or open-label, although 
the possibility of reporting bias in an open-label trial would need to be carefully considered. Figure19 
shows the power of such a trial with total 50-120 fast-progressing patients (MM, MV and VV), 
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(randomised 1:1 control:intervention and assessed every 10 days, to detect a 25% or 50% reduction in 
decline in the MRC scale.  
0
.2
.4
.6
.8
1
P
o
w
e
r
50 60 70 80 90 100 110 120
Total subjects
True effect 0% Prion scale Survival
True effect 25% reduction Prion scale Survival
True effect 50% reduction Prion scale Survival
Test of null hypothesis (rx=0%) (assessments every 10 days) (df=1 test, non-linear for scale)
 
Figure 19 Power for different sizes of randomised trial Assessments every 10 days, recruiting from the fast 
progressing population (MM, MV and VV); varying intervention efficacy. When the true reduction is 0% (light gray 
line), 5% of tests would be expected to fall below a p<0.05 by chance (red line). 
 
According to this analysis 120 patients would need to be randomised to provide 80% power to detect a 
50% reduction in neurocognitive decline. The same number of patients provides 5-10% greater power 
from using the repeated MRC scale measurements than a survival endpoint on the same population. 
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The MRC scale requires only a 2 minutes conversation to acquire information over the telephone and is 
highly acceptable to patients and their carers. We therefore considered the impact of more frequent 
measurements on power (Figure 20).  
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Figure 20 Intervention has a 50% reduction in decline, recruiting from the fast progressing population (MM, MV 
and VV): varying number of assessments. The survival is estimated in the same manner regardless of the number 
of times that assessments are made; variation in the estimates of power for a survival endpoint therefore reflect 
only sampling variation. 
 
The same power as achieved with 120 randomised patients measured every 10 days could be achieved 
by 110 patients every 5 days, 100 patients thrice weekly or 90 patients daily, as a consequence of 
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improved precision of estimation of rates of decline. Therefore power gains for daily measurement over 
a survival endpoint were 13-20% for the same number of patients. Lastly, given the substantially greater 
variability observed in rates of decline in the MM subgroup, we considered the impact on power of 
restricting a trial to different codon 129 subtypes (Figure 21).  
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Figure 21 Intervention has a 50% reduction in decline, assessments every 10 days: varying recruitment from the 
entire fast progressing population or according to codon-129 subtype. Codon 129 VV patients showed less 
variation and therefore fewer patients were required to achieve the same study power compared to codon 129 
MM and MV group. In this group only 40 patients were sufficient to provide 80% power to detect 50% decline in 
function.  
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Because the VV subgroup have less variability than the MM subgroup, but faster declines than the MV 
subgroup, only 40 randomised VV patients provided >80% power to detect 50% reductions in decline. At 
the observed population frequencies, however, 40 VV patients would be expected from a cohort of 167 
patients in total, which would have provided greater power overall.  
An alternative approach would be an open label study with comparisons made to the cohort natural 
history data presented here. Such non-randomised comparisons have well-recognised limitations, the 
most important being changes in external management. However, given the simulated randomised trial 
findings above, and the numbers already in the cohort, it is likely that similar power could be achieved 
with half the randomised patients. 
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3.3 Histopathological heterogeneity 
Spongiform change as already discussed in the introduction is typically seen in prion disease and this is 
shown in Figure 5, Introduction. Prion protein deposits are detected in synaptic, granular, plaque and 
peri-neuronal net patterns (Figure 5, Introduction). These deposits as already mentioned vary in 
intensity and may, in some cases, correspond biochemically to amyloid.  
Furthermore, we looked at the presence of amyloid-β in prion disease patients. Similar to Alzheimer’s 
disease, deposition of extracellular amyloid was observed with formation of amyloid-β plaques and 
other amyloid-β aggregates (Figures 22a–f). Amyloid- β accumulates diffusely (Figure 22a–c), or it can 
exhibit prominent and widespread deposition of dense amyloid plaques with a diameter of more than 
200 µm (Figure 22d–f), and similar to prion protein deposition elicits a considerable astrocyte and 
microglial reaction. 
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Figure 22 Intensities of amyloid-β deposits: a–c diffuse protein deposits without formation of plaques (ranging 
from mild to severe). a Score 1 (mild) describes occasional patchy deposits, occasionally seen on low power 
magnification. b Moderate, score 2 describes deposits that are seen in <50% of adjacent low power fields. c An 
example of heavier diffuse amyloid beta burden, indicating a presence in most of the low power field on a cortex 
section. Deposition and distribution of amyloid-β were assessed using the CERAD (Consortium to Establish a 
Registry for Alzheimer’s Disease) criteria. CERAD was funded by the National Institute on Aging in 1986 to develop 
standardized, validated measures for the assessment of Alzheimer’s disease (AD) including clinical, 
neuropsychological, neuropathological and behavioral assessments of AD. Dense core amyloid beta plaques in the 
figure, approximately corresponding to CERAD sparse (d), intermediate (e) and high (f). Scale bar 300 μm (a–f, g–i) 
 
Tau accumulation accompanies most neurodegenerative processes and is often found in the vicinity of 
prion protein and amyloid-β deposits. Figure 23 illustrates intensities and patterns of neocortical tau 
which accumulates in the vicinity of PrPSc and amyloid-β related deposits. Following detailed assessment 
of these proteins we concluded that tau pathology in areas of amyloid-β accumulation is probably an 
independent (meaning distinct from the association of prion protein and tau deposition) process of tau 
phosphorylation that starts in the entorhinal cortex and spreads over the limbic system to extend into 
neocortical regions.  
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Figure 23 Amyloid-β or PrP induced pattern of tau phosphorylation differ: a–c shows the range of PrP induced tau 
deposits. The scores of tau correspond to the scores of PrP, i.e. tau score 1 is typically seen in areas with PrP score 
1 and dense tau deposits (scores 2 or 3) are typically seen in areas with PrP scores 2–3 d–f. In contrast, amyloid-β 
induces a threaded tau phosphorylation pattern, with elongated dystrophic neuritis but very little stub- or rod-
shaped tau. All examples are from the frontal or parietal cortex. Scale bar 25 µm (a–f). 
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The morphology of hyperphosphorylated tau associated with abnormal prion protein is distinct from 
that elicited by amyloid-β, in particular in cases of synaptic PrP deposition (Figure 23). Prion protein 
related tau hyperphosphorylation appear as short stub- or rod-like structures (Figure 23a–c). The most 
subtle deposition forms small rod- or stub-like punctate inclusions (granules). Their shape resembles 
granules seen in argyrophilic grain disease (Ferrer et al., 2008). They do not extend to fibrillary or 
‘‘neuritic’’ tau, whilst the most subtle deposition of amyloid-β associated tau fibrils occurs in the form of 
thin, single neuritic threads in the cortex (Figure 23d). The next stage of amyloid-β induced tau 
phosphorylation is a more frequent presence of fibrils (Figure 23e), and finally the amyloid-β induced 
tau pathology amounts to a delicate network of dystrophic processes (Figure 23f), including 
neurofibrillary tangles. Amyloid plaques are generally surrounded by a small corona of dystrophic 
neurites, which are well known and have been frequently described in the literature.  
Accumulation of phosphorylated tau in the cerebellum has a characteristic appearance and usually 
corresponds to the severity of PrP deposits in the same regions. Figure 24 illustrates typical deposition 
of PrP and the corresponding phosphorylated tau in the cerebellum of sCJD, vCJD and inherited prion 
disease patients.  
The formation of conspicuous and well-demarcated PrP plaques was typically seen in inherited forms 
with codon P102L (Figures 24m, 25c) and A117V mutations (Figures 24n, 25d), whilst D178N or E200K 
(Figures 24o, 25e) mutations showed less well-defined plaque pathology. Other mutations, such as 
octapeptide repeat insert (OPRI) mutations presented histologically with a unique striping pattern of the 
cerebellum (Figure 24k, l). 
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Figure 24 Prion protein-triggered tau phosphorylation in the cerebellum: upper row shows deposition of abnormal 
PrP in sCJD with synaptic PrP deposition (a–c) and small plaques (d). vCJD cases showed heavy PrP burden with 
diffuse deposits as well as plaques (e). The corresponding tau phosphorylation is shown below (f–j). It is 
approximately proportional to the PrP
Sc
 burden and is closely associated with plaques. An exceptionally strong tau 
deposit was consistently seen in vCJD cerebella (j). The pattern of abnormal PrP deposition is distinct for each 
mutation. 96 and 144 bp OPRI form a characteristic striping pattern perpendicularly to the cerebellar surface (k, l) 
with moderate tau labeling in 96 bp OPRI and very little tau in the 144 bp OPRI. The extent of tau phosphorylation 
appears to be independent of the plaque load, with P102L and A117V cases showing similar tau burden as in E200K 
which features synaptic PrP deposition. Scale bar 120 µm (a–e, n, o); 250 µm (k, l, m) and 40 µm (f–j, p–t). 
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It has been observed that plaque-forming diseases are capable of generating phospho-tau deposits, but 
disease forms with synaptic PrP may be incapable to do so (Sikorska et al., 2009). To examine this 
further, we investigated patients with sCJD and compared them to cases with inherited prion disease 
and vCJD cases. Presence of hyperphosphorylated tau in sCJD with synaptic (Figures 24i, j) or pericellular 
PrP, in the absence of plaques (Figures 24a, b, e, f) has been demonstrated for the first time in this 
study. We detected a substantial formation of phospho-tau positive rods in vCJD (Figure 24j). In cases 
with concomitant amyloid-β pathology, we found both patterns, namely granular, rod-shaped PrP-
induced tau inclusions (Figure 23a–c) and thread-shaped amyloid-β related formations (Figure 23d–f). 
Cases of inherited prion disease (P102L, A117V, D178N, E200K, 96 and 144 bp octarepeat insert) showed 
accumulation of tau directly associated with prion protein plaques (Figures 24p–t, 25f–j). 
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Figure 25 PrP-induced tau phosphorylation in cortex of inherited prion diseases: upper row deposition of abnormal 
PrP in the frontal cortex; there is considerable variability of the intensity of PrP
Sc
 burden and some forms are 
characterized by distinct patterns of plaque formation, as described before. The lower row shows tau deposits 
corresponding to the area depicted above. (a), 96 bp OPRI mutation with almost undetectable PrP
Sc
 load, resulting 
in tau phosphorylation similar to the 144 bp OPRI (f, g), despite its significantly higher PrP
Sc
 load (b). c This case 
with a P102L mutation shows predominantly diffuse deposits and only very few plaques, as compared to the very 
heavily plaque-forming A117V case (d), both showing similar tau hyperphosphorylation (h, i). Another case with no 
plaque formation, E200K (e), shows a tau load similar to all other cases (j). Scale bar a–e 240 µm, f–j 60 µm. 
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Figure 12 in Methods shows the heat map used for quantitative analysis of tau phosphorylation and PrP 
deposits. The data were obtained by counting tau positive inclusions in the high power field and 
subsequently comparing these with the corresponding PrP deposits.  
Prof Brandner’s team performed post-mortem examinations and sample staining of brain tissues from 
135 patients with sporadic CJD, variant CJD and acquired CJD. Prion protein, tau and amyloid-β scores 
were obtained using the scoring scheme already described. We then graded the slides as no deposition, 
mild, moderate and severe from 0-3 (as described in Methods). In case of multiple concurrent PrP 
patterns, the highest individual score was used (e.g. granular score 2 and synaptic score 1 was used to 
obtain the final score (2). No cases with cerebellar amyloid-β were included in the study. In case of tau 
deposition the scoring ranged from 0-4 as discussed in the Methods. Genotype data at codon 129, 
disease duration and age at onset were compared with protein deposition and distribution.  
Deposition and distribution of prion protein in different brain regions is illustrated in the bar chart below 
(Figure 26). There was no statistically significant difference in prion protein deposition between each of 
the disease forms, sCJD, fCJD and vCJD for each of the examined brain regions using the Kruskal-Wallis 
test as demonstated below. 
 
Region Frontal Parietal Temporal Occipital Cerebellum 
p 0,104 0,213 0,056 0,158 0,646 
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Figure 26 shows prion protein deposition in different brain regions for each of the disease categories, sCJD, fCJD 
and vCJD (total of 135 cases). The colour code is used to differentiate between different disease groups. The mean 
PrP value was derived from the different scores ranging from 0-3 to account for no deposition, mild, moderate and 
severe protein accumulation. (Mean PrP = mean score value when all scores were added up and divided by a total 
number of 135 cases excluding the missing data; Region = brain region examined to include frontal, parietal, 
temporal, occipital and cerebellum). 
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Similarly, we investigated tau protein deposition in different brain regions. This is illustrated in Figure 27. 
There was no obvious difference in tau protein accumulation between different disease groups, sCJD, 
fCJD and vCJD using Kruskal-Wallis test. 
 
 
Figure 27 shows the mean value for tau protein value (ranging from 0-4) in each of the examined brain regions in 
prion disease patients. The colour code is used to differentiate between different disease groups, vCJD, fCJD and 
sCJD in a total of 135 CJD patients. The colour code is used to differentiate between different disease groups. The 
mean tau value was derived from the different scores ranging from 0-4 to account for no deposition, mild, 
moderate, severe and extremely high protein accumulation. (Mean PrP = mean score value when all scores were 
added up and divided by a total number of 135 cases excluding the missing data; Region = brain region examined 
to include frontal, parietal, temporal, occipital and cerebellum). 
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Furthermore, we investigated amyloid-β deposition in different brain regions for each of the discussed 
disease categories. This is illustrated in Figure 28. Amyloid-β deposition was lower in patients with vCJD 
which may be because these patients were much younger. Amyloid-β deposition in patients with fCJD 
was lower than in patients with sCJD. The reason for this may be the younger age of fCJD patients but 
also the interaction between amyloid-β and different prion strains. It may be that sCJD PrPSc interaction 
with amyloid-β is favored compared to the prion strain in fCJD patients. This may also account for the 
longer disease duration in inherited prion disease patients. There was an obviously lower deposition of 
amyloid-β in cerebellum in all disease groups.  
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Figure 28 shows the mean amyloid-β value (ranging from 0-3) for each of the examined brain regions in patients 
with vCJD, fCJD and sCJD totalling 135 CJD cases. The mean amyloid-β was derived when each of the scores (0-3) 
were added and divided by the number of samples tested. The figure shows a lower amyloid-β deposition in 
patients with fCJD compared to sCJD. There was also an obviously lower deposition of amyloid-β in the cerebellum 
in patients with all three disease forms. (Mean PrP = mean score value when all scores were added up and divided 
by a total number of 135 cases excluding the missing data; Region = brain region examined to include frontal, 
parietal, temporal, occipital and cerebellum). 
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Further analysis was performed on sCJD patients only. This subgroup included 65 patients with the 
diagnosis of definite sCJD. Deposition of each of the three proteins was assessed in 5 different brain 
regions: frontal, parietal, temporal, occipital and cerebellum.  
Figure 29 shows the mean value for PrP, amyloid-β and tau protein in the five examined regions. The 
Kruskall-Wallis test was used to compare the protein deposition between different brain regions. There 
was no statistically significant difference in the deposition of PrP and tau protein in different regions of 
the brain. However, there was significantly less deposition of amyloid-β in all regions when compared 
with the other 2 proteins. The difference was particularly striking in the cerebellum which contains 
significant deposition of tau and PrP protein with complete absence of amyloid-β.  
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Figure 29 shows the mean score value for each of the three proteins: PrP, tau and amyloid-β protein in 5 examined 
brain regions of 65 definite sCJD patients. The mean values on the y axis are derived from semi-quantitative 
analysis of protein deposition labeled from 0-3 referring to no deposition, mild, moderate and severe protein 
accumulation. In case of unusally high tau deposition, observed in a few cases, a score of 4 was used. The lower 
deposition of amyloid-β is particularly striking in the cerebellum. This is not surprising because there is also very 
little PrP and hyperphosphorylated tau in this brain region. (Mean PrP = mean score value when all scores were 
added up and divided by a total number of 135 cases excluding the missing data; Region = brain region examined 
to include frontal, parietal, temporal, occipital and cerebellum). 
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Further analysis involved examination of each of the proteins in different brain regions and comparing 
them with each other. This analysis was performed on 65 sCJD patients only. Mann-Whitney test was 
used to assess the correlation of prion protein deposition between different brain regions. Prion protein 
deposition was statistically significant when parietal lobe was compared to cerebellum (Table 8). 
Prion protein Parietal Temporal Occipital Cerebellum 
Frontal 0.497 0.068 0.781 0.031 
Parietal - 0.014 0.352 0.005 
Temporal - - 0.135 0.792 
Occipital - - - 0.070 
Table 8 shows the Mann-Whitney test used to assess the correlation of prion protein deposition between different 
brain regions (p<0.005 would be a suitable statistical threshold for significance that takes into consideration the 
multiple hypotheses tested here). Prion protein deposition was statistically significant when the parietal region 
was compared with the cerebellum.  
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Further analysis was performed tau deposition in different brain regions. Mann-Whitney test was used 
to assess the correlation of tau protein deposition between the examined brain areas. This showed that 
the lower deposition in the cerebellum is statistically significant when compared with the other brain 
regions. Similarly, when frontal and parietal regions were compared to the temporal and when parietal 
and temporal brain regions were compared to the occipital lobe the difference was statistically 
significant (Table 9). 
Tau protein Parietal Temporal Occipital Cerebellum 
Frontal 0.378 0.002 0.219 0.000 
Parietal - 0.022 0.044 0.000 
Temporal - - 0.000 0.000 
Occipital - - - 0.005 
Table 9 shows the results of the Mann-Whitney test used to assess the correlation of tau protein deposition 
between different brain regions (p<0.005). The difference is statistically significant when the frontal region was 
compared to the temporal, when the temporal brain region was compared to the occipital and when all brain 
regions were compared with cerebellum. 
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Similar analysis was performed to assess the deposition of amyloid-β in different areas of the brain. 
Table 10 shows the Mann-Whitney test used to compare the deposition of amyloid-β between different 
brain regions. The lower deposition of amyloid-β protein in cerebellum is statistically significant when 
compared with the other brain regions.  
A-β protein Parietal Temporal Occipital Cerebellum 
Frontal 0.958 0.150 0.658 0.000 
Parietal - 0.162 0.650 0.000 
Temporal - - 0.362 0.000 
Occipital - - - 0.000 
Table 10 The Mann-Whitney test was used to assess the correlation of amyloid-β protein deposition between 
different brain regions. The lower deposition of amyloid-β in cerebellum compared to frontal, parietal, temporal 
and occipital region was statistically significant.  
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We also analyzed the correlation between different proteins and disease duration in sCJD. The 
correlation between disease duration and deposition of each of the three proteins, prion protein, 
amyloid-β and tau protein is shown in tables 11-14. The Pearson correlation test between the mean 
prion protein deposition and disease duration showed that there was no statistically significant 
association.  
 
  PrP (mean) Months 
 Pearson correlation 1 0.204 
PrP (mean) Sig (2-tailed) - 0.058 
 N 102 87 
 Pearson correlation 0.204 1 
Months Sig (2-tailed) 0.058 - 
 N 87 114 
Table 11 shows the Pearson correlation for PrP deposition and disease duration in prion disease. The association 
between mean prion potein deposition and disease duration was not statistically significant in patients with sCJD.  
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Furthermore, the Pearson correlation test showed no statistically significant association between 
amyloid-β accumulation and disease duration in prion disease patients (Table 12). 
  Amyloid-β (mean) Months 
 Pearson correlation 1 -0.143 
A-β (mean) Sig (2-tailed) - 0.157 
 N 116 99 
 Pearson correlation -0.143 1 
Months Sig (2-tailed) 0.157 - 
 N 99 114 
Table 12 shows Pearson correlation for amyloid-β deposition and disease duration in prion disease. The 
association between mean amyloid- β deposition and disease duration was not statistically significant in sCJD 
patients. 
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Interestingly, the Pearson correlation test showed a statistically significant association between tau 
protein accumulation and disease duration in sporadic CJD patients (Table 13).  
  Tau (mean) Months 
 Pearson correlation 1 0.293 
Tau (mean) Sig (2-tailed) - 0.007 
 N 98 83 
 Pearson correlation 0.293 1 
Months Sig (2-tailed) 0.007 - 
 N 83 114 
Table 13 Pearson’s correlation for tau protein deposition and disease duration in sCJD patients.The correlation of 
mean tau protein deposition and disease duration is positive and the relationship is statistically significant. 
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3.4 Candidate genes and neuropathological analysis 
Several genetic loci are known to play a role in neurodegenerative disorders likely to share common 
pathophysiological mechanisms. It is already known that APOE Ɛ4 allele (Borgaonkar et al., 1993), 
homozygosity at polymorphic codon 129 of the PRNP gene (Palmer et al., 1991) and MAPT haplotype 
(Jun et al., 2015) are genetic risk factors for Alzheimer’ s disease (AD), prion disease and Parkinson’s 
disease (PD) respectively. We studied 7 candidate genes known to be associated with these diseases: 
PRNP Codon 129 (Mead et al., 2009a;Palmer et al., 1991), PRNP 1368-B haplotype (Mead et al., 2001), 
MAPT (Tobin et al., 2008), APOE(rs2075650) (Borgaonkar et al., 1993), CLU (rs11136000),(Harold et al., 
2009;Lambert et al., 2009), HECTD2 (rs12249854)(Lloyd et al., 2009) , SPRN (Beck et al., 2008). 
We looked at the influence of 7 candidate genes on the age of disease onset, duration and total 
accumulation of prion protein, amyloid-β and tau protein in 65 patients suffering from sCJD. The 
correlation of age of disease onset with duration was negative and significant at the level 0.01 which is 
consistent with the published literature (Appleby et al., 2009;Mead et al., 2011a;Thompson et al., 2013). 
This is illustrated in the graph and table below (Figure 30 and Table 13). 
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Figure 30 illustrates the correlation beween disease duration and age at disease onset in 65 patients with sCJD.  
The figure shows that the correlation of age of disease onset with duration was negative and significant at the level 
0.01. This observation is consistent with the published literature.  
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Further analysis was performed using Kolmogorov-Smirnov, Shapiro-Wilk, Mann-Whitney and Wilcoxon 
tests. This analysis was performed in order to ascertain the influence of each of the candidate gene 
polymorphisms on clinical traits such as disease duration, age at onset, prion protein, tau and amyloid-β 
accumulation. Assessment of the influence of PRNP polymorphisms on disease duration showed a 
statistically significant correlation of codon 129MM with shorter disease duration as illustrated in Table 
14 and Figure 31.  
Tests of Normality 
 
 PRNP 129 Kolmogorov-Smirnov Shapiro-Wilk 
  Statistic df Sig Statistic df Sig 
Months MM 0.209 35 0.000 0.870 35 0.001 
 MV 0.113 11 0.200 0.967 11 0.854 
 VV 0.226 13 0.068 0.908 13 0.174 
Table 14 shows the p values from a statistical analysis of polymorphisms at codon 129 versus disease duration in 
65 sCJD cases. The tests of normality were performed using the Kolmogorov-Smirnov and Shapiro-Wilk statistical 
tests. The data do not show normal distribution.  
 
 
This analysis is further illustrated in the bar chart below. The shorter disease duration is associated with 
methionine homozygosity (MM) at the polymorphic codon 129 (Figure 31). 
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Disease duration vs codon 129 polymorphisms 
 
Figure 31 shows the association of mean disease duration (months) in 65 cases of sCJD patients with different 
polymorphisms at codon 129 of the PRNP gene. Methionine homozygosity (MM) at the polymorphic codon 129 is 
associated with shorter disease duration in sCJD. Methionine valine heterozygosity is associated with the longest 
disease duration.  
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Apart from PRNP codon 129, the other six gene polymorphisms were not significantly associated with 
disease duration in CJD. None of the tested candidate genes influenced age of disease onset (data not 
shown). Finally, we tested the influence of the 7 candidate gene polymorphisms on the accumulation of 
proteins relevant to the process of neurodegeneration: prion protein, amyloid-β and tau protein. 
Genotyping was performed using real time PCR and gene sequencing. The PRNP 129, PRNP 1368 B 
haplotype, clusterin, HECTD2 and SPRN genes were not significantly associated with the total quantity of 
the accumulated prion protein, amyloid-β or tau protein (data not shown). However, MAPT haplotype 
and APOE gene were associated with increased accumulation of some of the proteins. Prion and tau 
protein deposition were significantly influenced by MAPTH1C haplotype (Figure 32 and Table 15). The 
amount of accumulated amyloid-β was influenced by APOE haplotype Ɛ4 (Figure 33, Table 16) as 
expected but not by PrP and tau genes.  
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Prion protein deposition vs MAPTH1c haplotype 
 
Figure 32 shows the mean value of the accumulated prion protein in 65 cases of sCJD patients (y axis) vs different 
MAPT polymorphisms (x axis). The mean PrP value was obtained when scores 0-3 were added up and the sum 
divided by the number of samples scored. The genotyping for MAPT haplotype 1c was performed using real time 
PCR. MAPTH genotype CT is associated with the highest prion protein deposition.  
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Multiple comparison analysis was performed using Tukey HSD test. This analysis involved multiple 
comparisons of each of the detected MAPT genotypes with the mean value for each of the three 
proteins PrP, tau and amyloid-β. A statistically significant association was detected between MAPT 
polymorphisms and PrP and tau protein deposits as shown in Table 15.  
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Multiple Comparisons 
Tukey HSD 
Dependent 
Variable 
(I) 
MAPTH1C 
(J) 
MAPTH1C 
Mean 
Difference (I-
J) 
Std. 
Error 
Sig. 95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
PrP_mean 
CC 
CT -,64722
*
 ,17375 ,002 -1,0730 -,2215 
TT -,24500 ,24007 ,569 -,8333 ,3433 
CT 
CC ,64722
*
 ,17375 ,002 ,2215 1,0730 
TT ,40222 ,26712 ,301 -,2523 1,0568 
TT 
CC ,24500 ,24007 ,569 -,3433 ,8333 
CT -,40222 ,26712 ,301 -1,0568 ,2523 
Tau_mean 
CC 
CT -,14286 ,14794 ,604 -,5076 ,2219 
TT -,66667
*
 ,21038 ,010 -1,1853 -,1480 
CT 
CC ,14286 ,14794 ,604 -,2219 ,5076 
TT -,52381 ,23650 ,085 -1,1069 ,0592 
TT 
CC ,66667
*
 ,21038 ,010 ,1480 1,1853 
CT ,52381 ,23650 ,085 -,0592 1,1069 
Abeta_mean 
CC 
CT ,41935 ,50817 ,690 -,8132 1,6519 
TT -,83065 ,79409 ,552 -2,7567 1,0954 
CT 
CC -,41935 ,50817 ,690 -1,6519 ,8132 
TT -1,25000 ,86295 ,325 -3,3431 ,8431 
TT 
CC ,83065 ,79409 ,552 -1,0954 2,7567 
CT 1,25000 ,86295 ,325 -,8431 3,3431 
*. The mean difference is significant at the 0.05 level. 
 
Table 15 shows the association of scores of PrP, amyloid-β and tau protein deposition with MAPT 
polymorphisms following multiple comparisons using the Tukey HSD test. The association for both 
accumulated PrP and tau protein with MAPT gene is statistically significant at the 0.05 level, although in 
consideration of multiple testing the finding needs to be replicated. 
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APOE ε4 is known to be associated with increased risk for development of Alzheimer’s disease. In our 
study increased deposition of amyloid-β protein in prion disease patients was associated with APOE ε4 
genotype and this association was statistically significant as shown in Figure 33 and Table 16. This 
finding is interesting as it points to a possibile interaction between PrP and amyloid-β (Lauren et al., 
2009) although it may also be just a coincidental association.  
 
Figure 33 shows the mean amyloid-β deposition score in sCJD patients with different APOE alleles. APOE Ɛ4 is 
known to be associated with an increased risk of AD. Increased amyloid-β deposition in prion disease patients is 
associated with APOE ε4 genotype and this association is statistically significant. 
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Multiple comparison analysis was performed using the Tukey HSD test. This analysis involved multiple 
comparisons of each of the detected APOE genotypes with the mean value for each of the three 
proteins PrP, tau and amyloid-β. A statistically significant association was detected between APOE Ɛ4 
and amyloid-β deposition in sCJD patients.  
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Multiple Comparisons 
Tukey HSD 
Dependent Variable (I) APOE (J) APOE Mean 
Difference (I-J 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
PrP_mean 
33 
44 -,61109 ,37823 ,384 -1,6342 ,4120 
34 -,19442 ,23519 ,841 -,8306 ,4418 
23 -,06442 ,23519 ,993 -,7006 ,5718 
44 
33 ,61109 ,37823 ,384 -,4120 1,6342 
34 ,41667 ,41891 ,753 -,7165 1,5498 
23 ,54667 ,41891 ,566 -,5865 1,6798 
34 
33 ,19442 ,23519 ,841 -,4418 ,8306 
44 -,41667 ,41891 ,753 -1,5498 ,7165 
23 ,13000 ,29621 ,971 -,6712 ,9312 
23 
33 ,06442 ,23519 ,993 -,5718 ,7006 
44 -,54667 ,41891 ,566 -1,6798 ,5865 
34 -,13000 ,29621 ,971 -,9312 ,6712 
Tau_mean 
33 
44 -,50000 ,27998 ,300 -1,2628 ,2628 
34 -,16667 ,17573 ,779 -,6454 ,3121 
23 -,20000 ,18876 ,716 -,7143 ,3143 
44 
33 ,50000 ,27998 ,300 -,2628 1,2628 
34 ,33333 ,30825 ,703 -,5065 1,1732 
23 ,30000 ,31586 ,778 -,5606 1,1606 
34 
33 ,16667 ,17573 ,779 -,3121 ,6454 
44 -,33333 ,30825 ,703 -1,1732 ,5065 
23 -,03333 ,22861 ,999 -,6562 ,5895 
23 
33 ,20000 ,18876 ,716 -,3143 ,7143 
44 -,30000 ,31586 ,778 -1,1606 ,5606 
34 ,03333 ,22861 ,999 -,5895 ,6562 
Abeta_mean 
33 
44 -2,80000
*
 ,97099 ,030 -5,3949 -,2051 
34 -1,05000 ,52905 ,210 -2,4639 ,3639 
23 ,77143 ,55809 ,517 -,7200 2,2629 
44 
33 2,80000
*
 ,97099 ,030 ,2051 5,3949 
34 1,75000 1,05112 ,354 -1,0590 4,5590 
23 3,57143
*
 1,06603 ,009 ,7225 6,4203 
34 
33 1,05000 ,52905 ,210 -,3639 2,4639 
44 -1,75000 1,05112 ,354 -4,5590 1,0590 
23 1,82143 ,68812 ,053 -,0175 3,6604 
23 
33 -,77143 ,55809 ,517 -2,2629 ,7200 
44 -3,57143
*
 1,06603 ,009 -6,4203 -,7225 
34 -1,82143 ,68812 ,053 -3,6604 ,0175 
Table 17 shows the association of PrP, amyloid-β and tau protein deposition with APOE polymorphisms following 
multiple comparisons using Tukey HSD test. The association for both accumulated amyloid-βprotein with APOE Ɛ4 
is statistically significant at the 0.05 level, although in consideration of multiple testing this finding needs to be 
replicated. 
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This analysis suggests that in addition of expected associations between homozygosity at codon 129 of 
the PRNP gene and disease duration and between APOE Ɛ4 haplotype and amyloid-β deposition there 
are further interesting associations. These include MAPT haplotype 1c which is significantly associated 
with both increased prion and tau protein accumulation suggesting a possible role of this genetic locus 
in the pathogenesis of prion disease. This polymorphism is known to be associated with alpha-synuclein 
accumulation thus suggesting possible common pathways with prion disease and other 
neurodegenerative conditions as previously discussed (Goedert, 2015). 
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3.5 Copy number variants as susceptibility loci to prion disease 
Copy number variants represent a potentially novel source of genetic susceptibility. In order to 
investigate their role in susceptibility to prion disease we analyzed CNV deletions and duplications in 
patients with UK sCJD, vCJD; German sCJD patients and resistance to kuru in PNG. The analysis was 
performed using 2 different softwares in Illumina Genome Studio. A full CNV analysis performed in this 
study is summarized at the end of the chapter.  
Pilot experiment 
Genome Studio supports several softwares for CNV data analysis to allow detection of 
deletions/duplications, loss of heterozygosity (LOH), their size and chromosomal location. In order to 
select the most appropriate software we created a 10 sample project which was analyzed using Quanti 
SNP, Penn CNV and CNV Partition. Each algorithm was tested for its ability to accurately detect small 
and large CNVs with a good confidence value. The project was created in Genome Studio using a unique 
sample sheet. Performance and accuracy of 3 different CNV softwares was initially assessed. PLINK a 
genome wide analysis tool was used to estimate type, genomic location and frequency of CNV deletions 
and duplications. It allowed estimation of genome-wide CNV burden as well as specific association 
analyses. The primary analysis was a chi2 test with the use of empirical p values. Three different 
algorithms were used to detect copy number value, confidence score, chromosomal location and copy 
number size. The report demonstrated that CNV Partition detects the highest number of even small CNV 
deletions and duplications with a high confidence value suggesting good dependability. Further 
case/control analysis of the larger sample set was performed using CNV Partition.  
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3.5.1 Copy number variants analysis using CNV Partition 
a) UK CNV detection analysis 
A total of 708 UK samples (509 sCJD, 123 vCJD and 76 inherited prion disease samples) were analyzed 
and compared to 902 Welcome Trust Case Control Consortium (WTCCC) controls. Patient samples were 
analyzed on Illumina Human-Hap 670 array and publicly available WTCCC2 controls on 1.2M Custom 
Duo array. The data were imported into Genome Studio and the 2 projects were analyzed using CNV 
Partition. The initial analysis revealed a significant discrepancy between cases and controls. This was 
thought to be due to platform differences between Illumina 670K array used for case analysis and 
Illumina 1.2M array used for control sample analysis. In order to overcome this problem the 2 projects 
were merged in Genome Studio using a unique sample sheet. The merged project contained CNV probes 
common to both cases and controls which led to a significant reduction in the number of probes. There 
was also a discrepancy associated with gender. Absence of the second X chromosome in males was 
detected as deletion by the software creating a false positive association. We excluded the X 
chromosome from further analysis. In addition, the confidence value was increased to minimize false 
positive associations. The CNV analysis was repeated using CNV Partition and the case/control 
association analysis performed using PLINK. 
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Total number of CNV 
deletions 
Number of CNV 
deletions per person 
Total number of CNV 
duplications 
Number of CNV 
duplications per person 
Cases 
>100kb 298 0.42 563 0.795 
Controls 
>100kb 540 0.59 792 0.878 
Cases 
>500kb 11 0.0155 52 0.073 
Controls 
>500kb 88 0.0975 157 0.174 
Cases 
>1Mb 6 0.0084 12 0.017 
Controls 
>1Mb 28 0.031 77 0.085 
Table 18. Summary table showing the total CNV burden in UK cases compared to controls. It shows the total CNV 
burden of deletions and duplications ranging from smallest (>100kb) to the largest (>1Mb). The number of CNVs 
per person for deletions and duplications is also shown in the table. 
 
We initially looked for the presence of CNV duplications and found several loci to have a genome-wide 
or near genome-wide statistically significant associations in cases compared to controls. These data are 
summarized in the table below.  
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Chr location of 
CNV 
duplication 
Number of 
duplications in 
vCJD cases  
Number of 
duplication in 
controls  
Number of 
duplications in 
sCJD cases  
Number of 
duplications in 
controls  
p value in 
vCJD 
p value in 
sCJD 
6p22.3 4/122 12/902 23/508 12/902 0.109189 0.00019998 
7p12.1 5/122 1/902 19/508 1/902 1.45 x 10-23 4.03 x 10-8 
10q11.22 6/122 23/902 46/508 23/902 0.1442 1.15 x 10-7 
12p 3/122 2/902 15/508 2/902 0.0128987 1.19 x 10-5 
12p13.31 1/122 12/902 25/508 12/902 1 0.00019998 
14q11.2 6/122 0/902 22/508 0/902 2.56 x 10-6 1.31 x 10-10 
16q12.2 4/122 13/902 27/508 13/902 0.130687 6.8 x 10-5 
16p11.2 0/122 0/902 9/508 0/902 1 0.00019998 
Table 19 Genetic loci associated with a genome-wide (<1x10
-8
) or near genome-wide (1x10
-5
-1x10
-8
) statistically 
significant p value following data analysis in PLINK. The p values are noted for case/control association analysis for 
both sporadic and variant CJD. The table also shows the number of cases and controls where the duplication was 
detected. 
 
b) Validation of UK findings 
Duplications on chromosomes 6, 7, 10, 12, 14 and 16 were validated by inspection in Illumina Genome 
Viewer. Chr 12 duplication was peri-centromeric and therefore less likely to be reliable. Chromosome 
7p12.1 and 16q12.2 CNV duplications were also detected in inherited prion disease samples and were 
therefore less likely to represent susceptibility loci. Chr 10 duplication is located next to GPRIN2 gene 
(Figure 34), a neural growth factor which has been well described whilst another gene PPYR1, pancreatic 
polypeptide receptor-1 is contained within the duplication.  
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Figure 34 shows an image of the chromosome 10q11.22 as visualized in the Illumina Genome Viewer. The first plot 
shows the control sample where the duplication is not present and the second plot shows a sample containing the 
duplication on chromosome 10. 
 
GPRIN2 and PPYR-1 genes were genotyped using real time PCR. Chromosome 14 CNV duplication was 
genome-wide significant in both sporadic and variant CJD samples. This duplication has been associated 
with early age at onset in Alzheimer’s disease (Brouwers et al., 2006). Olfactory gene OR11H12 which is 
contained within the chromosome 14 duplication was genotyped using real time PCR.  
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c) Real time PCR in UK sporadic CJD 
Figures 34-37 show the change in cycle number (dCt) in sCJD duplication positive samples compared 
with the duplication negative samples. Delta Ct values represent the number of additional cycles needed 
to achieve threshold amplification of a given DNA segment. Most primer sets that flank random regions 
of the genome display dCt values less than two.  Figure 35 demonstrates comparison of dCt values for 
GPRIN2 and APP duplication positive and duplication negative samples where APP duplication samples 
were used as controls. There is a clear difference between the 2 groups which is statistically significant. 
These data demonstrate that CNV duplications detected using CNV Partition and PLINK are also detected 
using real-time PCR thus, confirming our initial finding. 
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Figure 35 shows a change in the cycle number (dCt) for GPRIN2 and APP duplication positive and duplication 
negative samples. There is a clear difference between the duplication positive and duplication negative samples. 
APP duplication positive samples were used as controls in this assay.  
 
Figure 36 shows dCt values for sCJD patients with GPRIN2 dCt duplication compared to sCJD samples 
without the duplication. The graph shows that there are 2 distinct groups with a clear difference which 
is statistically significant. 
 
 
183 
 
 
 
Figure 36 shows GPRIN2 dCt in sCJD samples with the CNV duplication compared to sCJD samples without the 
duplication. There is a clear difference between the 2 groups which is statistically significant. The data suggest that 
the duplication positive samples extend to include the GPRIN2 gene. 
 
 
Chromosome 10 duplication is located next to GPRIN2 gene, whilst PPYR-1 is contained within the 
duplication. PPYR-1 gene was genotyped using real time PCR. Figure 37 shows PPYR1 Δ Ct in sCJD 
samples with the CNV duplication compared to sCJD samples without the duplication. There is a clear 
difference between the 2 groups which is statistically significant.  
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                                                                          PPYR-1 dCT    
 
Figure 37 shows PPYR1 Δ Ct in sCJD samples with the CNV duplication compared to sCJD samples without the 
duplication. There is a clear difference between the 2 groups which is statistically significant.  The data suggest that 
the duplication positive samples extend to include the PPYR-1 gene. 
 
Real time PCR was then performed for GPRIN2 and PPYR-1 duplication and their correlation was 
assessed. Figure 38 shows the correlation between the 2 assays which is good indicating that 
chromosome 10 duplication extends to include the GPRIN2 gene.  
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Figure 38 shows samples with the GPRIN2 CNV duplication vs. PPYR1 CNV duplication. Samples where the 
duplication is present are marked in blue and samples where the duplication is absent are labeled in red. There is a 
good correlation between the 2 assays indicating that the chromosome 10 duplication extends to include the 
GPRIN2 gene. The duplication negative samples that appear to be in the duplication positive groups are porbably 
contaminant or false positive. Similarly, the duplication positive samples that appear to be in the duplication 
negative group are likely to be false positives due to a ‘noisy’ test.  
 
Furthermore, we analysed the clinical information of patients thought to be chromosome 10 and 14 
duplication carriers, however they did not appear to have distinct clinical or pathological phenotypes, 
although in some cases the data was limited.  
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d) CNV analysis in German sporadic CJD 
In order to confirm the above findings we performed a CNV analysis in the German sCJD patients. A total 
number of 635 German sCJD cases and 822 control samples were analyzed in the final project. The cases 
were analyzed on 670K Illumina Genome Studio platform and the controls on an older 550K Illumina 
platform. The 2 projects were merged using a unique sample sheet leading to a loss of a large number of 
CNV only probes. CNV analysis was performed in Genome Studio using CNV Partition and PLINK for 
case/control association analysis. The significant associations in the UK population were not replicated 
in the German cohort.  The case/control association analysis in the German sCJD did not reveal any 
other significant associations. 
The UK findings are intriguing as they are suggestive of potential novel susceptibility loci in prion 
disease. However, they do not replicate in the German cohort. One reason for this is that CNV Partition 
detects very small CNVs and may be more prone to false positive associations. Another explanation may 
be the difference in phenotype between UK and German cases due to the selection criteria. German 
sCJD patients were all neuropathologically confirmed cases with classic sCJD presentation which 
typically included a combination of rapidly progressive dementia, ataxia and myoclonus. The UK sCJD 
included both definite and probable cases making this patient group more phenotypically heterogenous. 
As further prion disease patients were recruited into the study the CNV analysis was repeated using the 
Penn CNV software on a larger sample set.  
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3.5.2 Copy number variants analysis using Penn CNV 
CNV analysis using Penn CNV was performed on a larger sample set which included 1261 European 
patients (from Germany, France and UK) with prion disease and 5427 European controls. A total of 587 
CNVs were detected in prion disease patients and 2786 in controls. All of the CNVs were found at <1% 
frequency in the control population. They included more than 20 markers. The size of CNVs were >100kb 
and they scored >50 with the PennCNV quality score. Any specific CNVs were also verified by inspection 
of B allele and LogR ratios in Illumina Genome Viewer. No statistically significant excess of deletions or 
duplications were identified. A total CNV burden, of sizes >100kb, >500kb or >1Mb were tested in each 
disease group and compared with the controls. These are summarized in the tables below. Table 20 
shows the CNV analysis for deletions and duplications in UK sCJD. There was no statistically significant 
association for any of the CNV sizes as summarized in the table. 
UK sCJD          
  Number # CNVs 
per 
person 
P Number # CNVs per 
person 
P Number # CNVs per 
person 
P 
>100kb Cases       
(n=583) 
122 0.209  169 0.290  292 0.501  
 Controls 
(n=4632) 
1190 0.257 0.983 1275 0.275 0.293 2471 0.534 0.838 
>500kb Cases 5 0.009  37 0.063  42 0.072  
 Controls 82 0.018 0.969 316 0.068 0.679 398 0.086 0.865 
>1MB Cases 0 0.000  14 0.024  14 0.024  
 Controls 29 0.006 1.000 87 0.019 0.244 116 0.025 0.589 
Table 20 Total CNV burden in UK sCJD compared to controls. Total CNV counts, frequency and P value 
(uncorrected empirical test using PLINK) are shown in red where the nominal P value is <0.05. No category was 
statistically significant after correction for multiple testing. 
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Table 20 shows the CNV analysis for deletions and duplication in UK vCJD. This analysis included 114 
cases and 4632 controls. Total number of 583 cases were analyzed and compared to 4632 controls.  
Deletions and duplication were separated according to their size which include CNVs >100kb, >500kb 
and >1MB. There was no statistically significant association in cases vs. controls in any of the groups 
tested. 
UK vCJD          
  Number # CNVs 
per 
person 
P Number # CNVs per 
person 
P Number # CNVs per 
person 
P 
>100kb Cases       
(n=114) 
26 0.228  38 0.333  64 0.561  
 Controls 
(n=4632) 
1190 0.257 0.736 1275 0.275 0.151 2471 0.534 0.358 
>500kb Cases 1 0.009  7 0.061  8 0.070  
 Controls 82 0.018 0.863 316 0.068 0.664 398 0.086 0.741 
>1MB Cases 0 0.000  3 0.026  3 0.026  
 Controls 29 0.006 1.000 87 0.019 0.364 116 0.025 0.549 
Table 21 Total CNV burden in UK vCJD compared to controls. Total CNV counts, frequency and P value 
(uncorrected empirical test using PLINK) are shown in red where the nominal P value is <0.05. No category was 
statistically significant after correction for multiple testing. 
A numerical excess of large duplications were also seen in UK sCJD and vCJD as shown in Tables 20 and 
21 however, these changes were not statistically significant. Of the total 27 >1000kb duplications seen in 
European case samples, 3 overlap in a region of chromosome 16 (NCBI build 36, 15,387,380-16,197,033) 
comprising 7 genes, although this same region was involved in 6 large duplications in control samples. 
Due to differences related to platform and filtering we have not directly compared these frequencies 
with other studies.  
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CNV analysis in PNG samples and controls 
Further analysis was performed in elderly women resistant to kuru and compared to healthy Fore 
population. A total number of PNG cases included 122 patients and 273 controls. CNVs were separated 
into different groups according to their sizes (as discussed above). Total CNV burden which included CNV 
>100kb showed an association (p=0.046) following case/control analysis, however this was not 
statistically significant in consideration of the number of hypotheses tested. There was no other 
significant association in this disease group. 
Elderly Women Resistant to Kuru vs Health Fore      
  Numbe
r 
# CNVs 
per 
person 
P Number # CNVs per 
person 
P Number # CNVs per 
person 
P 
>100kb Cases       
(n=122) 
240 1.967  263 2.156  503 4.123  
 Controls 
(n=273) 
480 1.758 0.046 570 2.088 0.261 1068 3.912 0.102 
>500kb Cases 0 0.000  16 0.131  16 0.131  
 Controls 3 0.011 1.000 61 0.223 0.989 69 0.253 0.997 
>1MB Cases 0 0.000  9 0.074  9 0.074  
 Controls 2 0.007 1.000 42 0.154 0.991 44 0.161 0.996 
Table 22 Total CNV burden in elderly women resistant to kuru compared to healthy Fore. Total CNV counts, 
frequency and P value (uncorrected empirical test using PLINK) are shown in red where the nominal P value is 
<0.05. Total CNV burden for CNVs >100kb was statistically significant in case/control analysis. There was no other 
statistically significant association.  
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In PNG population a 1% filter was not applied as the control population was small, and the population 
genetics of the Eastern Highland region has not been studied in detail. We found a nominally significant 
excess of deletions >100kb in the Elderly Women Resistant to Kuru group however this was not 
significant after correction for multiple testing.  
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CNV analysis in German samples and controls 
CNV analysis was repeated in German sCJD patients. This analysis included 564 cases and 795 controls. 
CNVs were divided into groups according to their sizes ranging from >100kb, >500kb and >1MB. A 
nominally significant excess of large duplications (>1000kb) were seen in the German sCJD study, at a 
rate of 1.8% of cases vs. 0.5% of controls (p=0.033) however this was not statistically significant after 
taking into account multiple testing (Table 23). 
 
German 
sCJD 
   Deletions     Duplications     Deletions and 
duplications 
  Number # CNVs 
per 
person 
P Number # CNVs per 
person 
P Number # CNVs per 
person 
P 
>100kb Cases       
(n=564) 
103 0.183  124 0.220  231 0.410  
 Controls 
(n=795) 
152 0.191 0.661 159 0.200 0.242 315 0.396 0.374 
>500kb Cases 7 0.012  29 0.051  36 0.064  
 Controls 11 0.014 0.665 32 0.040 0.206 44 0.055 0.311 
>1MB Cases 5 0.009  10 0.018  15 0.027  
 Controls 5 0.006 0.399 4 0.005 0.033 9 0.011 0.039 
Table 23 Total CNV burden in German sCJD patients compared to controls. Total CNV counts, frequency and P 
value (uncorrected empirical test using PLINK) are shown in red where the nominal P value is <0.05. No category 
was statistically significant after correction for multiple testing.  
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Association studies 
For rare CNVs, no region showed a statistically significant excess of duplications or deletions in prion 
disease patients or elderly women resistant to kuru relative to their control group once multiple testing 
was taken into account. For common CNVs, similarly there were no statistically significant associations 
made. The top ranked nominal association was found in both the genome-wide and candidate gene 
studies: at the PARK2 gene (Figure 39) in UK sCJD vs. WTCCC controls (P=0.001). CNVs in PARK2 (protein 
product Parkin) are known to cause autosomal recessive juvenile Parkinsonism, although there remains 
a debate about a causal role for structural variation in the heterozygous state (Kay et al., 2010;Kitada et 
al., 1998), which have been found in Parkinson’s disease cases and controls overlapping exons 1-4, but 
in cases alone overlapping exons 5-12. 3 deletions overlapped exons 8 and 9 of PARK2 gene were found 
in sCJD patients. Two patients had a diagnosis of definite sCJD following autopsy, a third had a diagnosis 
of probable sCJD according to established clinical criteria which according to the recent literature 
predicts autopsy diagnosis with around a 98% probability (Zerr et al., 2009). All patients had a clinical 
phenotype typical of CJD without features of Parkinsonism. We went on to look for causal non-
synonymous variants in PARK2 using exome sequencing data from 132 UK prion disease patients. No 
mutations were found. 
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Figure 39  Structural variation at the PARK2 gene in sCJD. The top ranked nominal association was found in 
both the genome-wide and candidate gene studies: at the PARK2 gene in UK sCJD vs. WTCCC controls 
(P=0.001). 
CNVs overlapping loci of potential relevance to prion disease 
There are a number of genetic loci that have been reported to play a role in prion disease. These include 
PRNP, RARB-THRB, STMN2, HECTD2, SPRN, ZBTB38-RASA, BACE, MTMR7, NPAS2, PLCD, CPNE8, SOD1, 
STCH and CTSD (Akhtar et al., 2013;Beck et al., 2008;Kovacs et al., 2010;Lloyd et al., 2010;Lloyd et al., 
2009;Mead et al., 2009a;Mead et al., 2011b;Sanchez-Juan et al., 2012). We extended our study to look 
for overlapping CNVs in these regions. We did not find any overlapping genes in more than one 
individual in a case or control group. One control individual, sample provided by the UK blood service for 
genotyping by the WTCCC was shown to have a 240kb duplication entirely overlapping PRNP. No prion 
disease patient had a CNV overlapping this gene. We went on to test for association at 100 candidate 
loci previously identified in studies of autism, mental retardation, epilepsy, schizophrenia. No 
statistically significant associations were identified except for the finding discussed above in PARK2. 
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Figure 40 summarizes the CNV analysis using different softwares and sample sets. The performance of 
each of the softwares QuantiSNP, CNV Paritition and Penn CNV was compared using the 10 sample 
project. QuantiSNP was efficient in detecting large CNVs with a good confidence score however it was 
not efficient in detecting small CNVs. This software was not used for further analysis.  
CNV Partition was efficient in detecting both large and small CNVs however it was more prone to false 
positive associations. This software was used in the initial analysis of 708 UK CJD samples and 902 
WTCCC controls. Two duplications on chromosome 10 and 14 were found to have statistically significant 
association and were further confirmed by inspection in Illumina Genome Viewer and real-time PCR. The 
finding was not confirmed when the analysis was performed in the German population. 
Penn CNV is thought to be reliable in detecting large CNVs and some smaller CNVs. It is less prone to 
false positive associations but there is a possibility that it would miss very small CNVs. This software was 
used in the analysis of 1261 European samples and 5427 controls. Nominally significant association of 
CNV deletion at PARK2 was detected using Penn CNV and candidate gene studies.  
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Summary of CNV analysis performed in this study using different sample sets and softwares 
 
Figure 40 summarizes the CNV analysis using different softwares and sample sets. Ten sample project was initially analysed 
using Quanti SNP, CNV Partition and Penn CNV. Quanti SNP was not reliable in detection of small CNVs and was therefore not 
used in further analysis. CNV Partition was used in the analysis of 708 UK CJD samples and 902 WTCCC controls. Duplication on 
chromosome 10 and 14 were statistically significant in the case control association analysis. The finding was validated by 
inspection in Illumina Genome Viewer and confirmed using real-time PCR. CNV analysis was then performed on 635 German 
samples and 822 controls however the finding was not replicated in this sample set. As more samples became available the 
analysis was repeated using Penn CNV. 1261 European cases were compared to 5427 WTCCC controls. The case control 
association analysis revealed a nominally significant association at PARK2 gene in UK sCJD which was also detected using 
candidate gene analysis. 
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V DISCUSSION 
In this study we analyzed the clinico-pathological and genetic features in a large group of patients 
suffering from prion diseases. To this end we used complementary approaches including case studies, 
molecular pathology, candidate gene analysis and genome-wide copy number variants analysis. The 
results revealed unusual clinical presentations of variant CJD; relationship between heterozgosity at 
codon 219 and possible susceptibility to variant CJD; histopathological heterogeneity of prion diseases; 
and the relationship between neuropathological features and several candidate genes in CJD. The data 
obtained on the copy number variants appear to be conflicting and some suggestions to explain these 
findings are discussed. Taken together the data may contibute to better understanding of diagnostics 
and molecular epidemiology of CJD. 
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4.1 Phenotypical heterogeneity and susceptibility locus in variant CJD- clinical case reports 
4.1.1 Atypical clinical presentation in two patients with variant CJD, correctly diagnosed following 
neuropathological analysis 
In this study we describe 2 patients who presented with clinical features consistent with sCJD but were 
later found to have variant CJD following neuropathological analysis. Phenotypic variability is 
demonstrated by an unusually old age at disease onset and sporadic-like MRI appearances. This finding 
highlights the variation in important illness characteristics and diagnostic investigations observed in 
prion diseases. Appleby et al (Appleby et al., 2009) studied the clinical variability in patients with sCJD 
and reported 5 clinical variants in sCJD based on the heterogeneity of clinical and investigation findings: 
the classic, Heidenhain, Oppenheimer-Brownell, cognitive and affective subtypes. It is likely that these 
atypical disease forms remain underdiagnosed and there may be further yet unidentified disease 
subtypes (Knight, 2006). Stoeck et al (Stoeck et al., 2008) argue that the heightened incidence of sCJD in 
recent years, observed across many different countries (Klug et al., 2013), may be associated with a shift 
in the clinico-pathological profiles. In their study patients of these subtypes were significantly older and 
showed a skewed male to female ratio when compared to published cases of sCJD-types or to patients 
from the 1996-2000 cohort.They argue that improved detection of rare sCJD subtypes may contribute to 
increased disease incidence.  
Meissner et al (Meissner et al., 2009) have studied the brain MRI findings associated with each of the 
sCJD molecular subtypes.These included confirmed sCJD cases with codon 129 genotype (MM, MV, and 
VV), PrPSc type, and fluid-attenuated inversion recovery (FLAIR) or diffusion-weighted brain imaging 
(DWI) from seven different countries. All MRI scans were assessed for signal changes according to a 
standard protocol encompassing seven cortical regions, basal ganglia, thalamus, and cerebellum.The 
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authors found that cortical signal increase and hyperintensities in the basal ganglia and thalamus were 
detected on MRI scans across all molecular subtypes of sCJD. This makes our finding of MRI features 
typical for sCJD in patients with vCJD even more relevant. We would argue that typical features may be 
present not only across different disease subtypes in sCJD but also patients with vCJD that may have 
previously been misdiagnosed as sCJD based on unexpected clinical and investigation findings. This 
finding provides further evidence for clinico-pathological heterogeneity and overlap between disease 
subtypes.  It would be of interest to perform a retrospective clinico-pathological study on patients with 
sCJD and consider this possible unusual vCJD phenotype.  
A further observation by Gelpi et al (Gelpi et al., 2013) described an atypical neuropathological 
phenotype of sCJD case in a 64 year old patient presenting with a 5 months of rapidly progressive 
dementia, psychiatric disturbance and language disorder. MRI showed atrophy, diffuse cortical 
hyperintensities and high signal in the left caudate nucleus on T2W and FLAIR images. No typical EEG 
changes were observed and 14-3-3 assay was positive. Western blot studies demonstrated the co-
occurrence of PrPSc types 1 and 2 in the frontal cortex and a relatively weak type 2 signal in the 
cerebellum. PRNP genotyping showed methionine homozygosity at codon 129. Neuropathological 
analysis showed classical CJD changes with small cortical foci of large confluent vacuoles and a relatively 
well preserved cerebellum. A striking feature was the presence of abundant kuru-type plaques in the 
cerebral cortex and subcortical white matter. Sparse kuru-type plaques were also seen in cerebellum, 
although only in white matter.This case shows a previously undescribed combination of 
histopathological features which preclude its classification according to the current phenotypic and 
molecular sCJD classification although this subclassification system is not rigid. The observation 
demonstrates that kuru-type amyloid plaques may also occur in sCJD cases with short clinical course and 
the co-existence of PrPSc types 1 and 2. This finding represents a further example of phenotypic 
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heterogeneity as demonstrated by the clinico-pathological overlap between different prion disease 
groups. 
Given the complexity of the molecular and neuropathologic factors inherent within the spectrum of 
prion diseases further studies of phenotypic variability are justified to allow early diagnosis, treatment 
and clinico-pathologic correlation. One of the challenges faced by clinicians is dealing with the variability 
of clinical symptoms, signs and investigation findings in prion disease, which may pose a serious 
diagnostic challenge as evidenced by the cases described. It may result in a delayed diagnosis and 
delayed inclusion in therapeutic trials when relatives/patients desire to do so. There are potentially 
other further cases that remain unreported and pose potential risks for recipients of blood products and 
patients undergoing surgery with the prion infected surgical instruments. In order to prevent these 
incidents and gain further accurate information about the potential risks an increase in autopsy rate and 
use of new blood test which has 100% specificity and 70% sensitivity for prion protein detection 
(Jackson et al., 2014)plays an important role. 
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4.1.2 Heterozygosity at codon 219 may represent a susceptibility polymorphism to variant CJD 
In this study we describe clinical and investigation findings of two patients with vCJD who were 
heterozygous at the polymorphic codon 219. Both patients were homozygous for methionine at codon 
129. Heterozygosity at codon 219 is a common polymorphism in the healthy Japanese population and in 
populations in Oceania, South Asia, and the Middle East, but it has not been detected in Africans or 
Europeans (Beck et al., 2010;Mead et al., 2003;Soldevila et al., 2003). Eleven patients and controls with 
E219K all had Asian ethnicity or ancestry based on a heterogenous diagnostic referral series totaling 
more than 1800 samples at the MRC Prion Unit. Recent data from a transgenic animal knock-in model 
suggest that the 219E and 219K proteins can convert to PrPSc when challenged with sCJD or vCJD prions 
(Hizume et al., 2009). Human PrP 219K–expressing mice succumbed to vCJD with a shorter incubation 
time compared with human PrP 219E–expressing mice. The E219K heterozygous mice had a longer 
incubation time to vCJD than did either homozygous mouse. However, the present patients suggest that 
the heterozygous genotype at codon 219 is not protective against vCJD and may even confer increased 
risk. We do not know whether the PrPSc seen on Western blot of tonsillar tissue in patient 2 includes PrP 
with 219K or whether this is solely derived from the 219E PrP. The E219K polymorphism occurs as a 
result of a substitution of negatively charged E by the positively charged K. Further studies are necessary 
to establish whether this charge change may be critical in permitting the conversion of PrP to its 
abnormal isoform in vCJD but not sCJD. Our seemingly paradoxical observations may be interpreted in 
the context of the conformational selection model of prion transmission proposed by Collinge (Collinge 
J, 1999) in 1999 and Collinge and Clark (Collinge and Clarke, 2007) in 2007. This model proposes that 
prion transmission occurs efficiently when there is an overlap between the infecting prion and the 
permissible conformations of the host PrP. In this circumstance, the 219K protein may not adopt the 
molecular conformations found in sCJD, resulting in strong resistance to this disease. However, in vCJD, 
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the model proposes that the 219K protein permits or even favors the bovine spongiform 
encephalopathy strain, resulting in no resistance to disease or even increased susceptibility. 
Our finding points to a role of a genetic variant, other than codon 129, in susceptibility to vCJD. Further 
studies are necessary to confirm this finding however, as this polymorphism is rare in the populations 
exposed to BSE, it may not be possible to explore its significance in a large number of patients with 
clinical vCJD. 
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4.2 Phenotypic heterogeneity- National Prion Monitoring cohort (NPMC) study 
In this study we confirm a key predictor of functional decline in rapidly progressive forms of prion 
disease, codon 129 subtype, enabling us to assess the potential gains from a stratified medicine 
approach to future clinical trials. Through use of natural history data collected in a prospective 
observational cohort study we have optimised a clinical trial model to increase power to detect clinically 
relevant effects, on a pre-mortality endpoint measuring functional decline, that is judged highly relevant 
by patients and carers. Our two key findings are, first, that genetic variation in the prion protein gene 
has a profound influence on the rate of functional decline in rapidly progressive human prion disease, 
and is therefore likely the essential factor on which to stratify a trial model. Second, that a combination 
of factors, including the use of a bespoke functionally-orientated rating scale, the use of frequent 
assessments by telemedicine, the rapidly progressive nature of prion disease, and the stratification by 
codon 129 contribute to the potential for remarkably powerful clinical trials. 
Despite the fact that codon 129 was known to be an important modifier of susceptibility and phenotype 
of prion diseases (Pocchiari et al., 2004), we were surprised by the magnitude of the effects we 
observed on functional decline after diagnosis. The homotypic protein-protein interactions in PRNP 
homozygous prion disease patients may occur faster than heterotypic interactions in heterozygous 
individuals (Palmer et al., 1991) resulting in more rapid propagation of prions and/or generation of 
neurotoxic forms of abnormal PrP. Further to this, codon 129 is known to be an important strain 
selection factor (Collinge and Clarke, 2007). Prion strains, analogous to strains of bacteria or viruses, are 
associated with distinct types of misfolded PrP, and distinct and transmissible clinicopathological 
features. It is likely that some of the distinction between the rates of decline for codon 129 
homozygotes are related to strain selection by codon 129. PrPSc type, which is measure of abnormal PrP 
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conformation and strain, did provide some limited additional value beyond codon 129 alone, but was 
only able to be measured in ~40% of the cohort, retrospectively, seriously limiting its use as a factor in 
clinical trials. The lack of a role of PrPSc type may relate to the fact that this is highly correlated with 
codon 129 genotype, and that, whilst autopsy rate in the study was high, missing data are substantial. 
We note that variation in the slopes of decline of codon 129 methionine homozygous patients was 
greater than for other genotypes, suggesting that strain diversity/permissibility may be greatest in this 
genotype. 
The last decade has seen the advent of genome-wide technologies which have driven the discovery of 
many risk factors in neurodegeneration (Singleton et al., 2010). Although examples are emerging 
(Cruchaga et al., 2010), phenotypic heterogeneity is less well understood, in part because the imperative 
to study large sample sizes has come at the expense of well characterised clinical cohorts. Clinical trials 
in common neurodegenerative diseases do not typically stratify by genetic factors. One exception is 
APOE in some studies of Alzheimer’s disease immunotherapy, although this decision was primarily 
driven by an increased susceptibility to amyloid-related imaging abnormalities in APOE4 carriers 
(Sperling et al., 2012). The potent genetic effects we observed in this study hints at the potential of 
using genetic modifiers to improve power in clinical trials in neurodegeneration more widely.   
There are some limitations of this study. A concern about avoiding making a diagnostic error, and a 
sense that it is important to diagnose only treatable disorders, means that referral to specialist centres 
often occurs late in the clinical course of human prion disease, when confirmatory tests are complete. 
Consequently the majority of patients enrolled in our Cohort study had advanced neurodisability at 
enrolment. As a rough rule of thumb to simplify decision making and due to the rapidity of progression 
in sCJD, patients with an MRI brain suggestive of prion disease, who are either able to walk (even with 
 
 
204 
 
 
help) or speak some words should be referred promptly, particularly when clinical trials are active, as 
these patients are highly likely to have prion disease. Although this is by far the largest study of its type, 
we are still underpowered to detect the modifying effects of certain factors, particularly for rare 
combinations of PrPSc type and codon 129 genotype which might be associated with atypical clinical 
courses.  
Biomarker analysis is a highly active area of research in neurodegeneration and is a key component of 
the Cohort study. In prion disease however, where diagnostic accuracy (once referred) is high and 
progression rapid, the need for a surrogate marker of progression is less compelling than in slowly 
progressive disease syndromes. In the multivariate analysis, standard diagnostic MRI, EEG and CSF 
biomarkers did not add significantly to codon 129 subtype for predicting the slopes of functional decline. 
In our analysis, the number of samples for PrPSc type was also very small which made it difficult to assess 
its role as a potential disease modifier. The analysis of quantitative MRI parameters which seem 
promising as predictors of the severity of microscopic tissue pathology is beyond the scope of this report 
(Siddique et al., 2010). The propensity of abnormal PrP seeds to trigger the polymerisation of 
recombinant PrP in vitro, for example by the PMCA or RT-QUIC reactions, have potential as highly 
responsive therapeutic biomarkers in CSF and will be important adjuncts to future trials.  
Functional endpoints in other neurodegenerative diseases typically require several hundred or 
thousands of patients for adequately powered studies (Green et al., 2010). Here we have shown that 
using repeated measurements of a functional scale can reduce sample sizes by 10-30 patients, 
depending on the frequency of assessment. The functional scale also has advantages in that it is not 
affected by personal decisions regarding end-of-life care (including PEG feeding, antibiotics etc), which 
can add substantial variation obscuring treatment differences in small trials using a survival endpoint. It 
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is now accepted by some that common neurodegenerative disorders share fundamental mechanisms 
with prion disease, termed prion-like. Immunotherapeutics and small molecules have been developed 
which can clear prion infection from cultured neuronal cells, and cure infection or greatly impede it in 
vivo(Silber et al., 2013;Wagner et al., 2013;White et al., 2003). The prognosis for rapidly progressive 
prion disease is particularly severe and the unmet need is great, analogous to advanced cancer, which 
has proven to be a very effective test-bed for novel therapeutics. We hope that our study will modify 
the view of human prion disease as an orphan disorder futile for clinical study, into a tractable disorder 
for testing of therapeutics. 
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4.3 Histopathological heterogeneity 
As already discussed, spongiform change, neuronal loss, astrocytosis, glial proliferation and prion 
protein deposition represent the typical neuropathological changes associated with CJD. 
Hyperphosphorylated tau and amyloid-β accumulation are also present suggesting that prion diseases 
belong to a wider spectrum of neurodegenerative diseases that share common neuropathological 
pathways.  In order to assess the role and possible interaction of different proteins associated with 
neurodegeneration we investigated the distribution and accumulation of amyloid- β, prion protein and 
hyperphosphorylated tau in prion disease patients. We found that tau accumulation tends to co-localize 
with the prion protein deposition. Interestingly, amyloid- β deposits are also present in these patients 
but total accumulation is significantly lower than the accumulation of either prion protein or 
hyperphosphorylated tau. The difference is particularly striking in the cerebellum where the amyloid-β 
deposits appear to be virtually absent compared to the other two proteins. This finding highlights the 
importance of the interaction of the different proteins with the host tissues. The mechanism underlying 
the selective targeting of specific brain regions by different neurodegenerative diseases is an intriguing 
phenomenon. It is already known that cholinergic neurons of the cerebral cortex as well as the 
hippocampal neurons are affected in Alzheimer’s disease (Francis et al., 1999), whereas dopaminergic 
neurons of the substantia nigra are targeted in Parkinson’s disease (Sulzer and Surmeier, 2013).  
However, the reasons why other brain regions remain spared are still unknown (Jackson, 2014). A better 
understanding of the selective vulnerability of different tissues to neurodegeneration may allow 
development of targeted therapeutic approaches that would alter disease course and prevent 
progression. This selective vulnerability is thought to be determined by the interaction of different 
protein conformers with host microenvironments affected by a wide range of contributory factors. The 
interaction of misfolded proteins with the combination of cell-type –specific environments and brain-
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region-specific neural features ultimately determine selective vulnerability. The spreading of the 
neurodegenerative process is likely controlled by a combination of opposing factors that facilitate or 
restrict spread of the disease. A better understanding of how these factors interact and contribute to 
the process of neurodegeneration is likely to play a key role in the discovery of therapeutics in prion 
diseases and other neurodegenerative disorders.  
Another interesting finding is the statistically significant correlation between disease duration and total 
accumulation of hyperphosphorylated tau in prion disease patients. Spillantini et al (Spillantini and 
Goedert, 2013) argue that the conversion of soluble to insoluble filamentous tau protein is central to 
many human neurodegenerative diseases. Tau is an unfolded microtubule-associated protein that binds 
to and might have a role in the assembly and stabilization of microtubules. Because the assembly of tau 
is concentration dependent, regional variation in expression of the protein could favour its 
accumulation. Tau hyperphosphorylation seems to precede filament assembly, but whether this process 
is necessary or sufficient for filament assembly is unknown. It appears to take time and this may explain 
its positive correlation with disease duration i.e. increased tau accumulation correlates with increased 
disease duration and increased disease severity. Van Everbroeck et al (Van et al., 2002) have found that 
in the sCJD population determination of both 14-3-3 and tau protein concentrations are of a high 
diagnostic value. In their study they showed that high phosphorylated tau concentration in the 
cerebrospinal fluid is clinically correlated with a significantly shorter disease duration and early onset of 
akinetic mutism. These findings reconfirm the complex pathology observed in prion diseases and 
overlap between neuropathology of different disease groups. Whether there is a correlation between 
increased tau accummulation in the CNS tissue with more severe clinical picture in prion diseases 
remains to be established. This may be further evidence towards the interplay between the intra and 
extracellular hyperphosphorylated tau and different protein isoforms essential for the pathogenesis of 
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neurodegeneration that would provide a potential therapeutic target for prion diseases but possibly also 
other tauopathies.  
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4.4 Candidate gene analysis vs. neuropathological analysis in prion diseases 
In addition to protein heterogeneity we investigated the role of several candidate genes known to be 
associated with the process of neurodegeneration. Their role in prion diseases is poorly understood or 
completely unknown. However, as they govern some of the processes common to prion and other 
neurodegenerative diseases we investigated their role in our cohort of sCJD patients.  
As shown in the results we found MAPT gene to be associated with both increased deposition of prion 
and tau protein. This finding did not surpass multiple testing and will therefore need to be replicated. 
This finding if confirmed provides further evidence for disease overlap and common pathological 
pathways in different neurodegenerative diseases. The conversion of soluble to insoluble filamentous 
tau protein is central to many human neurodegenerative diseases collectively referred to as 
tauopathies. Therefore tau presents a potential therapeutic target with broad relevance. Because the 
assembly of tau is concentration dependent, regional variation in expression of the protein determined 
by the variation in MAPT gene could favor or restrict its accumulation (Spillantini and Goedert, 2013). 
Although some tau sites are more phosphorylated in the diseased than in the healthy brain, others are 
phosphorylated only in the diseased brain. Tau phosphorylation seems to precede filament assembly, 
but whether this process is necessary for protein aggregation remains unknown. Distinct brain regions 
and cell types are affected in different human tauopathies. These differences are partly due to different 
isoforms of filaments. Interestingly, all 6 isoforms are present in tau filaments in the brains of patients 
with Alzheimer’s disease whereas filaments in patients with cortico-basal degeneration and progressive 
supranuclear palsy are made of four-repeat tau and tau filaments of patients with Pick’s disease are 
made of three-repeat tau (Delacourte et al., 1996;Flament et al., 1991;Spillantini et al., 1997). 
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MAPT in populations of European descent is characterized by two haplotypes that result from a 900-kb 
inversion (H1) or non-inversion (H2) polymorphism. Inheritance of the H1 haplotype is a risk factor for 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and idiopathic Parkinson’s 
disease (IPD) (Conrad et al., 1997;Houlden et al., 2001;Pastor et al., 2000). Subhaplotype H1c in a 
regulatory region in intron 0 of MAPT is associated with increased risk of PSP and CBD. The association 
of the H1 MAPT haplotype with PSP has a higher odds ratio than the association between APOE4 and 
Alzheimer’s disease. APOE4 is the major risk factor allele for late-onset Alzheimer’s disease (Corder et 
al., 1993). The H2 haplotype is associated with increased expression of exon 3 of MAPT in grey matter, 
suggesting that the inclusion of exon 3 is protective against PSP, CBD and PD. Thus tau isoforms 
containing exon 2 and 10 promote tau aggregation and exon 3-containing isoforms inhibit tau 
accumulation. Additional receptors for oligomeric amyloid-β are likely to exist and it remains to be seen 
whether their protein aggregates can activate the same pathway.  
Although most drug trials in Alzheimer’s disease so far have focused on amyloid- β, interest in tau-
targeted treatments is becoming more relevant because of the discovery of the important role of tau in 
neurodegeneration and the difficulties associated with targeting of amyloid-β to develop mechanism-
based treatments for Alzheimer’s disease. The pathway leading from soluble and monomeric to 
hyperphosphorylated insoluble tau is central to human tauopathies. Therefore, inhibition of aggregation 
and dissembly of tau aggregates are both promising therapeutic possibilities. The hyperphosphorylation 
of tau seems to be an early and crucial event in tau-mediated neurodegeneration. The amount of 
phosphorylation depends on the conformation of tau and on the balance between the activities of tau 
kinases and phosphatases.  
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If tau aggregates propagate between cells, they are likely to pass through an extracellular stage. The 
removal of extracellular tau aggregates by specific antibodies constitutes a potential mechanism-based 
treatment. Interference with the spread of tau aggregates at a preclinical stage might therefore prevent 
the appearance of clinical features in tauopathies but also other neurodegenerative disorders 
characterized by tau accumulation such as prion diseases.  
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4.5 Copy number variants as susceptibility loci to prion disease  
In this study we report the first genome-wide analysis for risk conferred by structural variation in human 
prion diseases. They have not been previously studied in these disorders. CNVs in non-coding regions 
can have profound effect on human phenotypes by altering the copy number of an entire gene that is 
predisposed to dosage effect (Klopocki and Mundlos, 2011). CNVs can also result in position effects and 
cause long-distance effects as far as 1Mb from the translocation breakpoints. CNVs have an impact on 
the miRNA-mediated post-transcriptional network by modulating or predisposing to certain complex 
genetic diseases (Persengiev et al., 2013). Whereas single-nucleotide polymorphisms and their role in 
disease pathogenesis have been studied extensively, the role of structural genomic variants is still poorly 
understood. They have been associated with several neuropsychiatric disorders such as autism, 
schizophrenia and bipolar disorder. They have also been associated with PD and early onset AD which 
supports the possibility of the existence of CNVs-driven mechanisms in the process of 
neurodegeneration and brain aging.  
In order to identify common variants that associate with complex diseases multiple genome-wide 
association studies have been performed. Some of the strongest effects of common variants have been 
found in late-onset diseases and in drug response. The major histocompatibility complex has also shown 
association with a variety of disorders. Although there have been some positive findings in 
neuropsychiatric genetics, common variation has explained little of the high heritability of these traits. 
In contrast, early studies of rare copy number variants have led rapidly to a number of genetic loci that 
strongly associate with neuropsychiatric disorders. It is likely that the use of whole-genome sequencing 
to investigate the role of variation in neuropsychiatric and neurodegenerative disorders will greatly 
advance our understanding of these conditions.  
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Maillard et al (Maillard et al., 2014) investigated the variation in brain anatomy in 16p11.2 deletion and 
duplication carriers. They showed that the number of genomic copies is negatively correlated to the 
grey matter volume and white matter tissue properties in cortico-subcortical regions implicated in 
reward, language and social cognition. The pattern of brain anatomy changes in carriers overlapped with 
the well-established structural abnormalities associated with autism spectrum disorders and 
schizophrenia. A combination of molecular, neuroimaging and clinical approaches will help a better 
understanding of contribution of genes to neuropsychiatric and neurodegenerative disorders by 
measuring their effect on local brain anatomy.  
A recent review by Flaherty et al (Flaherty and Brennand, 2015) using patient-derived human induced 
pluripotent stem cells (hiPSCs) to model neuropsychiatric copy number variations argues that it has the 
potential to reveal the underlying disease mechanisms in schizophernia. Genetic risk in schizophrenia is 
thought to be conferred by both common variants of relatively small effect and rare variants with high 
penetrance. Genetically engineered mouse models can recapitulate rare variants, displaying some 
behavioral defects associated with schizophrenia; however, these mouse models cannot recapitulate 
the full genetic architecture underlying the disorder. HiPSCs present an alternative approach for 
studying rare variants, in the context of all other risk alleles. Genome editing technologies, such as 
CRISPR-Cas9, enable the generation of isogenic hiPSC lines with which to examine the functional 
contribution of single variants within any genetic background. Studies of these rare variants using hiPSCs 
have the potential to identify commonly disrupted pathways in schizophrenia and allow for the 
identification of new therapeutic targets. It is possible that some of these techniques will be applicable 
in better understanding of role of CNVs in neurodegenerative diseases such as prion diseases.  
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CNVs encompass more nucleotide content per genome than SNPs thus their significance to genetic 
diversity is likely to be high.  A genome-wide map of CNVs shows that between 6-19% of each 
individual’s chromosomes exhibit CNVs. The mechanisms involved in the progress of brain aging and 
associated with neurodegenerative diseases are complex and are likely to be a result of disturbance of 
numerous genes. Thus, miRNAs dysregulation that would inevitably alter the expression of multiple 
genes might provide a better understanding for neuronal cell deterioration. Multiple factors participate 
in the control of miRNA expression. Persengiev et al  (Persengiev et al., 2013) argue that CNVs-miRNA 
interactions are an important part of increased brain susceptibility to external and internal influences 
during the aging process. The authors highlight the urgency to annotate CNVs which can potentially alter 
miRNA expression and should be considered high-priority candidates in genotype-phenotypes mapping 
studies of brain-related disorders.  
In this study we investigated the role of CNVs as possible novel susceptibility loci to prion diseases. The 
initial analysis revealed several CNV duplications with genome-wide significance on chromosomes 6, 7, 
10, 12 and 14. The analysis was performed using CNV Partition which is a software supported by Illumina 
Genome Studio. The software was selected following analysis of the performance of three different 
softwares: Penn CNV, QuantiSNP and CNV Partition. CNV Partition was found to select the highest 
number of even very small deletions and duplications. This software has high sensitivity however it is 
potentially prone to making a higher number of false positive associations. In order to avoid these we 
selected a high confidence value and used stringent quality control criteria. The finding on 
chromosomes 10 and 14 were further confirmed using real-time PCR. This finding was not replicated 
when we tested the German CJD cohort and compared with the German control samples. The reason for 
this may be because the analysis of the German cohort was performed on an older platform which 
included only 550 000 probes that have not been enriched to detect CNVs. These were mainly SNP 
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probes and when compared to the 670K UK project contained a significantly lower number of CNV 
probes. It is possible that the German analysis was not sensitive enough to detect the significant 
associations observed in the UK CNV analysis.  
The other explanation may be the patient selection criteria. German patients were all 
neuropathologically confirmed cases of classic sCJD with a rapidly progressive dementia, while the UK 
cases were more phenotypically heterogenous and included a number of probable sCJD patients. The UK 
and German patients were not matched for age, gender, duration and clinical presentation as this would 
have led to a significant reduction in sample size. However, majority of patients in both cohorts were in 
their 60ies at the time of presentation and had disease duration of several months. It may be that the 
CNV duplications detected in the UK population are associated with more atypical phenotypes and were 
therefore not replicated in the German case/control analysis. 
Furthermore, CNV duplications on chromosomes 10 and 14 were not detected when the analysis was 
repeated on a larger number of UK cases and controls. The repeat analysis was performed using Penn 
CNV. This software has been widely used and is well described in the published literature. It is very 
sensitive for detecting large CNV deletions and duplications. It is less reliable for detecting small CNVs. It 
may be that the associations were not possible to detect due to the small sizes of the duplications. 
Otherwise, it is possible that the association detected using CNV Partition are spurious and for that 
reason were not replicated on a larger sample set or in a different population group.  
An interesting association at PARK2 was the top ranked locus in the genome wide analysis however it 
did not surpass the threshold required for statistical significance. A role for heterozygous exon deletion 
in the etiology of Parkinson’s disease remains unclear. In the most detailed population study to date 
CNVs overlapping exons 5-12 of PARK2 were found in PD cases but not in controls. Our findings were 
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similar, in that we found 3 deletions of PARK2 exons 8 and 9 in sCJD cases, but no CNVs overlapped 
these exons in the WTCCC control series. In order to further support an association at this locus we 
looked for evidence of replication in the other disease cohorts, and by testing for heterozygous causal 
SNPs in PARK2 in prion disease remain speculative.  
Mutations in the PARK2 gene have been associated with juvenile Parkinsonism and there have been 
reports of the association with peripheral neuropathy (Vital et al., 2015). The autosomal recessive form 
of juvenile Parkinsonism is considered to be the most common form of familial PD and has been 
identified in European, North American, Turkish and Japanese families. It is known that the role of 
parkin protein in the brain is to break down misfolded proteins such as ubiquitin-protein ligase (Hattori, 
2002). Although there are exceptions, the lack of Lewy bodies in parkin-mutated brains suggests its 
fundamental role in Lewy body formation. The elucidation of the exact role of parkin protein provides 
the mechanisms of the formation of Lewy bodies in common forms of sporadic PD. Therefore, it is 
important to detect the substrates for the parkin protein. Recently, several candidate substrates have 
been reported including CDCrel-1, synphilin-1, alpha-synuclein-22 (o-glycosylated alpha-synuclein), and 
Peal-receptor. The question is accumulation of which substrates are responsible for the nigral neuronal 
death in Park 2 linked brain. CNV deletion in this region provides further evidence for the overlap 
between related neurodegenerative conditions and possible common neuropathological mechanisms in 
disease pathogenesis as already discussed. 
The possible role for altered expression of PRNP in resistance or susceptibility to prion disease has long 
been speculated since it was known that transgene copy number and the hemizygous state in mouse 
conferred strong effects on incubation time to mouse prions (Bueler et al., 1993), and suggestive 
haplotypic associations were found at the PRNP locus in sCJD (Mead et al., 2001). However, subsequent 
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larger GWA studies did not confirm the initial haplotype findings at PRNP (Mead et al., 2011b) and CNVs 
were not identified in a case series focusing on APP and PRNP (McNaughton et al., 2012). The 
identification of a duplication overlapping PRNP in a UK Blood Service control sample and not in cases is 
further evidence against the potential causal association of increased PrP expression due to PRNP 
duplication.  
The absence of PRNP deletion in elderly women resistant to kuru is intriguing as this group experienced 
intense selection pressure during the kuru epidemic (Mead et al., 2009b). Potential explanations include 
the incompatibility of healthy human adult life with a half-dose of PRNP. Alternatively, the dominant-
negative effects of amino acid changing variants of PRNP, such as 127V, may offer greater opportunities 
for selection to take place.  
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4.6 Future Work  
This study revealed several interesting and potentially important findings.   
1. Heterozygosity at codon 219, a polymorphism common in the Asian populations is protective 
against sCJD but appears neutral or may even confer susceptibility to vCJD. Our finding was 
based on the 2 samples in a large referral series at the MRC Prion Unit due to its rarity in the UK 
population. It would be of interest to investigate the relevance of this polymorphism in 
susceptibility to vCJD in a larger population set exposed to the BSE epidemic. Other genetic loci 
with modest effects may play a role and have cumulative impact on the susceptilibility and 
phenotypic heterogeneity in prion diseases.  
2. We described 2 vCJD patients with unusual clinical presentation (in terms of age at presentation 
and MRI findings) who were correctly diagnosed following neuropathological analysis. Atypical 
clinical cases should be investigated not only to prevent misdiagnosis but also because they may 
be associated with novel genetic loci and PrPSc strain types. 
3. MAPTH1c haplotype appeared to play a role in both prion protein and hyperphosphorylated tau 
deposition. The finding provides evidence for possible link between prion disease and other 
neurodegenerative conditions and should be repeated in a larger sample set.  
4. There was no strong evidence that CNVs play a significant role in susceptibility to prion diseases. 
As CNVs encompass such a large proportion of the human DNA and their role remains poorly 
understood further collaborative studies would be justified on a larger number of samples. In 
this circumstance a case-control analysis should be performed using the same platform for DNA 
analysis and software for data interpretation to prevent potential discrepancies due to probe 
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and analysis differences. If possible, the patients should be matched for age, gender and disease 
subtype although this may lead to a reduction of an already small sample set.   
5. Our studies demonstrated that patient stratification and detailed assessments using MRC Rating 
Scale allowed collection of a comprehensive data set on disease progression in CJD patients. 
Therefore, only 90 patients would provide adequate study power to evaluate new therapeutic 
approaches in future clinical trials.  
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Abstract This article highlights the features that connect
prion diseases with other cerebral amyloidoses and how these
relate to neurodegeneration, with focus on tau phosphoryla-
tion. It also discusses similarities between prion disease and
Alzheimer’s disease: mechanisms of amyloid formation,
neurotoxicity, pathways involved in triggering tau phosphor-
ylation, links to cell cycle pathways and neuronal apoptosis.
We review previous evidence of prion diseases triggering
hyperphosphorylation of tau, and complement these ﬁndings
with cases from our collection of genetic, sporadic and
transmitted forms of prion diseases. This includes the novel
ﬁnding that tau phosphorylation consistently occurs in spo-
radic CJD, in the absence of amyloid plaques.
Cerebral amyloid, tau phosphorylation and cell death:
how are they connected?
Human prion diseases represent a clinically and patholog-
ically diverse group of neurodegenerative disorders
including (1) sporadic Creutzfeldt–Jakob disease (sCJD),
(2) inherited forms of prion diseases (inherited prion dis-
ease, IPD) such as Gerstmann–Stra¨ussler–Scheinker
syndrome (GSS) or fatal familial insomnia (FFI) and (3)
acquired forms, such as variant CJD (vCJD), iatrogenic
CJD (iCJD) and Kuru. We avoid the term ‘‘familial CJD’’,
as CJD was originally deﬁned as a clinicopathological
syndrome which is distinct from e.g. GSS or FFI. The term
IPD links the different syndromes by pathogenesis and is
therefore preferred.
According to the protein-only hypothesis [40], infectious
prions are composed predominantly, if not entirely, of
aggregates of misfolded, host-encoded, cellular prion protein
(PrPC), commonly designated PrPSc [83]. PrPSc arises from
normal prion protein (PrPC) through conformational conver-
sion. The commonneuropathological feature of prion diseases
is a predominantly extracellular accumulation of PrPSc in the
central nervous system. Prion protein deposits are highly
variable in their intensity (Fig. 1; Table 1), pattern, i.e. pla-
ques (Fig. 1m–o), perineuronal labelling (Fig. 1p–r), synaptic
deposition (Fig. 1j–l) and formation of coarse granular
deposits (Fig. 1g–i) and their distribution within the CNS.
These deposits correspond biochemically to amyloid, i.e.
aggregates of protein with high content of b-sheets. The
deposits are accompanied by spongiform change with neu-
ronal vacuolation and degeneration (Fig. 1a–f) and astrocytic
and microglial reaction, all of which can vary considerably
within the CNS and between different individuals.
Whilst prion diseases can be readily transmitted via
various routes and between species, the most common Ab
amyloidosis is transmissible at a considerably lower efﬁ-
ciency, and has to date been limited to experimental
settings [29]. Another well recognised CNS amyloidosis,
familial British dementia (FBD) has not been experimen-
tally tested for transmissibility.
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In the last few years, a striking number of epidemio-
logical, neuropathological, and biochemical similarities
between prion diseases and Alzheimer’s disease have been
identiﬁed, in particular the fact that there are interactions
between the two proteins [41, 59, 74] and between the
signalling pathways involving both proteins.
Epidemiologically and clinically, both disorders are
dementing illnesses that mainly occur sporadically, but can
also occur as familial forms. Histopathologically, both are
characterised by the deposition of an extracellular amyloid
that is produced by neurones. In both diseases, there is
formation of amyloid oligomers and ultimately also of
solid amyloid aggregates in the brain (Figs. 1g–o, 2a–f;
Table 1): both amyloid proteins can accumulate diffusely
(Fig. 2a–c), or they can exhibit prominent and widespread
deposition of dense amyloid plaques with a diameter of
more than 200 lm (Fig. 2d–f), and both elicit a consider-
able astrocyte and microglial reaction, variable neuronal
Fig. 1 Spongiform changes and
PrP deposition in sporadic prion
disease: severity of spongiform
changes, ranging from mild to
moderate and severe, with
diffuse, homogenous
spongiform changes (a–c) and
patchy conﬂuent vacuolisation
(d–f). Patterns and intensities of
commonly observed prion
protein deposits: g–i coarse
granular deposits of prion
protein, which may form
conﬂuent aggregates. j–l
Synaptic PrP, ranging from mild
to severe, and m–o, formation
of plaques in sporadic CJD. All
patterns and intensities are used
in the scoring scheme to
compare with tau burden in our
series; 160 lm (a–c, m–o),
300 lm (d–f, p–r), 80 lm (j–l)
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loss, and occasionally deposition of amyloid in or around
vessels walls.
Biochemically, both diseases are characterised by
aggregation of a protein that is encoded and expressed by
the host. It was recently suggested that Ab42 may act
through a PrP receptor [41, 59]. Experimental data suggest
that there is a functional link between PrPC and Ab pro-
cessing: (1) knockdown of PrPC in N2A cells increases Ab
levels in vitro, (2) PrP knockout mice as well as scrapie-
infected mice show increased Ab level and (3) PrPC
overexpression reduces Ab formation by downregulating
the APP cleaving enzyme b-secretase [77].
Recent genetic evidence also links prion disease to
Alzheimer’s disease, in that the APOE-E4 allele, a well-
established risk factor for AD, also may increase the risk
for sporadic CJD [57], but surprisingly may delay onset of
inherited prion disease with the P102L mutation [92]. A
detailed discussion of the similarities between CJD and
AD, the relationship between codon 129 polymorphism
and a model of Ab42 action through PrPC receptor are
given in a review by Gunther and Strittmatter [41].
The amyloid cascade hypothesis
According to the amyloid cascade hypothesis, proposed by
Hardy and Higgins [44] the increased production or
decreased clearance of amyloid beta (Ab) peptides results in
the accumulation of the hydrophobic Ab40 and Ab42 pep-
tideswith subsequent aggregation and formation of insoluble
plaques. This induces a cascade of deleterious changes, such
as neuronal death and eventually causes Alzheimer’s
disease. Since then, this hypothesis underwent several
transformations due to the accumulating data supportive of
or inconsistent with the theory [81]. The current version
assumes a toxic role of soluble preﬁbrillar oligomers based
on the several in vivo and in vitro experiments [37, 42]. The
results contradicting these ﬁndings [61, 86, 90] and the
recognised experimental artifacts [7] make it more difﬁcult
to elucidate their genuine role in disease development.
However, a number of recent studies in transgenicmice have
further strengthened the concept of the amyloid cascade
hypothesis: intracerebral injection of Ab seeds trigger the
aggregation of endogenous Ab: intracerebral inoculation of
APP23 transgenic mice with brain homogenates from Alz-
heimer’s patients or with brain extracts from aged APP23
transgenicmice elicits amarked anticipation of the disease in
young APP23 mice [69]. This ﬁnding can be interpreted as
prion-like transmission or as seeding process. The latter is a
more likely scenario, as implantation of small steel wires
coated with minute amounts of Ab-containing brain
homogenate into the brain of APP23 transgenic mice trig-
gered signiﬁcant deposition of Ab in the CNS, whilst
peripheral inoculation of these mice with Ab did not seed in
the CNS [29]. It may be argued that the presence of a prion
receptor, but not of an ‘‘Ab’’ receptor in peripheral tissues,
such as nerve endings or immune cells.
Cerebral amyloid and tau hyperphosphorylation:
what is the trigger?
A prominent feature of cerebral amyloidoses is the induc-
tion of tau hyperphosphorylation. This is very well
Fig. 2 Intensities of Ab deposits: a–c diffuse protein deposits
without formation of plaques (ranging from mild to severe). a Score
1 (mild) describes occasional patchy deposits, occasionally seen on
low power magniﬁcation. b Moderate, score 2 describes deposits that
are seen in\50% of adjacent low power ﬁelds. c An example of
heavier diffuse amyloid beta burden, indicating a presence in most of
the low power ﬁeld on a cortex section. Dense core amyloid beta
plaques, approximately corresponding to CERAD sparse (d), inter-
mediate (e) and high (f). Scale bar 300 lm (a–f, g–i)
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established for Alzheimer’s disease (AD), but is also a
prominent feature in the rare FBD and has been sporadi-
cally described for prion diseases mostly in the context of
the presence of plaques, such as in vCJD or in many
inherited forms. A prominent feature of AD is the accu-
mulation of hyperphosphorylated tau within or in the
vicinity of cortical amyloid deposits (Fig. 3d–f). Impor-
tantly, this direct association of tau pathology in areas of
Ab accumulation has to be separated from a probably
independent process of tau phosphorylation that starts in
the entorhinal cortex and spreads over the limbic system
and ﬁnally extends into neocortical regions. This latter
process has been characterised in detail and was formalised
in a staging system developed and deﬁned by Braak and
Braak [10, 11]. The clinical dementia correlates better with
the Braak stage than with the deposition of Ab.
FBD is an autosomal dominant, neurodegenerative dis-
order, presenting with dementia, spastic tetraparesis, and
cerebellar ataxia, also known as Worster–Drought syn-
drome [68, 82, 85, 94]. Similar to Alzheimer’s disease,
in particular its inherited forms, the neuropathological
hallmarks of FBD include extensive cerebral amyloid
angiopathy (CAA), cerebellar degeneration with severe
CAA and parenchymal amyloid plaques. There are also
hippocampal amyloid plaques as well as neuroﬁbrillary
tangles, and white matter degeneration similar to that seen
in Binswanger’s disease [50]. Deposition of hyperphos-
phorylated tau in FBD is indistinguishable from that in AD,
both immunohistochemically and ultrastructurally.
In prion disease, hyperphosphorylation of tau has been
described, but it is not a well-known or well-characterised
feature. Not much is known about the relationship between
disease duration, PRNP codon 129 genotype, glycotype,
histological manifestations and the degree of tau phos-
phorylation. Several studies have reported the deposition
of hyperphosphorylated tau in small series of sporadic,
familial and variant forms of prion diseases. These reports
highlight the role of prion amyloid plaques as an essential
prerequisite to elicit tau phosphorylation and raise impor-
tant questions related to the mechanism responsible for tau
phosphorylation. A detailed discussion of these reports is
given below.
Ab, PrP and tau: their connection to cell cycle
and cell death
Several pathways are thought to play a role in neurode-
generative processes, some of which are unusual suspects.
A number of cell cycle proteins have recently been
implicated in neurodegenerative processes. CDK5, GSK3b,
and pAkt are all well-characterised mediators of growth,
survival and inhibitors of neur(on)al differentiation. All are
now also linked to the family of neurodegeneration—prion
protein, Ab and tau phosphorylation.
CDK5, a serine-threonine kinase, is a cell cycle protein
that is also responsible for processes, such as axonal
guidance, cortical layering and synaptic structure/plastic-
ity, and it is mainly expressed in postmitotic neurones [18,
78]. Dysregulation of CDK5 has been implicated in neu-
rodegeneration for some years [17, 18, 20, 71, 78, 88] and
it is now likely to be involved in abnormal phosphorylation
Fig. 3 Amyloid beta or PrP induced pattern of tau phosphorylation
differ: a–c the range of PrP induced tau deposits. The scores of tau
correspond to the scores of PrP shown in Fig. 1, i.e. tau score 1 is
typically seen in areas with PrP score 1 and dense tau deposits (scores
2 or 3) is typically seen in areas with PrP scores 2–3. d–f In contrast,
Ab induces a threaded tau phosphorylation pattern, with elongated
dystrophic neuritis but very little stub- or rod-tau. All examples are
from the frontal or parietal cortex, and correspond to diffuse a beta
deposits scores 1–3. Scale bar 25 lm (a–f)
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of tau. In keeping, CDK5 inhibition alleviates tau phos-
phorylation and cytoskeletal lesions [96].
GSK3b has recently been identiﬁed as a likely candidate
directly to phosphorylate tau and mechanistic links
between GSK3b, tau [60, 84] and Ab [45, 46, 51] have
been established. A less well described, but mechanisti-
cally appealing connection has also been made to PrP,
which makes the hypothesis of cell cycle related proteins
and neurodegeneration attractive [79].
Another pathway that has been implicated in neurode-
generation involves PTEN/pAkt. The tumour suppressor
PTEN antagonises the phosphorylation of Akt, hence
downregulation of PTEN increases the phosphorylated,
active form of Akt (pAkt), which has pro-survival, pro-
proliferation effects and counteracts apoptosis and cell
differentiation. However, whilst this function of pAkt is
important and relevant for cells capable of self-renewal and
proliferation, i.e. the developing CNS, it is different for
quiescent/postmitotic cells, such as neurons, where con-
stitutive activation of Akt can cause neurodegeneration
[67], including abnormal phosphorylation of tau, mediated
by CDK5 in a GSK3b independent fashion [56, 71]. Whilst
the role of Ab triggering tau phosphorylation is well
established [9, 38, 62, 75], a recent study also showed that
tau phosphorylation is transmissible too, which may have
wide ranging implications for the concept of the involve-
ment of Ab as the sole trigger for hyperphosphorylated tau
in Alzheimer’s disease [23].
Experimental evidence for the connection of tau, Ab and
PrP comes from work of from Perez et al. [79]. Using PrP
106–126 peptides, a widely used paradigm to test prion
toxicity in vitro, GSK3b mediated tau phosphorylation was
induced. Other studies provide compelling evidence that
CDK5, PrP and Ab are mechanistically connected and
involved in neurodegeneration [64, 65].
The PrP–tau connection (I): inherited prion diseases
and phosphorylation of tau
Inherited prion diseases display a wide spectrum of path-
ological deposition of prion protein. The formation of
conspicuous and well-demarcated amyloid plaques is typ-
ically seen in inherited forms with codon P102L (Figs. 4m,
5c) P105L, and A117V mutations (Figs. 4n, 5d), whilst
D178N or E200K (Figs. 4o, 5e) mutations show less
well-deﬁned plaque pathology. Other mutations, such as
octapeptide repeat insert (OPRI) mutations present histo-
logically with a unique striping pattern of the cerebellum
(Fig. 4k, l).
Reports of tau pathology in inherited prion diseases
consistently describe marked dystrophic neurites with
hyperphosphorylated tau, accentuated in the vicinity or
located within amyloid plaques. The ﬁrst reports were those
of classical GSS with the PRNP P102L mutation [5, 8, 34,
35, 73, 89]. Later studies of P102L GSS with detection of
abundant phospho-tau concluded that this may be an effect
of PrP-mediated phosphorylation rather than a Ab related
effect, as there were only minimal Ab deposits seen [52].
However, it may be argued that this latter study detected tau
phosphorylation in the entorhinal cortex which has formed
independently from the prion amyloid deposition, in the
context of Alzheimer’s disease corresponding to Braak and
Braak stage I. Other mutations associated with the clinical
phenotype of GSS (A117V mutation [91]), or P105L [53,
95] reported similar ﬁndings. In vitro experiments with a
prion protein peptide carrying the A117V mutation
decreased the rate of microtubule formation more efﬁ-
ciently than wild-type PrP106–126. This was thought to be
related to the displacement of tau, where A117V mutation is
more efﬁcient at inhibiting microtubule formation [13].
OPRI mutations, such as 96 bp [21], or 144 bp inserts
[22] into the N-terminal octarepeat region, are character-
ised by a unique pattern of immunoreactivity for PrP,
which is oriented perpendicularly to the cerebellar surface
(Fig. 4k, l), also show a marked tau phosphorylation, which
co-localises with PrP deposits. A case report of a 216 bp
OPRI mutation instead showed a pattern different from
those with a shorter insert, with the formation of large
amyloid plaques, again co-localising with hyperphospho-
rylated tau [27].
Finally, the stop mutation 145X [33] with formation of
plaques and cerebral amyloid angiopathy (‘‘PrP-CAA’’)
showed similar results with tau co-localising to plaques.
The PrP-tau connection (II): tau phosphorylation
in sporadic and variant CJD
Following the observation of hyperphosphorylated tau in
inherited prion diseases with remarkable tropism to amy-
loid plaques, but not in sCJD, several studies analysed this
phenomenon further: Giaccone et al. [36] compared tau
phosphorylation patterns of AD and vCJD and found the
same three bands of 68, 64 and 60 kDa in an immunoblot
probed for tau. Morphologically, hyperphosphorylated tau
co-localised with ﬂorid plaques. However, it was also
found that unlike in AD, there was no detectable soluble
hyperphosphorylated tau in vCJD. In contrast to the ﬁnd-
ings that we report in our series (see below), their study did
not detect hyperphosphorylated tau in brains of sCJD
patients [36]. A study comparing the ultrastructure of prion
amyloid in GSS and vCJD [87] came to a similar conclu-
sion, but in addition found that dystrophic neurites
containing hyperphosphorylated tau occurs in sCJD with
small plaques. It was concluded that plaque-forming prion
10 Acta Neuropathol (2011) 121:5–20
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diseases are capable of generating phospho-tau deposits,
but forms with synaptic PrP deposits may be incapable to
do so [87].
To examine this further, we examined 79 brains from
patients with sporadic CJD and compared them to 12 cases
with inherited prion disease and 5 vCJD cases. We can
Fig. 4 Prion protein-triggered tau phosphorylation in the cerebellum:
upper row deposition of abnormal PrP; sporadic CJD with synaptic
PrP deposition (a–c) or with small plaques (d). e vCJD with heavy
PrP burden with diffuse deposits as well as plaques. The correspond-
ing tau phosphorylation is shown below (f–j): it is approximately
proportional to the PrPSc burden and is also closely associated with
plaques. However, an exceptionally strong tau deposit is consistently
seen in vCJD cerebella (i). Inherited forms of prion disease show
variable amounts of p-tau deposits, which do not correlate with the
PrP burden and also do not correlate with the pattern (plaque or
synaptic): The pattern of abnormal PrP deposition is distinct for each
mutation. 96 and 144 bp OPRI form a characteristic striping pattern
perpendicularly to the cerebellar surface (k, l) with moderate tau
labelling in the 96 bp OPRI and very little tau in the 144 bp OPRI.
The extent of tau phosphorylation appears to be independent of the
plaque load, with P102L and A117L cases showing similar tau burden
as in the E200K which features synaptic PrP deposition. Scale bar
120 lm (a–e, n, o); 250 lm (k, l, m) and 40 lm (f–j, p–t)
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demonstrate for the ﬁrst time that there is indeed presence
of hyperphosphorylated tau in sCJD with synaptic
(Figs. 1j–l, 6i, j) or pericellular PrP, notably also in the
absence of plaques (Figs. 3a–c, 6a, b, e, f). When consid-
ering with the previous reports, we detected a very
substantial formation of phospho-tau positive rods in ﬁve
cases of vCJD, including two cases of blood transfusion
related transmission (Fig. 4j). In those cases with con-
comitant Ab amyloid pathology (mild, n = 14), we found
both patterns, namely granular, rod-shaped PrP-induced tau
inclusions (Fig. 3a–c) and thread-shaped Ab related for-
mations (Fig. 3d–f). Cases of inherited prion disease
(P102L, A117V, D178N, E200K, 96 and 144 bp octarepeat
insert) show accumulation of tau directly associated with
prion protein plaques (Figs. 4p–t, 5f–j).
The PrP-tau connection (III): neocortical PrPSc
and pTau correlate in sporadic and in inherited
forms of prion diseases
In our series of sporadic, inherited and variant forms of
prion diseases (n = 79), we found a correlation of prion
protein burden (Fig. 1) and the formation of rod or stub-
shaped tau deposits in the neocortex (Fig. 3; Tables 2, 3).
Previously, the ability of prion protein to hyperphospho-
rylate tau was thought to be associated with the presence of
amyloid plaques, as seen in vCJD, GSS or certain forms of
sCJD. We show here in a large cohort, that indeed synaptic
PrP is directly associated with the presence of minute
deposits of hyperphosphorylated tau. Regions in which
prion protein deposits across the entire thickness of the
cortex also show the presence of tau rods in the same area
(Fig. 6i, m). Other cases where the burden of abnormal
prion protein is restricted to deeper cortical layers show a
distribution of tau rods congruent with prion protein
accumulation and neurodegeneration (Fig. 6a, e). In sCJD,
deposition of tau signiﬁcantly correlates with the intensity
of prion protein load (correlation coefﬁcient r = 0.69,
p\ 0.01), but does not correlate with disease duration
(r = -0.037, n.s.). Importantly, the size of tau granules in
sCJD with homogenous synaptic PrP was smaller than that
in sCJD with formation of large PrP granules.
To exclude that the tau phosphorylation was induced by
coexisting Ab amyloid, we stratiﬁed for presence or
absence of Ab amyloid (Tables 2, 3). Almost half of the
cases (n = 36) were entirely free of any form of Ab, a
small number showed patchy, mild and diffuse deposits of
Ab (corresponding to Fig. 2a) (n = 13) and the remainder
showed more intense diffuse Ab and/or core plaques (see
Fig. 2b–e) (n = 27). The morphology of hyperphospho-
rylated tau associated with abnormal prion protein is
remarkably distinct from that elicited by Ab, in particular
in cases of synaptic PrP deposition (Fig. 3). Prion protein
related tau hyperphosphorylation shows as short stub- or
rod-like structures (Fig. 3a–c). The most subtle deposition
forms small rod- or stub-like punctate inclusions (gran-
ules). Their shape resembles granules seen in argyrophilic
grain disease [31]. They do not extend to ﬁbrillary or
‘‘neuritic’’ tau, whilst the most subtle deposition of Ab-
associated tau ﬁbrils occurs in the form of thin, single
neuritic threads in the cortex (Fig. 3d). The next stage of
Ab-induced tau phosphorylation is a more frequent pres-
ence of ﬁbrils (Fig. 3e), and ﬁnally the Ab-induced tau
pathology amounts to a delicate network of dystrophic
processes (Fig. 3f), including neuroﬁbrillary tangles.
Amyloid plaques are generally surrounded by a small
corona of dystrophic neurites, which are well known and
have been frequently described in the literature. The tem-
poral and entorhinal cortex was excluded from the analysis
because this area shows a tau pathology that emerges
independently from Ab or prion protein pathology, and is
likely to represent an independent pathogenic process,
which may explain the ﬁndings of Ishizawa et al. [52]. It is
possible, but difﬁcult to prove whether phosphorylation of
tau in this area may be enhanced by the deposition of prion
protein.
Those forms of prion diseases, which show labelling of
perineuronal networks and small plaques [87], show tau
rods in the vicinity of the perineuronal nets and around
small plaques. In our series, microplaques in sCJD
(Fig. 4d) as well as inherited forms with prominent plaques
(Fig. 5) showed an obvious accumulation of tau at a higher
density (Fig. 6e–h) forming short processes resembling
dystrophic neurites. However, these intraplaque and pe-
riplaque neurites were still more granular than those
associated with Ab plaques. Importantly, this phenomenon
was observed in the absence of any Ab pathology. The
most straightforward explanation of PrP-associated tau
phosphorylation is a simple dose-dependent direct toxicity
whereby PrP amyloid is directly involved in the process.
Alternatively, a critical level of toxic species may be pro-
duced during the conversion process, which is thought to
involve a number of conformational intermediates or side
products during prion conversion and propagation, variably
named as PrP* [1] or PrPL (lethal) [24]. These toxic (by-)
products, may directly or indirectly trigger pathways
mentioned above and hence contribute to tau phosphory-
lation. However, considering the kinetics of abnormal
protein accumulation in prion diseases [24], and the rela-
tive abundance of prion amyloid in comparison to
hyperphosphorylated tau, makes the latter a likely side
effect rather than a main trigger of prion neuropathogene-
sis. However, the dissection of the events involved in tau
phosphorylation may well be the key to understand prion
neurotoxicity.
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Phosphorylation of tau in the cerebellum:
an underestimated feature?
In our series of sporadic, inherited and variant forms of
prion diseases, we detected formation of rod-shaped tau
deposits in the molecular and granular layers. Some forms
of sporadic prion diseases form abundant small plaques,
alongside with synaptic PrP, which is associated with
marked periplaque hyperphosphorylation of tau. The same
observation is made in inherited prion disease with the
predominant formation of cerebellar plaques, such as
P102L GSS, where tau is associated with, but not limited
to, plaques. We show here that sporadic forms trigger tau
phosphorylation in the cerebellum in a ‘‘load-dependent’’
Table 2 Summary of all cases
analysed in this study
All PrP, tau and Ab scores were
obtained using the scoring
scheme shown in Figs. 1, 2,
and 3. In case of multiple
concurrent PrP patterns, the
highest individual score (e.g.
granular score 2 and synaptic
score 1 = ﬁnal score 2) was
used. No cases with cerebellar
Ab were included in this study.
A score 4 for frontal cortex tau
was given in cases that clearly
exceeded the intensity shown in
Fig. 3. One case (sCJD VV)
scored 0 for tau and was
omitted. All other cases had a
tau score of 1 or greater. Cases
with a tau score of 4 (exceeding
the density shown in Fig. 3) are
also shown sCJD MM, MV,
VV sporadic CJD with PRNP
codon 129 genotype,
IPD inherited prion disease
Acta Neuropathol (2011) 121:5–20 13
123
fashion (Fig. 4; Table 3), where cases with a relatively low
cerebellar burden of abnormal PrP show fewer rod-shaped
tau positive inclusions (Fig. 4a, f) than those with an
intermediate (Fig. 4b, g) or high PrP load (Fig. 4c, h). This
correlation is statistically signiﬁcant for sCJD (correlation
coefﬁcient r = 0.39, p\ 0.01) which increases when all
forms of prion diseases are included (r = 0.50 p\ 0.01).
Tau phosphorylation in the cerebellum occurs in the
molecular layer (Fig. 4f), granular layer (Fig. 4g) and in
the Bergmann glia/Purkinje cell layer (Fig. 4h, i). vCJD is
characterised by a particularly heavy deposition of abnor-
mal PrP in the neocortex and the cerebellum (Fig. 4e),
again there is a signiﬁcant and dense deposition of hyper-
phosphorylated tau in all areas (Fig. 4j, molecular layer).
Fig. 5 PrP-induced tau phosphorylation in cortex of inherited prion
diseases: upper row deposition of abnormal PrP in the frontal cortex;
there is considerable variability of the intensity of PrPSc burden and
some forms are characterised by distinct patterns of plaque formation,
as described before. The lower row shows tau deposits corresponding
to the area depicted above. A, 96 bp OPRI mutation with almost
undetectable PrPSc load, resulting in tau phosphorylation similar to
the 144 bp OPRI (f, g), despite its signiﬁcantly higher PrPSc load (b).
c This case with a P102L mutation shows predominantly diffuse
deposits and only very few plaques, as compared to the very heavily
plaque-forming A117V case (d), both showing similar tau hyper-
phosphorylation (h, i). Another case with no plaque formation,
E200K (e), shows a tau load similar to all other cases (j). Scale bar
a–e 240 lm, f–j 60 lm
Table 3 Statistical analysis of relationship between prion protein deposition, tau phosphorylation and disease duration
Parameter 1 Parameter 2 Number of cases R Signiﬁcance level
Tau (frontal cortex), no Ab amyloid PrP deposits: the strongest score
was taken into account
28 0.69 \0.01
Tau (frontal cortex), no Ab amyloid Duration of illness 28 -0.037 n.s.
Tau (cerebellum), all prion diseases) PrP deposits 69 0.50 \0.01
Tau (cerebellum), all prion diseases Duration of illness 63 0.063 n.s.
Tau (cerebellum), sCJD only PrP deposits 52 0.39 \0.01
Tau (cerebellum), sCJD only Duration of illness 49 -0.16 n.s.
Parameters 1 and 2 were correlated in Pearson’s test (n.s. not signiﬁcant)
Fig. 6 PrP deposits are congruent with hyperphosphorylated tau rods.
Left column (heatmaps) (a, e); i,m numbers of tau rods or granuleswere
determined per high power ﬁeld on a section in the cortex and a small
strip of adjacent subcortical white matter (immunostaining for AT8
Tau). Each ﬁeld shows the count and a colour coded representation,
(heat map).Middle column b, f, j, n a parallel tissue section, stained for
abnormal PrP shows deposits corresponding to the tau heat map. Right
column c, d, g, h, k, l, o, p high power magniﬁcation of the areas
indicated by a blue square in the heatmap and in the overview of the PrP
labelled section (corresponding to ca 25% of the blue square). Arrows
in the tau labelled section indicate very small granules (d, l):
c perineuronal net pattern of abnormal PrP, no plaque formation and
moderate density of tau particles (d), g more intense PrP deposition
and formation of small plaques, which elicit heavier tau deposition (h).
The homogenous synaptic deposit (j) corresponds to a homogenous
distribution of tau, which appears in very small granules (i). The coarse
granular PrP deposits (n, o) are associatedwith larger, better discernible
tau granule (p). Scale bar b, f, i 1,500 lm, c, d, g, h, k, l 140 lm
c
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When comparing the cerebellar tau in brains with
96 bp OPRI, 144 bp OPRI, P102L, A117V and E200K
mutations (Fig. 4k–t), we found that (1) plaque and
synaptic PrP elicit a similar degree of tau hyperphosph-
orylation, but (2) varies between genotypes, which is
particularly evident when comparing with 96 and 144 bp
OPRI (Fig. 4s, t).
These ﬁndings can be interpreted as follows: (1) within
one type of PrP (e.g. sCJD prion protein) the degree of tau
phosphorylation is likely to be dose (or load-) dependent,
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as shown in Fig. 4a–c and f–h; whilst (2) each genetic
mutation is able to elicit a response that is speciﬁc to a
given mutation, suggesting that the PrP load and tau
phosphorylation may not be comparable between different
mutations (Fig. 4p–t). The relatively small number of
inherited forms investigated here does not allow for robust
statistical analysis. It has been argued that the long duration
may contribute to the extent of tau phosphorylation, as
vCJD and GSS show signiﬁcantly higher tau load and have
longer incubation times than sCJD. We show here that
there is no correlation between the duration of the illness
and the degree of tau phosphorylation. Prion protein
load appears to be the main factor triggering tau
phosphorylation.
The capacity of cerebellar neurons to hyperphosphory-
late tau has only recently been recognised and is probably
generally underestimated. Primary tauopathies, such as
progressive supranuclear palsy (PSP) are examples of the
capacity of cerebellar Purkinje cells [55, 80] or neurones
of the dentate gyrus [93] to hyperphosphorylate tau. In
patients with PSP or corticobasal degeneration, the clinical
phenotype of cerebellar ataxia is directly associated with
the progressive accumulation of hyperphosphorylated tau
in Purkinje cells [55]. Another disease featuring tau phos-
phorylation in cerebellar neurones is Niemann–Pick
disease where defects in the intracellular trafﬁcking of
exogenous cholesterol causes neurodegeneration. Neuroﬁ-
brillary tangles in the cortex of Niemann–Pick brains are
morphologically similar to those in AD. In the cerebellum,
there is a marked deposition of phospho-tau in the dentate
nucleus and granular layers of the cerebellum [66], but a
remarkable absence of neuroﬁbrillary tangles (NFT) is
noted [17]. Several mouse models have addressed this [18]
and whilst accumulation of hyperphosphorylated tau in
cerebellar granule or Purkinje neurones can be successfully
achieved in several mouse models (stress-induced [76],
Niemann–Pick disease type C [18], pAkt-mediated tau
phosphorylation [71]), no model has yet achieved forma-
tion of NFT, highlighting a speciﬁc pathway or cellular
machinery required for NFT formation that is absent in the
cerebellum [18]. A transgenic mouse expressing human
P301L mutant tau did not show cerebellar tau at all [63].
One of the reasons that cerebellar tau phosphorylation is
widely underestimated is the presence of abundant cortical
phospho-tau in the neocortex in Alzheimer’s disease whilst
it is strikingly absent from the cerebellum, due to the lack
of signiﬁcant Ab accumulation in the cerebellum. If at all,
Ab deposits in the cerebellum only at late stages of the
disease process. Only few studies have demonstrated Ab
deposition in the cerebellum [4] forming diffuse deposits,
but no plaques with dystrophic neurites [58]. Cases of
familial AD can show a signiﬁcant Ab burden in the cer-
ebellum, and can form deposits of various shapes and sizes
[32]. In the same series, cases with sporadic AD showed
diffuse and granular deposits, and may, therefore, have
represented a group with high overall Ab load [4]. More
commonly, vascular Ab may cause cerebellar haemor-
rhages [26] or infarctions [19]. Familial AD cerebella
accumulate mutant Ab42 [54, 72], whilst in sporadic AD,
these deposits are composed of Ab40 amyloid in humans
[70] as well as in experimental models [48].
Most studies including recent multicenter studies of the
neuropathology of AD have not systematically examined
tau hyperphosphorylation in the cerebellum [2, 3]. A recent
biochemical and confocal imaging study has demonstrated
co-localisation of tau and Ab in synaptosomes of all brain
regions, including the cerebellar samples, which showed
the lowest levels within the CNS [30].
In contrast to Alzheimer’s disease where cerebellar Ab
is essentially absent, most sporadic, inherited and trans-
mitted forms (iatrogenic CJD, variant CJD and Kuru) of
prion disease are characterised by a substantial prion pro-
tein deposition in the cerebellum (Fig. 4e). In sCJD,
cerebellar prion protein is often seen as synaptic, homog-
enous deposit in the molecular layer and to a lesser extent,
in the granular layer (Fig. 4a–d). Other typical patterns are
characterised by small granular deposits, which may
become conﬂuent to form microplaques. Kuru, an acquired
prion disease in humans, transmitted by oral uptake during
mortuary feasts in the Fore linguistic group in Papua New
Guinea, is clinically characterised by cerebellar ataxia,
rather than dementia, and shows a marked involvement of
the cerebellum, with formation of dense plaques of variable
sizes [12, 43].
Iatrogenic prion disease can be caused by a wide variety
of procedures, mostly due to the transmission of CJD pri-
ons contained in contaminated growth hormone derived
from human cadavers, or by implantation of contaminated
dura mater grafts [15, 39], transmission of CJD prions
during corneal transplantation [28, 47], contaminated
electroencephalographic (EEG) electrode implantation or
surgical operations using contaminated instruments or
apparatus [14]. The pattern of prion protein deposition is
characterised by synaptic PrP and formation of small and
medium sized plaques in neocortex and in the cerebellum.
Finally, vCJD in the UK and other countries, caused by
human exposure to BSE prions from cattle (Collinge et al.
1996; Bruce et al. 1997; Hill et al. 1997; Collinge 1999;
Asante et al. 2002), is characterised by extensive plaque
formation including the cerebellum.
Conclusion
The capacity of disease-associated PrP to trigger phos-
phorylation of tau has been discovered sequentially. Early
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reports have described this phenomenon in obvious cases,
where abundant plaques were present. Increasing awareness
and understanding of this phenomenon and reﬁnement of
immunohistochemical and biochemical techniques have
subsequently triggered additional studies, extending the
observation to variant CJD and plaque-forming sporadic
prion diseases. In parallel, the recognition of prionopathies
and prion-like mechanisms as a concept for neurodegener-
ative disease pathogenesis has triggered a wealth of
comparative experiments which led to the discovery of
similarities and functional relationships between Ab and
prion protein. Tau takes part in this process and we have
highlighted the evidence that may represent a mechanism of
amyloid toxicity. Although the relationship between
amyloid toxicity and tau phosphorylation appears straight-
forward in our cohort of sCJD cases, the issue may be more
complicated in inherited prion diseases. Other parameters
that were not systematically addressed in our study are
genetic (tau haplotype, PRNP codon 129 genotype) or
demographic factors (e.g. age of onset). Our data presented
here underpin the concept of amyloid-triggered tau phos-
phorylation, further contribute to the understanding of the
relationship between prion amyloid and tau toxicity and set
the scene for future research on larger cohorts. Furthering
the study of pathways involved in tau phosphorylation may
also be the key to understand prion neurotoxicity.
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Abstract
Background: Establishing a confident clinical diagnosis before an advanced stage of illness can be difficult in
Creutzfeldt-Jakob disease (CJD) but unlike common causes of dementia, prion diseases can often be diagnosed by
identifying characteristic MRI signal changes. However, it is not known how often CJD-associated MRI changes are
identified at the initial imaging report, whether the most sensitive sequences are used, and what impact
MRI-diagnosis has on prompt referral to clinical trial-like studies.
Methods: We reviewed the MRI scans of 103 patients with CJD referred to the National Prion Clinic since 2007 and
reviewed the presence of CJD-associated changes, compared these findings with the formal report from the
referring centre and reviewed the types of sequence performed.
Results: In sCJD we found CJD-associated MRI changes in 83 of 91 cases (91% sensitivity). However, the referring
centres documented CJD-associated MRI changes in 43 of the sCJD cases (47% sensitivity). The most common
region not documented by referring centres was the cortex (23 of 68 sCJD cases), but there was a statistically
significant discrepancy in all regions (p<0.0001). Patients in whom MRI abnormalities were missed by the referring
hospital were more advanced at the time of recruitment to a clinical trial-like study (p=0.03).
Conclusions: CJD-associated MRI changes are often not documented on the formal investigation report at the
referring centre. This is important as delay makes enrolment to clinical trials futile because of highly advanced
disease. If a diagnosis of CJD is suspected, even if the initial imaging is reported as normal, a specialist MRI review
either by an experienced neuroradiologist or by a prion disease specialist unit could facilitate earlier diagnosis.
Keywords: Prion, MR imaging, Creutzfeldt-Jakob disease, Dementia
Background
Creutzfeldt-Jakob disease occurs as a sporadic, iatro-
genic and genetic fatal neurodegenerative disorder [1].
With the exception of genetic types, CJD can only be de-
finitively diagnosed by tissue examination, usually brain
biopsy or at autopsy. However, using clinical and investi-
gative criteria, WHO sought to define the likelihood that
a patient has CJD. The original criteria include dementia
with variety of neurological signs, the presence of 14.3.3
proteins in the CSF and characteristic EEG with pseudo-
periodic complexes. More recently MRI criteria have
been added giving a sensitivity and specificity >90% for
probable CJD [2,3]. These changes comprise alterations
on diffusion weighted (DWI) and FLAIR images in the
basal ganglia, thalamus and cortex [4,5]. However these
changes can be subtle and easily missed by a clinician
unfamiliar with such a rare disorder. With the develop-
ment of potential therapies to alter the natural history of
the disease early diagnosis is essential to give the max-
imum chance of salvaging functional brain tissue [6]. As
MRI is the most widely available non-invasive test assist-
ing diagnosis, it is important that clinicians are aware of
the imaging features. At present it is not known how
often the MRI abnormalities are reported by radiologists
in cases of definite CJD. We therefore reviewed images
from 133 consecutive patients referred to the National
Prion Clinic and compared the report from the referring
clinician and our own specialist radiologists; 103 were
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suitable for the study of whom 70% had an autopsy or
cerebral biopsy.
Methods
Experimental procedures
Patients
In 2004 the Chief Medical Officer wrote to UK neurolo-
gists requesting that all patients with suspected CJD are
referred to both the National CJD Surveillance Unit in
Edinburgh and the National Prion Clinic (NPC) based at
the National Hospital for Neurology and Neurosurgery
(NHNN), London. All patients underwent PRNP analysis
for genetic mutations. MRI scans from all visited patients
are requested by the NPC. The scans studied in this work
were from patients who were referred to the NPC by
their local physician with full consent and the patients
were enrolled into either the clinical trial PRION-1 or
the on-going National Prion Monitoring Cohort study.
Both studies were approved by the Eastern Medical
Research Ethics Committee and are compliant with
the Helsinki Declaration.
MRI evaluation and reporting
NPC MRI review The first MRI scan were reviewed by
one of two senior neuroradiologists (H.H. and J.S.) at
The National Hospital for Neurology and Neurosurgery
(NHNN and the NPC). The radiologists were aware of
the suspicion of CJD at the time of reporting but were
not aware of the results of any biopsy or post mortem
results at the time of reporting. The available MRI se-
quences were reviewed together as the sensitivity of indi-
vidual sequences was not being compared. Three types of
high signal intensity lesions were accepted as CJD-
associated MRI changes on DWI and/or Fluid Atte-
nuated Inversion Recovery (FLAIR) and/or T2-weighted
sequences:
1. Lesions in the striatum (caudate or putamen or both)
2. Lesions in the thalamus including the pulvinar
3. Lesions along the cortical ribbon (cerebral or
cerebellar)
External MRI formal report review All external reports
were reviewed for whether:
1. The MRI was normal
2. The MRI differential diagnosis included CJD
3. CJD-associated abnormalities were specifically
documented in the caudate, putamen, thalamus or
cortex
Exclusion criteria and classification
All patients in whom a clinical diagnosis other than CJD
was suspected, or those who did not fulfil the criteria for
CJD were excluded, as were all scans before 2007 when
specific scan review was not routine. Patients who were
referred to the NPC with a suspected diagnosis of inhe-
rited prion disease (IPD) were also excluded, as prion
gene sequencing resulted in a definite diagnosis and
MRI rarely shows any signal change with the majority of
mutations. Two cases with the E200K mutation and one
case with the P102L mutation detected at a later stage
were included as the clinical picture at the time was in-
distinguishable from sCJD.
The remaining patients were categorised by CJD type
with all available investigations; those with sporadic CJD
were further sub-categorised at the time of initial referral
as: possible, probable or definite using the WHO criteria.
We then re-classified the sCJD patients using the modi-
fied criteria suggested by Zerr et al. [3] for both the re-
ferred MRI report and then our own MRI impression to
see whether our MRI interpretation altered the classifi-
cation of these patients. Where available, the scales data
was documented, based on a composite functional scale
derived from the Barthel ADL index and Clinical De-
mentia Rating Scale Sum of Boxes.
Statistical analysis
The patient population characteristics and the compari-
son of the presence of CJD-associated MRI images be-
tween NPC and referring centre were assessed using the
Chi2 test (GraphPad Prism).
Results
We obtained 133 MRI scans from 113 patients referred
to the NPC between 01.03.2007 and 24.05.2010 with a
suspected diagnosis of CJD. 30 scans were excluded: 21
cases did not fulfil the WHO diagnostic criteria for CJD
or were thought clinically to be due to a different cause;
the referring report could not be obtained in 9 cases.
A total of 103 reported scans were available for review
of which 56% were from males. The eventual diagnosis
was sCJD in 91 cases with a median age of onset of
65 years (3 possible, 35 probable and 53 definite). Two
cases of iatrogenic CJD (iCJD) from cadaver sourced
growth hormone were identified (both 41 years old when
symptomatic), 3 patients with inherited prion disease
and 7 patients had vCJD with a median age of onset of
22 (2 probable and 5 definite) (Table 1).
In sCJD, we found characteristic increases in MRI sig-
nal intensity in 83 of the 91 cases at NPC review, a sen-
sitivity of 91% for MRI in the diagnosis of CJD in this
series (Table 1). CJD-associated changes were not de-
tected in 8 a total of cases, 2 of whom did not have a
DWI (2 definite sCJD). The remaining 6 cases had a
DWI sequence performed (two definite, three probable
and one possible sCJD) (Table 1). The referring centres,
however, described CJD-associated MRI changes in 43 of
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the 91 sCJD cases (sensitivity of 47%), with unreported
CJD-associated MRI changes in 40 of the 83 sCJD cases
found to have MRI changes at NPC review (p<0. 0001
compared with our identification of similar changes
using Chi2 with Yates’ correction and 1 degree of free-
dom). In cases with unreported CJD-associated MRI
changes, there was no significant difference between
cases referred from a neurological centre or general hos-
pital (Table 1). Occasionally CJD-associated MRI changes
were commented upon but thought to be calcification of
the basal ganglia, but more commonly there was no
mention of critical thalamic/cortical signal changes.
To further investigate whether referring centres identi-
fied CJD-associated MRI changes we reviewed specific
locations of increased MRI signal in sCJD cases (Figure 1).
We found that the most common sites for CJD-associated
MRI changes were cortex (74%) (Additional file 1: Figure
S1B and S1C) and caudate (73%) with thalamus being the
least affected (37%) (Figure 1). The most common region
not documented by referring centres was the cortex (23 of
68 sCJD cases), but there was a statistically significant dis-
crepancy in all regions (p<0.0001 Figure 1).
All reports of vCJD were concordant with our own.
Interestingly, two definite cases did not have a pulvinar
signal increase greater than that of the basal ganglia and
were initially classified as sCJD. In contrast, both iCJD
cases were initially reported to have had normal scans
(Table 1, Additional file 1: Figure S1A). When the diag-
nosis was categorised according to the modified criteria
suggested by Zerr et al. [3] at the time the patient pre-
sented to the NPC, using the MRI report and our own
MRI impression, we found that the diagnosis changed
from possible to probable sCJD in only two cases as all
other patients with negatively reported scans had either
characteristic EEG changes or positive CSF 14-3-3 pro-
tein (data not shown).
DWI sequences were performed in 83 of the 103 MRI
studies (79%) (Table 1). In the 20 patients for whom
DWI was not performed, CJD-associated MRI changes
were detected in 16 MRI studies. In all the MRI studies,
FLAIR and T2-weighted sequences were present.
A subset of the cohort which included 62 patients
were rapidly reviewed by the National Prion Clinic team
and scales data obtained based on a composite func-
tional scale derived from the Barthel ADL index and
Clinical Dementia Rating Scale Sum of Boxes. Where
the MRI abnormalities were detected by the referring
hospital (n=40), patients had a significantly higher (less
advanced disease) (p=0.03) median functional score of
5/35 (range 0–31) compared to median MRC score of
Table 1 The characteristics and MRI report comparison of 103 CJD patients
Final
diagnosis (n)
Median age
of Onset
(min-max)
No. DWI
sequences (%)
No. cases with
“CJD-associated
changes” on
MRI (%)
No. cases from
neurological
centre (%)
No. cases with
unreported changes
from neurological
centre (%)
Possible Probable Definite Total NPC
review
Referring
centre
sCJD 3 35 53 91 65 (38–85) 75 (82) 83 (91) 43** (47) 55 (60) 19 (43%)
vCJD 2 5 7 22 (20–53) 6 (86) 7* (100) 7 (100) 5 (71) 0
iCJD 2 2 41 (0) 1 2 0 2 (100) 2 (100)
IPD 3 3 1 - -
E200K 2 67 (63–70) - 2 0 0 -
P102L 1 61 (0) - 1 1 0 -
The scans and corresponding reports of 103 CJD patients were reviewed. The population comprised 91 sCJD, 7 vCJD, 2 iCJD and 3 IPD patients. The number of
scans with DWI is shown as is the incidence of CJD-associated changes as noted by NPC and referring centre.
*= 2 of the 7 patients had MRI changes normally associated with sCJD.
**= p<0.0001 compared with NPC opinion of CJD-associated changes using Chi2 with 1df and Yates’ correction.
Figure 1 The MRI scans of 91 patients with sCJD were reviewed
and compared with the corresponding report from the
referring centre. The overall sensitivity of MRI scans found by the
NPC was 91% compared with 47% from the referring centre
(p<0.0001). The NPC found that 74% of cases had cortical high
signal, 73% of cases had changes in the caudate, 59% of cases had
changes in the putamen and 37% in the thalamus. The region that
there was the most discrepancy between the two impressions was
the cortex but there was a significant difference in all regions
evaluated (p<0.0001).
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2/35 (range 0–27) when the MRI abnormalities were
missed by the referring hospital (n=22).
Discussion
We have shown that MRI signal changes are often not
identified on initial scan at referring hospitals in patients
with CJD. Signal abnormality characteristically occurs in
the basal ganglia and thalamus [7-9] but this was
reported in only about half the referred patients and cor-
tical abnormalities were reported in even fewer patients.
Missed diagnosis was associated with a more advanced
clinical state at enrolment in clinical-trial like studies.
There are a number of reasons why the MRI signal ab-
normalities were not reported by the referring clinicians.
Firstly, the rarity of CJD means radiologists, even in a
neurological centre, have not seen many cases and will
be unfamiliar with the characteristic MRI findings. Sec-
ondly, it is possible that CJD at the time of original scan-
ning was not suspected, or was not mentioned on the
original request for MRI scanning, which would make the
radiologist consider a much wider range of possibilities.
The heightened suspicion of CJD at referral to our centre
is highly likely to be a factor in the increased ascertain-
ment. It is possible that after joint multidisciplinary meet-
ings with added clinical information, new interpretations
of the scan were not updated on the actual MRI report.
Thirdly, abnormality can be difficult to detect when
the MRI is degraded by movement artefact, a common
phenomenon in confused patients with CJD. In these
situations, it is even more imperative to perform a DWI
sequence which is relatively short compared to other
MRI sequences and can provide good quality informa-
tion in an uncooperative patient. Despite the inclusion
of DWI sequences in many routine MRI protocols, we
found that DWI was only performed in 79% of MRI
studies. When a patient is uncooperative, performing the
DWI sequence earlier in an MRI protocol may be more
helpful than persisting in acquiring good quality images
in other sequences.
Finally, the MRI abnormalities may have been detected
but dismissed as artefact and not reported. Increased
signal abnormality in the neocortex was seen in 17% of
controls subjects in a study by Young et al. [4] which
could lead to caution in interpretation of DWI findings
by many radiologists. However, visualisation of the
DWI-trace image in conjunction with the Apparent Dif-
fusion Coefficient (ADC) map where corresponding de-
creased signal is seen (Additional file 1: Figure S1D), can
confirm initial suspicion of DWI abnormalities. Perform-
ing an additional DWI sequence at a high b-value such as
b=3000 s/mm2 can increase confidence when DWI signal
abnormality is suspected [10]. DWI using a standard b-
value of 1000 s/mm2 and a high b-value of 3000 s/mm2
are routinely performed as part of the MRI Protocol for
the diagnosis of prion diseases at our institution. Asym-
metrical cortical or deep grey nuclei involvement can
also increase confidence in abnormal signal interpret-
ation. Nevertheless cortical ribboning must be inter-
preted with caution; this particularly applies to use of
machines with field strength higher than 1.5 T used in
the present study.
We found evidence of a less advanced clinical state
once patients were referred to our centre in patients
where the MRI abnormalities were detected by the refer-
ring centre compared to those where the MRI abnormal-
ities were initially missed. At present a high proportion
of CJD patient present to specialist centres with very
advanced neurodisability (often within a few days of
death) when clinical trials are futile. MRI is usually one
of the initial investigations when a patient is admitted
which could allow a clinical diagnosis to be made at an
earlier stage, avoiding uncertainty amongst patient rela-
tives and the need for further unnecessary investigations.
We believe that in patients where the initial MRI find-
ings were missed by the referring centre, further investi-
gation delayed referral leading to a more advanced
clinical state at specialist referral.
Conclusion
MRI is a useful tool in the diagnosis of CJD but the
characteristic changes are often not identified at initial
scan in the early stages of disease. This does not imply
an adverse criticism of the radiologists who have prob-
ably never, or rarely seen, an MRI from a patient with
CJD and to whom the diagnosis has not been raised as a
possibility. However CJD MRI findings have been
reported in the literature for over a decade and it is im-
portant if experimental therapeutics are to be success-
fully tested in human trials. If a diagnosis of CJD is
suspected, even if the initial imaging is interpreted as
normal, specialist MRI review either by an experienced
neuroradiologist or by a prion disease specialist unit
could facilitate earlier diagnosis.
Additional file
Additional file 1: Figure S1. Selection of 4 cases from the 40 cases
where CJD-associated MRI changes were missed at the referring centre.
(A) A probable iCJD (growth hormone treated) patient: axial T2W images
demonstrates hyperintensity within the basal ganglia and thalamus
bilaterally; (B) A “probable” sCJD patient: axial DWI images show cortical
hyperintensity in the frontal cortex bilaterally; (C) A “definite” sCJD
patient: axial DWI shows hyperintensity in the head of caudate nucleus
and occipital cortex bilaterally; (D) A “definite” sCJD patient: axial ADC
map demonstrates restricted diffusion in the head of caudate and
putamen bilaterally.
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The Medical Research Council Prion Disease
Rating Scale: a new outcome measure for prion
disease therapeutic trials developed and validated
using systematic observational studies
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Progress in therapeutics for rare disorders like prion disease is impeded by the lack of validated outcome measures and a paucity
of natural history data derived from prospective observational studies. The ﬁrst analysis of the UK National Prion Monitoring
Cohort involved 1337 scheduled clinical assessments and 479 telephone assessments in 437 participants over 373 patient-years
of follow-up. Scale development has included semi-quantitative and qualitative carer interviews, item response modelling
(Rasch analysis), inter-rater reliability testing, construct analysis and correlation with several existing scales. The proposed
20-point Medical Research Council Prion Disease Rating Scale assesses domains of cognitive function, speech, mobility,
personal care/feeding and continence, according to their relative importance documented by carer interviews. It is quick and
simple to administer, and has been validated for use by doctors and nurses and for use over the telephone, allowing for frequent
assessments that capture the rapid change typical of these diseases. The Medical Research Council Scale correlates highly with
widely used cognitive and single item scales, but has substantial advantages over these including minimal ﬂoor effects. Three
clear patterns of decline were observed using the scale: fast linear decline, slow linear decline (usually inherited prion disease)
and in some patients, decline followed by a prolonged preterminal plateau at very low functional levels. Rates of decline and
progress through milestones measured using the scale vary between sporadic, acquired and inherited prion diseases following
clinical expectations. We have developed and validated a new functionally-oriented outcome measure and propose that future
clinical trials in prion disease should collect data compatible with this scale, to allow for combined and comparative analyses.
Such approaches may be advantageous in orphan conditions, where single studies of feasible duration will often struggle to
achieve statistical power.
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Introduction
The prion diseases are a group of rare neurodegenerative condi-
tions for which no proven disease-modifying treatment is avail-
able. They are characterized by templated misfolding of the
normal cellular prion protein (PrPc) into abnormal disease-
associated forms (generally referred to as PrPSc) but they may
have genetic, idiopathic or acquired aetiologies. There is remark-
able clinical heterogeneity both within and between these differ-
ent aetiological disease types (Collinge, 2001).
The transmissibility of prion disease both within and between
mammalian species, leading to fatal neurodegeneration that faith-
fully reproduces the clinicopathological features of the human
disease, provides a uniquely robust opportunity for laboratory
validation of experimental therapeutics for a human neurodegen-
erative disease. As a result of these animal models, and rapidly
advancing understanding of the molecular pathogenesis of prion
disease, development of putative therapeutic agents for use in
human trials (both small molecules and monoclonal antibodies
that bind to PrPc) has now reached an advanced stage (Mallucci
et al., 2002, 2003, 2007; White et al., 2003; Nicoll and Collinge,
2009; Nicoll et al., 2010; Klohn et al., 2012). However, if the
promise of these agents is to be realized, it is vital that trial meth-
odology is optimized and a number of challenges speciﬁc to prion
disease trials are overcome. Even a highly effective therapeutic
agent may fail to produce conclusive results without an optimal
trial design.
The Medical Research Council (MRC) PRION-1 trial demon-
strated that a large clinical trial in a single country is feasible,
but was limited by the lack of a validated measure of clinical
progression (Collinge et al., 2009). Anticipating this issue, the
trial protocol included a variety of existing rating scales designed
to probe neurological, cognitive, psychiatric and general functional
status. Analysis of the performance of eight of these scales in
PRION-1 in terms of validity, practicality and statistical power in
simulated clinical trials supported the use of functionally-orientated
measures relative to global, neurological, cognitive or psychiatric
scales (Mead et al., 2011). However, a number of unresolved
issues remained: no single scale captured progression across the
full range of functional physical and cognitive domains affected by
any of the individual categories of prion disease; patients could not
be visited frequently enough to capture the very rapid decline that
is typical of Creutzfeldt-Jakob disease (CJD); ﬂoor effects (large
numbers of subjects with the worst possible score) were observed
in all scales except the Glasgow Coma Score; and the patient
sample was too small to allow reliable analysis of important aetio-
logical or severity-stratiﬁed subgroups (Mead et al., 2009).
With the aim of developing a single, functionally-orientated and
validated outcome measure, tailored to the particular demands of
a prion disease clinical trial, we modiﬁed and combined elements
of three rating scales that showed relative strengths in the
PRION-1 analysis and are well established in other neurological
settings: the Modiﬁed Barthel Activities of Daily Living Index
(Barthel) (Mahoney and Barthel, 1965; Collin et al., 1988), the
Clinical Dementia Rating Sum of Boxes (Morris, 1993), and the
Glasgow Coma Score (Teasdale and Jennett, 1974). We carried
out semi-quantitative interviews to assess patients’ relatives and
carers on which manifestations of prion disease are of greatest
concern to them, and ensured that these were reﬂected in the
domains assessed by our scale. We assessed reliability of use
over the telephone (allowing much higher assessment frequency),
and used Rasch analysis (Hobart et al., 2007) to reﬁne an out-
come measure that had the most favourable statistical properties
when used in this patient group. Finally, we illustrate the natural
history of symptomatic patients in the National Prion Monitoring
Cohort study and/or PRION-1 trial using the MRC Prion Disease
Rating Scale, and performance relative to existing scales.
Materials and methods
Patient referral, clinical diagnosis and
enrolment
A national referral system for prion diseases was set up in the UK in
2004. UK neurologists were asked by the Chief Medical Ofﬁcer to
refer all patients with suspected prion disease jointly to the National
CJD Research and Surveillance Unit (Edinburgh, UK) and to the NHS
National Prion Clinic (London, UK). This enables epidemiological sur-
veillance, provision of specialist clinical care and also participation in
clinical research, including the PRION-1 trial (2001–2007) (Collinge
et al., 2009) and the National Prion Monitoring Cohort study (subse-
quently ‘Cohort study’, 2008–2012). Collinge et al. (2009) provides
details of enrolment into the PRION-1 trial, which were similar to
those described for the Cohort study below.
The Cohort study began in October 2008, and aimed to enrol all
symptomatic patients with prion disease in the UK thereafter. This
includes all cases of probable or deﬁnite prion disease (sporadic CJD,
variant CJD, iatrogenic CJD, and inherited prion disease). Also eligible
for enrolment are asymptomatic individuals known to be at risk of
inherited prion disease (tested asymptomatic gene mutation carriers
or untested ﬁrst degree relatives of those with a conﬁrmed pathogenic
PRNP mutation), or variant CJD (recipients of implicated whole or
leucodepleted blood transfusion notiﬁed by the Health Protection
Agency). A small group of healthy control subjects were also recruited
(friends or relatives without pathogenic PRNP mutations or other
known risk factors). ‘At risk’ individuals and healthy control subjects
did not contribute to the development of rating scales.
Enrolment by National Prion Clinic staff took place at hospitals,
nursing homes, hospices and patients’ homes around the UK.
Diagnoses and eligibility were reviewed by senior National Prion
Clinic clinicians (J.C., S.M. and/or P.R.) within a week of enrolment,
or prior to enrolment if there was clinical uncertainty. Probable spor-
adic CJD diagnosis was made according to World Health Organization
criteria, with the addition of brain MRI as a supportive investigation
following recent recommendations (pathological signal change on
FLAIR or diffusion weighted sequences in the basal ganglia, thalamus
MRC Prion Disease Rating Scale Brain 2013: 136; 1116–1127 | 1117
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and/or 52 cortical regions) (Zerr et al., 2009). Patients not meeting
criteria for sporadic CJD were enrolled if this was thought to be the
most likely diagnosis at reveiw by a panel of senior NPC clinicians.
Probable variant CJD diagnosis was made according to World Health
Organization criteria (WHO, 2001). Inherited prion disease was diag-
nosed by gene test. Iatrogenic CJD was diagnosed using sporadic CJD
criteria with a relevant history of exposure. If patients died during the
study and underwent post-mortem examination, or had relevant tissue
biopsy (brain or tonsil) during life, the pathological results were used
to conﬁrm diagnosis.
A further 26 patients were recruited but not included in study par-
ticipant totals or any analysis because an alternative diagnosis became
more likely than prion disease during follow-up, due to their clinical
course (e.g. persistent improvement) and/or clinical investigation
results (e.g. presence of serum voltage-gated potassium channel
complex antibodies, post-mortem results).
Consent and ethics
Informed consent was obtained directly from study participants if pos-
sible, or otherwise from relatives, carers or Independent Mental
Capacity Advocates as appropriate. Ethical approval was obtained
from the Scotland A Research Ethics Committee (Cohort) or the
Eastern Research Ethics Committee (PRION-1).
Stratiﬁcation and assessment schedule
Participants were stratiﬁed at enrolment to the Cohort according to
their likely rate of disease progression based on diagnosis:
Stratum 1: Symptomatic patients with sporadic CJD, variant CJD, iat-
rogenic CJD and forms of inherited prion disease likely to have rapid
clinical progression (due to 4-octapeptide repeat insertion, E200K,
D178N, E211Q or V210I mutations); Stratum 2: Symptomatic patients
with inherited prion disease likely to have slow progression (those with 5
and 6-octapeptide repeat insertion, P102L, P105L, Q212P, A117V or
Y163Xmutations); and Stratum 3: At-risk and healthy control individuals.
Patients in Stratum 1 had face-to-face follow-up assessments initially
every 6–8 weeks. If clinical progression proved to be slower than the
expected signiﬁcant deterioration over this interval (i.e. minimal or no
change by overall clinical impression over 6–8 weeks), study physicians
could decide to reduce follow-up frequency for subsequent assess-
ments (up to a maximum interval of 24 weeks). Patients in Strata 2
and 3 had follow-up assessments every 6 to 12 months. The following
rating scales were administered at study assessments: Modiﬁed Barthel
Activities of Daily Living index (Mahoney and Barthel, 1965; Collin
et al., 1988), Clinical Dementia Rating Sum of Boxes (Morris, 1993),
Glasgow Coma Score (Teasdale and Jennett, 1974), Rankin (Rankin,
1957), and Mini-Mental State Examination (Folstein et al., 1975). In
September 2009 an initial scale was also introduced, as described
below. In addition, a systematic clinical history, neurological examin-
ation and a short neuropsychological test battery were done at all
assessments, unless precluded by the level of disease severity or pa-
tient fatigue. From May 2010 patients in Stratum 1 also had telephone
assessments every 1 to 2 weeks between follow-up assessments.
These were discontinued if there was minimal change between
consecutive assessments (at worst possible score).
Survey of carer priorities
The Barthel Activities of Daily Living Caregiver Interview Summary
form was used to gather semiquantitative data from relatives/carers
on the aspects of prion disease of greatest importance to them and the
patients in their daily lives. Up to four symptoms or impairments of
greatest concern to them at the time of assessment were ranked in
order of importance. This was completed at 69 assessments, by carers
of patients affected by different prion disease types. These data were
supplemented by discourse analysis of 10 in-depth structured inter-
views with carers.
Development pathway for novel
rating scale
Building on and extending the analysis of the pre-existing scales in
PRION-1 (Mead et al., 2011), an iterative approach was taken to
develop and reﬁne a novel scale for use in prion disease. An initial
version took into account the relative performance and limitations of
different pre-existing scales and their subcomponents in the PRION-1
analysis, the reported priorities of patients and carers, the need to
include a range of both physical and cognitive domains, and the
pooled clinical experience of the National Prion Clinic medical, nursing
and neuropsychology staff. This scale version was then administered at
all Cohort assessments alongside the range of scales above (from
September 2009), as well as over the telephone (from May 2010).
The performance of this scale version was assessed with respect to
ease of use, ability to capture clinically evident decline, inter-rater
reliability between treating clinicians and nurses, reliability of use
over the telephone, ﬂoor and ceiling effects. As it consisted of a com-
bination of slightly modiﬁed subcomponents from existing scales used
in PRION-1 and throughout the Cohort, a close approximation of the
scale could be calculated for all assessments carried out prior to its
introduction, allowing a larger number of patients and assessments to
be included in sensitivity/additional analysis.
Rasch analysis
Rasch analysis was performed on the ﬁrst two initial scale version
assessments post September 2009 per individual, to ensure that the
analysis was not unduly affected by a small minority of patients with
many assessments, and to permit testing the function of the scale over
time. Rasch analysis was used to see whether the initial scale ﬁtted this
model using Rasch Unidimensional Measurement Model 2030 soft-
ware. The partial credit variant of the polytomous model was chosen
to reﬂect multiple successively ordered response categories of varying
difﬁculty (Andrich et al., 2008). We took the following recommended
(Tennant and Conaghan, 2007) iterative steps to optimize the ﬁt of
our scale to the Rasch model: (i) exploring item–person interactions (to
examine the degree to which the Guttman pattern was achieved) and
item–trait interactions using 2-based ﬁt statistics; (ii) rescoring items
that demonstrated disordered thresholds (i.e. an item’s scoring cate-
gories do not progress in a logical order); (iii) removing the most
poorly ﬁtting items, or combining items into super-items where appro-
priate; (iv) examining local dependencies between items that could
confound the assumption of unidimensionality of the scale, and drop-
ping items when misﬁt was still apparent; (v) investigating differential
item functioning for gender, age, time of assessment (ﬁrst versus
second assessment), assessor (doctor versus nurse administering
scale) and mode of assessment (telephone versus face-to-face). We
also analysed a random sample of later follow-up assessments to
evaluate whether there was differential item functioning for the selec-
tion of the follow-up visit to include in the main analysis; (vi) examin-
ing local dependencies using residual correlation matrices, and
exploring unidimensionality of the scale using principal components
analysis to select the highest positive and highest negative items
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followed by post hoc t-tests on person locations determined by these
items; and (vii) reviewing summary ﬁt statistics after all modiﬁcations
to the scale were made. Cronbach’s Alpha statistic was used to con-
ﬁrm reliability of the ﬁt statistics. The ﬁnal scale, termed the MRC
Prion Disease Rating Scale (or MRC Scale) was selected when satis-
factory ﬁt was achieved overall, no items showed poor ﬁt and the
scale was shown to be compatible with unidimensionality. To increase
numbers, a sensitivity analysis also used scores derived from the indi-
vidual component scales (Barthel, Clinical Dementia Rating Sum of
Boxes, and Glasgow Coma Score) prior to September 2009 (Tools
was scored as missing) for individuals who did not have two scores
post-September 2009.
Results
Patients
Four hundred and thirty-seven participants consecutively enrolled
into the Cohort and/or PRION-1 studies (up to April 2012) were
included in the analysis; 240 patients with sporadic CJD, 25 with
variant CJD, 12 with iatrogenic CJD, and 81 with symptomatic
inherited prion disease (three, seven and 19 patients with 4, 5
and 6 octapeptide repeat insertion, respectively, seven with
A117V mutation, four with D178N, eight with E200K, 26 with
P102L, one patient each with E211Q, P105L, Q212P and V210I
mutation and three with Y163X) together with 34 individuals at
risk of inherited prion disease, 10 at risk of variant CJD, and 35
healthy control subjects. Three hundred and eleven patients died
during the study, 192 (62%) of these underwent post-mortem
examination, which conﬁrmed the diagnosis of prion disease in
all cases. Eighty-nine (20%) had diagnosis conﬁrmed in life by
gene test (all 81 inherited prion disease) or tissue biopsy (n = 8)
some also with post-mortem examination. One hundred and
ﬁfty-ﬁve (35%) were diagnosed using clinical and investigation
ﬁndings alone.
Figure 1 illustrates enrolment, stratiﬁcation, follow-up and
drop-out from the studies. Ninety-seven per cent of symptomatic
patients judged eligible for the Cohort study at the initial National
Prion Clinic assessment were enrolled, suggesting that the study is
highly effective at capturing recognized prion disease in the UK.
Less than 1.5% withdrew from the studies. Baseline characteristics
are shown in Table 1.
Scale development
Table 2 summarizes the scale development process. Ranked
symptoms and impairments reported by caregivers were grouped
into functional domains. The most frequently recorded were within
Figure 1 Study proﬁle. iCJD = iatrogenic CJD; IPD = inherited prion disease; NPMC = National Prion Monitoring Cohort;
PM = post-mortem; sCJD = sporadic CJD; vCJD = variant CJD.
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domains of mobility (55/236 ranked items, 23%), personal
care/continence (30/236, 13%), communication/speech (29/236,
12%), behaviour/hallucinations (29/236, 12%), eating/swallowing
(27/236, 11%) and cognition/memory/navigation (21/236, 9%).
Symptoms or impairments from other domains were reported
in56% of responses. These were the key domains for representa-
tion in our outcome measure.
The initial scale, based on that proposed in Mead et al. (2011),
consisted of slightly modiﬁed versions of all subcomponents of the
Modiﬁed Barthel Activities of Daily Living Index, the memory,
orientation and judgement/problem-solving subcomponents of
the Clinical Dementia Rating Sum of Boxes, the best verbal re-
sponse subcomponent of the Glasgow Coma Score and a novel
subcomponent assessing ability to use tools (15 items, 35 thresh-
olds) (Mead et al., 2011). It was designed for completion based
on a brief interview with a closely-involved relative or carer as
inability of patients to participate was a major cause of poor com-
pletion rates for some scales in PRION-1. Compared with their
parent scales, minor modiﬁcations were made to a number of
subcomponents at this stage to make them more easily applicable
to patients with prion disease e.g. to account for severe expressive
dysphasia/mutism, and to add additional intermediate response
categories at severe levels of impairment, aiming to improve
discrimination and reduce ﬂoor effects.
The initial scale was completed on a total of 977 occasions, in 266
patients. This consisted of 498 face-to-face assessments and 479
telephone assessments. The scale proved to be simple and easy to
use, being completed in less than 5min. In addition to this, an ap-
proximation of the initial scale could be calculated from Barthel,
Clinical Dementia Rating Sum of Boxes and Glasgow Coma Score
scale data for a further 839 assessments pre-September 2009.
The initial scale was acquired over the telephone by a doctor and a
specialist nurse within 24h of each other on 50 occasions, over the
telephone by a nurse within 24 h of a face-to-face assessment by a
doctor on two occasions, and by both doctor and nurse attending the
same visit on two occasions. In all cases each assessor was blinded to
the other’s score. Agreement across all paired assessments was good
or excellent (Cohen’s kappa40.6) for all but three items: dressing,
which was subsequently dropped from the scale; best verbal re-
sponse, which subsequently underwent item threshold rescoring;
and orientation, which was subsequently merged with memory.
The ﬁt to the Rasch model of the 15-item initial scale was ﬁrst
assessed in all individuals across all symptomatic disease types, and
demonstrated poor ﬁt in this heterogeneous population (2 =
166.16, df = 30, P50.0001). As Rasch analysis relies on the as-
sumption that there is a single construct being measured by all
items in a scale, including patients with different disease types that
are known to vary widely in their typical clinical progression, it is
Table 1 Baseline characteristics at enrolment
All patients sCJD IPD vCJD iCJD At risk Control
Enrolled 437 240 81 25 12 44 35
Median age (years; range) 61 (14–92) 67 (40–87) 48 (26–92) 30 (14–63) 42 (27–51) 42 (20–92) 48 (23–75)
Gender (M/F) 207/230 105/135 39/42 17/8 10/2 19/25 17/18
Median time (months) since
ﬁrst symptoms (IQR)
6 (3–13) 4 (2–8) 26 (7–63) 8 (5–10) 8 (5–14) N/A N/A
Rankin
Number assessed 430 238 79 23 11 44 35
Asymptomatic (0) 75 0 0 0 0 41 34
No or slight symptoms (1/2) 29 4 18 2 3 1 1
Moderate disabilty (3) 51 18 26 6 1 0 0
Moderate to severe disability (4) 89 56 17 12 3 1 0
Severe disability (5) 186 160 18 3 4 1 0
Barthel index
Number assessed 424 238 76 20 12 43 35
Median (IQR) 4 (0–19) 0.5 (0–3.5) 14.5 (2–19.5) 10 (5.6–16.1) 6.3 (2–17) 20 20
MMSE
Number assessed 385 205 72 19 11 43 35
Median (IQR) 12 (0–27) 0 (0–10) 18 (5–24.8) 16 (12–21.5) 15 (1.5–27) 30 (29–30) 30
CDR
Number assessed 353 178 69 21 9 42 34
Median (IQR) 11 (2–18) 18 (12–18) 8 (3–15) 11 (5.5–16) 10 (4–18) 0 0
GCS
Number assessed 399 232 64 20 10 38 35
Median (IQR) 14 (10–15) 11 (9–14) 15 (11–15) 15 (13.8–15) 14 (13.3–15) 15 15
MRC Scale
Number assessed 388 212 67 18 12 44 35
Median (IQR) 9 (2–19) 3 (1–8.8) 16 (5.5–19) 13 (9–17.5) 11.5 (5–17.3) 20 20
Interquartile ranges (IQR) are shown. ‘At risk’ and ‘Control’ groups did not contribute directly to development of the novel scale.
CDR = Clinical Dementia Rating Sum of Boxes; GCS = Glasgow Coma Score; iCJD = iatrogenic CJD; IPD = inherited prion disease; MMSE = Mini-Mental State Examination;
sCJD = sporadic CJD; vCJD = variant CJD.
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plausibly impossible to establish a ﬁt to the Rasch model using the
whole data set. As our primary objective was to develop an outcome
measure tailored to sporadic CJD, all other disease groups were
excluded and the analysis repeated using 205 records from 132 pa-
tients with sporadic CJD (all of those in whom the initial scale had
been administered). Fit improved somewhat, but was still unsatisfac-
tory (2 = 77.01, df = 30, P50.0001) so further exploratory ana-
lyses were performed to identify the reasons for this.
The 15 individual items were examined for threshold ordering,
individual item ﬁt, differential item functioning and local item
dependencies, and changes made to address these issues as rec-
ommended with consequent improvements in ﬁt (e.g. rescoring of
disordered items, dropping of most poorly ﬁtting item) (Tennant
and Conaghan, 2007). These changes are summarized in Table 2.
Item dependencies were identiﬁed between grooming and bath-
ing; transfers and mobility; toilet and stairs; bathing, orientation
and memory. We created two ‘super-items’ by combining pairs of
heavily dependent items in a clinically meaningful way: transfers
and mobility; and memory and orientation. The structure and
scoring of these super-items can be seen in Table 3. Once item
Table 3 Final MRC Prion Disease Rating Scale
Item Category criteria Score
Bowel function At least one episode of incontinence in last 7 days 0
Continent for last 7 days 1
Bladder function Always incontinent or catheterized 0
Continent or occasional accidents 1
Toilet use Fully dependent 0
Needs some help 1
Independent 2
Bathing Fully dependent or needs some help 0
Independent 1
Feeding Unable or NG/PEG/RIG fed (takes nothing by mouth) 0
Needs help but can swallow (even if unsafe) 1
Independent 2
Transfers and mobility Bedbound, unable to sit 0
Can sit, but cannot mobilize or transfer without help (from person or
walking aid)
1
Can transfer or mobilize independently or both 2
Stairs Unable 0
Needs help 1
Independent 2
Best verbal response Mute 0
Incomprehensible sounds 1
Single words 2
Sentences, but difﬁculty in ﬁnding words, uses incorrect words or is
often disoriented/confused
3
Normal conversation 4
Memory and orientation
to surroundings
Shows no awareness of surroundings or any evidence of memory 0
Evidence of retaining some highly learned material (e.g. recognizing
familiar people) or awareness of surroundings but no evidence of
acquiring new material
1
Able to retain some new information but memory consistently
impaired
2
Memory normal or some impairment off and on 3
Judgement and problem
solving
Unable to show any judgement or problem-solving 0
Able to show some judgement or problem-solving, even if this is se-
verely impaired
1
Use of tools Unable to use any tools or objects 0
Able to use some tools or objects, with help if necessary 1
NG = nasogastric; PEG = percutaneous endoscopic gastrostomy; RIG = radiologically inserted gastrostomy.
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rescoring, appropriate ordering and local dependencies were
addressed, items were dropped if ﬁt was still not achieved.
A revised scale including all of these modiﬁcations, termed the
MRC Scale, demonstrated a good ﬁt (2 = 25.19, df = 22,
P = 0.29). The mean ﬁt residual for all 11 items in this scale was
-0.498 with a standard deviation (SD) of 0.993, illustrating a good
ﬁt of the items to the model. Cronbach’s alpha was 0.91, implying
a high level of conﬁdence in the reliability of the assessment of ﬁt,
and the Person Separation Index was 0.90. No individual item had
a ﬁt residual of magnitude 42. Examination for all items across all
person factors conﬁrmed the data to be free of differential item
functioning when Bonferroni probability adjustment for multiple
testing was applied, with gender, age quartile, assessor (doc-
tor or nurse), assessment mode (face-to-face or telephone)
included as person factors.
Principal components analysis demonstrated that the greatest
variance in the data existed between the most positively loaded
items; those assessing speech and cognitive functions (speech,
memory/orientation, judgement and use of tools) and the most
negatively loaded items which assessed some aspects of mobility,
personal care and continence (toilet, bowels, bladder, stairs, mo-
bility/transfers). Feeding and bathing had no strong loading.
Comparing the person locations from positively loaded items
with a factor loading 40.4 (speech and memory/orientation) to
negatively loaded items with a factor loading 50.4 (toilet,
stairs, bladder, bowels and transfers/mobility) produced signiﬁcant
results at the 1% level in 9/205 (4.4%) individuals and at the 5%
level in 16/205 (7.8%) individuals. Overall, our analyses of multi-
dimensionality suggest that differential progression in speech/cog-
nitive and mobility/personal care/continence domains is the
second most important dimension (after the Rasch model) but
did not grossly compromise the unidimensionality of the scale
and the construct of sporadic CJD disease progression.
Including earlier data derived from the original component
scales (Barthel, Clinical Dementia Rating Sum of Boxes, and
Glasgow Coma Score) along with the data collected using the
initial scale allowed a total of 380 scales in 239 patients with
sporadic CJD to be analysed. The overall ﬁt to the Rasch model
was less good but remained acceptable (2 = 33.75, df = 22,
P = 0.052), suggesting that the modiﬁed items introduced for
the initial scale were performing better than pre-existing scale
components. These item modiﬁcations were therefore retained in
the ﬁnal scale. Testing the MRC Scale’s ﬁt in all Stratum 1, rapidly
progressive patients, including a rapidly progressive subset of in-
herited prion disease along with sporadic CJD, also demonstrated
acceptable ﬁt to the model (2 = 30.14, df = 22, P = 0.11).
Unsurprisingly, testing ﬁt for patients with inherited prion disease
alone and for all symptomatic patients (all disease groups including
Stratum 2) continued to result in a poor ﬁt due to the heterogen-
eity of clinical syndromes that comprise inherited prion disease
(such as the distinction between the late cognitive features of
Gerstmann-Stra¨ussler-Scheinker syndrome, and early predominant
cognitive decline in 6-octapeptide repeat insertion prion disease).
The ﬁnal format of the rating scale is shown in Table 3. The
inter-rater reliability in administration between doctors and nurses
of the ﬁnal scale as a whole was excellent (interclass correlation
coefﬁcient = 0.96). Figure 2 shows the correlation of the MRC
Figure 2 Correlation of the MRC Scale with other commonly
used rating scales. The area coloured for each circle is propor-
tional to the total number of patients from each aetiological
group of prion disease with these scores. These plots illustrate
the relative absence of ﬂoor effect with the MRC Scale when
compared with the Rankin or the Mini-Mental State
Examination (MMSE) scales, but not the Glasgow Coma Score,
as patients with minimum/worst score on the Mini-Mental State
Examination and Rankin can still be distinguished with the MRC
Scale. In addition these illustrate the multidimensionality of the
inherited prion disease (brown) group in that some patients
decline in function with normal Mini-Mental State Examination
(typically patients with Gerstmann-Straussler-Scheinker disease)
and others decline in Mini-Mental State Examination with high
levels of function (typically 6-octapeptide repeat insertion mu-
tation patients). iCJD = iatrogenic CJD; IPD = inherited prion
disease; sCJD = sporadic CJD; vCJD = variant CJD.
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Scale with Mini-Mental State Examination, Rankin and Glasgow
Coma Score across all assessments at which these scales were
acquired. This illustrates the novel scale’s relative resistance to
ﬂoor effects, as patients at minimum (or unrecordable) score for
Mini-Mental State Examination or Rankin can still be separated by
the novel scale. Whilst Glasgow Coma Score has the ability to
separate patients scoring zero on the current scale (Glasgow
Coma Score ranging 3–11), these distinctions are difﬁcult to inter-
pret clinically and would require a clinical examination.
The natural history of prion diseases
Figure 3 shows individual patient trajectories for the MRC Scale
over time, colour-coded by disease type. Patients in Stratum 2
have been included for comparison purposes with the caveat
that the MRC Scale is not measuring a single progression construct
in these patients. These plots illustrate the remarkable heterogen-
eity of disease progression between, and to a lesser extent within,
prion disease types. Several distinct patterns of progression are
apparent: rapid decline over weeks or a few months (mostly pa-
tients with sporadic CJD) and slow decline over years (almost ex-
clusively patients with inherited prion disease). A slightly less rapid
decline is observed in patients with sporadic CJD who are hetero-
zygous at PRNP codon 129, patients with variant CJD and iatro-
genic CJD and some patients with inherited prion disease (Figs 3
and 4). In all groups, decline measured with the MRC Scale gen-
erally appears to be linear.
In most rapidly progressing patients, death occurs shortly after a
very low score is reached, but in some there is an extended
‘preterminal plateau’ phase at a very low score. A prion disease
clinical trial design needs to consider these different patterns of
decline.
Figure 5 illustrates the typical progression of a patient with spor-
adic CJD through the functional/cognitive milestones of the MRC
Scale, and the spread of difﬁculty of items in the ﬁve measured
domains. These observations are in keeping with our clinical ex-
perience of these patient groups and are consistent with the val-
idity of the MRC Scale.
Figure 3 Trajectories of change in patients up to 600 days post-enrolment for all patients (combined), sporadic CJD (sCJD), inherited
prion disease (IPD), iatrogenic CJD (iCJD) or variant CJD (vCJD) only. Three broad patterns are seen: a slow decline in inherited prion
disease patients, a rapid and somewhat variable decline in all aetiological groups, and a pattern of decline followed by a preterminal
plateau at low levels of function in all aetiological groups. All sporadic CJD trajectories are also shown for the ﬁrst 100 days only for clarity
of short duration cases. Data are also available up to 10 years in some patients with inherited prion disease.
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Discussion
In this paper we have sought to overcome a fundamental obstacle
on the route to developing effective treatments for prion disease:
the lack of both a validated outcome measure for clinical trials and
a large resource of clinical progression data. Using a range of
complementary approaches, and taking into account analysis of
rating scales data from the PRION-1 trial (Mead et al., 2011),
we have developed, reﬁned and validated a bespoke rating scale
in the context of the Cohort study, the largest prospective clinical
study of the natural history of prion disease. Our outcome meas-
ure aims to maximize the likelihood of future trials giving a clear
answer on therapeutic efﬁcacy. This study also illustrates that the
advanced neurodisability at referral of patients with sporadic CJD
to our clinical research team is a major outstanding problem for
UK clinical trials; improved early diagnosis and referral will be key
to success of clinical trials.
Prion disease trials have and will continue to use survival as a
key outcome measure, but this has major limitations. It does not
directly measure progression of disease, as patients may survive
for long periods in a very advanced stage of disease or may die
before, at or after reaching the end stages of disease progression
(e.g. due to aspiration pneumonia). Existing rating scales, which
are well validated in other neurological settings, are far less well
suited to prion disease. For example, the Mini-Mental State
Examination and Alzheimer’s Disease Assessment Scale – cognitive
subscale, routinely used as an outcome measure in Alzheimer’s
disease clinical trials, suffer from a marked ﬂoor effect (Mead
et al., 2011) and fail to capture the profound physical impairments
that are fundamental features of these diseases and may be pre-
sent despite preserved cognitive function. Cognitive decline is itself
a fundamental feature of prion diseases, and we have included
items assessing cognitive function in a way that is more robust in
this population, by assessing carer-reported level of function.
The remarkable clinical heterogeneity of prion disease, com-
bined with its rarity, represents a major challenge to trial design.
Very inclusive enrolment criteria will maximize patient numbers,
Figure 5 Schematic of the pattern of decline in a patient with sporadic CJD that would be most consistent with the Rasch model.
Progression is represented by the logit scale used in the Rasch analysis reﬂecting the relative difﬁculties of the thresholds that comprise the
MRC Scale. This diagram illustrates the validity of the progression construct, as the ordering of the items is consistent with clinical
experience and there is a reasonable spread of item difﬁculty in different functional domains.
Figure 4 Trajectories of patients with sporadic CJD either
homozygous (129MM or 129VV) at codon 129 of the prion
protein gene or heterozygous (129MV). This genetic factor ap-
pears to be a strong determinant of rates of decline.
MRC Prion Disease Rating Scale Brain 2013: 136; 1116–1127 | 1125
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but may have a paradoxically negative effect on statistical power if
they greatly increase variability, or reduce the possible beneﬁts
that can be observed either due to permanent neurological
damage that cannot be rescued, or due to relatively preserved
functioning at enrolment. Designing a single outcome measure
that can capture rapid global decline in a patient with sporadic
CJD and changes in patients with some slowly progressive forms
of inherited prion disease has not been possible. Patients with
inherited prion disease are highly variable in clinical presentation
with predominantly mobility or predominantly cognitive progres-
sion. It is likely that the detection of subtle changes required to
deﬁne the onset of disease in inherited prion disease will require
analysis of neuropsychological testing that is ongoing in the
Cohort study. Our ﬁndings suggest that, for maximum efﬁciency,
the main group that should be targeted for future trial recruitment
should be those Stratum 1 patients not already at very low levels
of functioning. This group of patients were also most likely to
choose to take the investigational drug quinacrine in PRION-1
(Collinge et al., 2009).
While we have tried to design a scale that reﬂects the priorities
of patients and their carers, a compromise must be struck with
methodological concerns. Our scale does not include any direct
assessment of neuropsychiatric symptomatology, sleep disturbance
or movement disorder (e.g. myoclonus), all of which are common
features of prion disease and of concern to patients and carers.
These features have limited value as markers of disease progres-
sion however, as they often ﬂuctuate through the course of the
disease, may improve in the later stages, and may be signiﬁcantly
affected by non-disease modifying treatments (e.g. benzodiazep-
ines, anticonvulsants). As such they are not included in our out-
come measure, but we are currently investigating them using
other methods (e.g. use of the Neuropsychiatric Inventory), and
these data will be reported elsewhere. Analyses of the baseline
predictors of rates, patterns of decline, simulations of clinical
trials to estimate power, and ﬁtting of linear mixed models are
ongoing.
We have built up a large and detailed natural history data set,
with the intent that this can act as a supplementary historical
control group against which to compare treatment groups in
future trials, with potentially large beneﬁts for statistical power.
To this end, the data set can be made available to other physicians
conducting clinical trials, and we encourage research groups
worldwide to take advantage of this in planning clinical trials. To
enable this direct comparison of results from different studies, we
propose that the MRC Prion Disease Rating Scale be adopted as a
standard outcome measure for prion disease clinical research.
Clinical research into rare diseases is extremely challenging for
logistic, statistical and ﬁnancial reasons, but it is essential that we
work towards overcoming these challenges. Considered together,
‘rare diseases’ make up a signiﬁcant proportion of the burden of
neurological disease, and it is essential to collect systematic data
on which to base the treatment of these patients. Studying rare
diseases can often provide valuable insights into more common
conditions. In the wider ﬁeld of neurodegeneration there is great
interest in the hypothesis that templated protein misfolding mech-
anisms (referred to as ‘prion-like’) may be fundamental to a wide
range of other conditions including Alzheimer’s and Parkinson’s
diseases. Demonstrating a disease-modifying effect of a thera-
peutic agent in prion disease may therefore lead to insights with
wider implications.
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Filamentous white matter prion protein
deposition is a distinctive feature of multiple
inherited prion diseases
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Abstract
Background: Sporadic, inherited and acquired prion diseases show distinct histological patterns of abnormal prion
protein (PrP) deposits. Many of the inherited prion diseases show striking histological patterns, which often
associate with specific mutations. Most reports have focused on the pattern of PrP deposition in the cortical or
cerebellar grey matter.
Results: We observed that the subcortical white matter in inherited prion diseases frequently contained
filamentous depositions of abnormal PrP, and we have analysed by immunohistochemistry, immunofluorescence
and electron microscopy 35 cases of inherited prion disease seen at the UK National Prion Clinic. We report here
that filamentous PrP is abundantly deposited in myelinated fibres in inherited prion diseases, in particular in those
with N-terminal mutations.
Conclusions: It is possible that the presence of filamentous PrP is related to the pathogenesis of inherited forms,
which is different from those sporadic and acquired forms.
Keywords: Creutzfeldt-Jakob disease, Inherited prion disease, White matter, PRNP gene mutation, Octapeptide
repeat insert mutation, OPRI, Gerstmann Sträussler Scheinker Syndrome, GSS, Transgenic mice, Axons, Myelin basic
protein
Background
Human prion diseases represent a clinically and patho-
logically diverse group of neurodegenerative disorders
which invariably progress to a fatal outcome. Prion dis-
eases comprise sporadic forms (Creutzfeldt-Jakob disease
(sCJD)), inherited prion diseases (IPD) (sometimes also
classified as familial CJD (fCJD), Gerstmann-Sträussler-
Scheinker Syndrome (GSS) and fatal familial insomnia
(FFI)), and acquired forms with variant CJD (vCJD), iatro-
genic CJD and kuru. The common neuropathological
characteristics of human prion diseases are intraneuronal
vacuolation with neuronal loss (spongiform degeneration)
in the grey matter, reactive astrocytosis and microglia
activation as well as a highly variable accumulation of
abnormal prion protein (PrPSc), which represents
misfolded forms of normal cellular prion protein (PrPC).
The patterns of PrPSc deposition in prion diseases are well
characterised at immunohistochemical and ultrastructural
levels [1,2] and most observations focus on pathological
changes in the grey matter. Involvement of the cerebral
and cerebellar white matter in sCJD has been described
and suggested to be a primary or secondary process in
panencephalopathic type CJD [3,4]. Cerebellar white
matter PrP deposition is a prominent feature in the “VV2”
subtype type [5]. It also occasionally occurs in other forms
of prion diseases, where it is thought to be secondary to
cortical degeneration and neuronal loss. The presence of
PrP plaques in the white matter has been described in
various plaque-forming types of CJD including variant
CJD [6] and cases of sCJD with methionine homozygosity
* Correspondence: s.brandner@ucl.ac.uk
†Equal contributors
1Division of Neuropathology, National Hospital for Neurology and
Neurosurgery, Queen Square, London, UK
2Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Full list of author information is available at the end of the article
© 2013 Reiniger et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Reiniger et al. Acta Neuropathologica Communications 2013, 1:8
http://www.actaneurocomms.org/content/1/1/8
at codon 129 of the PRNP gene (PRNP 129MM) [7]. In a
series of 20 autopsy cases of CJD, white matter deposition
of abnormal PrP was examined in four cases by immuno-
histochemistry and transmission electron microscopy [8].
Abnormal PrP accumulation in the white matter is also
seen in sheep with atypical scrapie [9] as well as in scrapie-
infected Syrian hamsters where an intense white matter
PrPSc signal was seen in histoblot studies. This was thought
to support the hypothesis that PrPSc is transported along
axons [10].
Having observed conspicuous filamentous deposits of
abnormal PrP in the white matter in autopsy material
from patients with inherited prion disease attending the
National Prion Clinic and examined at autopsy between
2004 and 2012, we have subsequently analysed our cases
systematically for the presence of white matter PrP de-
posits. We distinguished the patterns of small granular
deposits or small plaques that are known for sCJD from
a fine, thread like pattern that was seen in inherited
cases. The present study describes the frequency, inten-
sity and incidence of this pattern in a series of 35 cases
of inherited prion diseases, comprising octapeptide re-
peat insertions (4OPRI, 5OPRI and 6OPRI) and PRNP
point mutations of the codons 102, 117, 178, 200 and
210. In addition we give a brief overview of the salient
PrP pathology that has been described previously in
these inherited forms [11]. We have deliberately omitted
a detailed description and discussion of other features
such spongiform degeneration, neuronal loss, gliosis,
and the glycotype patterns, as these have been exten-
sively reported elsewhere.
Methods
Research governance, post mortem examination and
tissue preparation
Ethical approval for these studies was obtained from the
Local Research Ethics Committee of UCL Institute of
Neurology/National Hospital for Neurology and Neurosur-
gery. Informed consent to use the tissue for research was
obtained. Clinical data, disease history, PRNP mutation
and PRNP codon 129 status were available for all cases.
Autopsies were carried out in a post mortem room desig-
nated for high risk autopsies. Brains were removed and
stored in buffered formalin. The frontal, temporal, parietal
and occipital cortex and the cerebellum were dissected
during the post mortem procedure and immersed in 10%
buffered formalin for up to one week, immersed into 98%
formic acid for one hour and postfixed for 24 h in 10%
buffered formalin. Tissues were then processed through
graded alcohols and embedded in paraffin wax. In a small
subset of cases, a small tissue block was prepared from the
frontal cortex and white matter and immersed into glutar-
aldehyde for preparation of semithin resin section and
electron microscopy. Frozen tissue of frontal brain and
cerebellum was collected routinely and banked. The re-
maining brains were stored permanently in 10% formalin
and additional brain regions were dissected and processed
to paraffin blocks at later time points.
Antibodies and immunohistochemistry
In this study we used anti-PrP ICSM35 (D-Gen Ltd,
London, UK, raised in Prnpo/o mice against recombinant
human PrP as previously described [12];) and anti PrP
KG9 TSE Resource Centre, Roslin Institute University of
Edinburgh [13]. ICSM35 recognises residues 93–102 and
KG9 binds to residues 140–180 of human PrP. To detect
abnormal PrP deposition, mounted sections were treated
with 98% formic acid for 5 min, placed on an automated
Ventana Discovery staining machine, heated to 95°C in
2.1 mM Tris–HCl, 1.3 mM EDTA, 1.1 mM sodium cit-
rate, pH 7.8, for 30 min, digested for 16 min with a low
concentration of protease (Protease 3, 0.02 U/ml alkaline
protease, order no 760–2020 Ventana Medical Systems),
incubated in Superblock for 10 min, then exposed to the
primary antibody followed by biotinylated anti mouse IgG
secondary antibody and visualised using the iView detection
kit Haematoxylin was used as counterstain.
Immunofluorescence
Immunofluorescent dual labelling was carried out on se-
lected, representative frontal lobe sections of cases with
4OPRI, 6OPRI, P102L, A117V, D178N, E200K mutations
and sCJD 129MM, MV, and VV. For dual labelling and
co-localisation of abnormal PrP in white matter struc-
tures we applied the same antigen retrieval conditions as
above. Then we dispensed the antibody ICSM35 (1:1500)
together with either anti-Neurofilament (NF200, SIGMA
N5389; 1:100) or anti-Myelin Basic Protein (SMI94,
Covance, 1:250) followed by the secondary antibodies
labelled with fluorochromes Alexa 488 (goat anti Mouse
IgG1) or Alexa 546 (goat anti mouse IgG2b). Images were
taken on a ZEISS LSM510Meta Laser Scanning confocal
microscope, using a Plan-Apochromat 63×/1.4 Oil object-
ive. All images were taken at a scanning resolution that
matched the optical resolution of the lens (pixel size cor-
responding to 99.6 nm on the section).
Transmission electron microscopy
Tissue blocks of no more than 2 mm3 were immersed in
2.5% glutaraldehyde, treated with formic acid for 24 h
and following postfixation on glutaraldehyde, processed
for resin (Epon) embedding. Resin sections were stained
with Toluidine blue and suitable regions were selected
for electron microscopy. Ultra-thin sections were stained
with lead citrate and examined in a Jeol 100-CXII elec-
tron microscope. Images were recorded on a 4Megapixel
SIS Megaview digital camera.
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Western blotting and glycotyping
Brain tissue homogenates (10% w/v) from frozen samples
of frontal cortex were prepared in Dulbecco’s phosphate
buffered saline lacking Ca2+ or Mg2+ ions using tissue
grinders or by serial passage through needles of decreasing
diameter. Aliquots (typically 20 μl) were removed and
proteinase K added from a 1 mg/ml stock solution (pre-
pared in water) to give a final concentration in the sample
of 50 μg/ml. Following incubation at 37°C for 60 min,
samples were centrifuged at 16100 g for 1 min before
termination of the digestion by the addition of an equal
volume of 2 × SDS sample buffer (125 mM Tris–HCl,
pH 6.8, 20% v/v glycerol, 4% w/v sodium dodecyl sulphate,
4% v/v 2-mercaptoethanol, 0.02% w/v bromophenol blue)
containing 8 mM 4-(2-aminoethyl)-benzene sulfonyl
fluoride and immediate transfer to a 100°C heating block
for 10 min. Samples were centrifuged at 16100 g for
1 min prior to electrophoresis in 16% tris-glycine gels
(Invitrogen). Gels were electroblotted onto PVDF
membrane (Immobilon-P; Millipore) and subsequently
blocked in PBS containing 0.05% v/v Tween-20 (PBST)
and 5% non-fat milk powder for 60 min. After washing
in PBST, the membranes were incubated with anti-PrP
monoclonal antibody 3F4 (0.2 μg/ml in PBST) before
washing in PBST (60 min) and incubation with alkaline-
phosphatase-conjugated goat anti-mouse IgG secondary
antibody (Sigma-Aldrich Prod. No. A2179) diluted 1:10,
000 in PBST. After washing (1 h with PBST and 2 × 5 min
with 20 mM Tris pH 9.8 containing 1 mM MgCl2) blots
were incubated for 5 min in chemiluminescent substrate
(CDP-Star; Tropix Inc) and visualized on Biomax MR film
(Kodak). Control samples (of known PrPSc type) were
analysed in parallel and run on the same blots to enable
assignment of molecular strain type according to the
London classification [14,15].
Examination and quantification
We analysed 35 autopsy cases of inherited prion disease
seen at the National Prion Clinic, NHNN and these were
compared with 26 cases with sCJD (9 cases with codon
129 MM, 10 with MV and 7 with VV polymorphism).
The inherited cases included the following PRNP gene
mutations (numbers of cases in brackets): 4 octapeptide/
96 base pair repeat insertion [4OPRI] (3), 5OPRI/120 bp
(1), 6OPRI/144 bp (4), P102L (10), A117V (4), D178N
(3), E200K (9) and V210I (1).
Brains were examined in the following areas: Frontal,
temporal, parietal, occipital and cerebellar cortex. More
regions were available for some of the brains, sometimes
with very extensive sampling, but we restricted our
analysis to the above-mentioned representative areas of
subcortical white matter. Using a semi-quantitative scor-
ing scale (Table 1), all features were recorded for the
cortical areas and the cerebellum. Intensity and the
deposition pattern of PrP were recorded for the cortical
grey matter and the subcortical white matter, as well as
the cerebellar molecular and granular layers and the
cerebellar white matter. The following features were ob-
served and recorded: in the cortical grey matter, there
was synaptic labelling and deposition of plaques, in
addition filamentous PrP was present in the white mat-
ter fibres extending into the cortex. In the white matter,
we recorded small granules as well as thin threads of
variable length, which depended on the orientation of
the white matter tracts. The scores 0-3 reflect the abun-
dance of PrP deposits (threads or granules), which is
listed in Table 1. The quantity and the pattern of cortical
prion pathology was recorded for all cases as shown in
Table 2.
Statistical analysis
The quantity score of thread pathology was transformed
into numerical values (− = 0, + = 1, ++ =2, +++ =3.
4OPRI, 5OPRI and 6OPRI cases; and D178N, E200K,
V210I cases, were grouped together to allow group sizes
exceeding 3. The null hypothesis was the assumption of
no difference between groups. Table 3 shows the results
of the statistical analysis.
Results
35 cases of inherited prion disease were analysed, scored
for PrP staining patterns and compared with 26 cases of
sCJD. We observed changes in the grey and white mat-
ter that were similar to previously published patterns of
abnormal PrP deposition. The specific findings and indi-
vidual white matter staining pattern for each case with
mutations in the PRNP open reading frame, relevant
clinical data, codon 129 genotype, western blotting re-
sults, and cortical PrP pattern, are summarized in Table 2
and subsequently in this paragraph. In addition, a de-
tailed description of the findings is given below. PrPSc mo-
lecular strain typing analysis was performed for about half
the cases (Table 2). Where determined, molecular strain
types were consistent with those published previously [15]
however some brain samples were scored negative
for PrPSc (Table 2). The apparent absence of detectable
Table 1 Description and definition of the quantification
of the filamentous or granular depositions
Score (granules or
threads)
Number of inclusions (High power field
(HPF) with a 40× objective)
0 Less than 1 inclusion per 4 HPF
1 More than 1 inclusion per 4 HPF, up to
5 inclusions per 1 HPF
2 5-20 inclusions per 1 HPF
3 More than 20 inclusions per 1 HPF
Scoring scheme used to semiquantitatively assess the frequency and density
of granular or filamentous inclusions in DAB stained paraffin sections on a
LEICA DM2500 with a 40× HCX Pan Apochromat objective.
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Table 2 List of all cases analysed for white matter PrP in this study
Figure Case no Mutation
Codon 129
status
PrPSc molecular
strain type* Gender
Age at
death
Disease
duration
(mo)
Amount of
PrPSc in
WM
PrP pattern WM Other pathology
T = Threads
D = Dots
FB Cer FB Cer Cortical PrP pattern Spongiosis
1 V210L MV 2 M 69 5 + — T, D — S1, PN1, D2 +
2 E200K MM 2 M 65 4 + — D — S2, GR1, PN1 +
3 E200K MV ND M 67 24 + — D — S1 +
4 E200K MM ND F 57 6 ++ + D D S1, PN1 +
Figure 2D-F,
Figure 4A, B
5 E200K MV 2/3 F 45 38 +++ + T, D D S3, GR2 +++
6 E200K MM ND M 61 6 ++ + D D S2, GR2, PV2 +
7 E200K MM 2 M 65 5 — — — — S1, PN1 ++
8 E200K MM 2 M 65 9 + — D S1 +
9 E200K MM 2 F 69 4 + + D — S2, PN1 ++
10 E200K MM ND M 47 19 ++ ++ T, D T, D S2, D1, PV2 +
11 D178N MM Negative M 60 7 +++ + D D P3, D2 o
Figure 2A-C,
Figure 3I, J
12 D178N MV ND M 60 24 ++ — D — S2, GR1, P1 +++
13 D178N MV ND F 51 20 — — — — S1, GR1 ++
14 A117V MV Negative M 43 6 +++ ++ T D S2, P3, D3 o
15 A117V VV Negative M 40 46 +++ ++ T D S2, P3 ++
Figure 1M-P,
Figure 3G, H
16 A117V MV Negative M 47 47 +++ — T — S1, P3 o
Figure 5C, D 17 A117V MV ND F 40 98 +++ + T T, D S2, P3 ++
18 P102L MV Negative M 53 64 ++ ++ T T, D P3, D2 o
19 P102L MM 1 M 58 53 + + T D P3, D2 ++
20 P102L MM ND M 64 24 — + — T, D S1, P1 o
Figure 1I-L 21 P102L MM ND M 59 49 +++ +++ T, D T, D P3, D2 ++
22 P102L MV 2 F 64 33 +++ ++ D D S2, P3, D2 ++
23 P102L MV ND M 61 50 +++ +++ T, D T, D S2, P3, D1 +++
24 P102L MM 2 F 65 64 + ++ T, D T, D S1, P3, D2 ++
Figure 3E, F 25 P102L MM Negative F 62 48 ++ + D D S2, P3, D1, PV1 +
26 P102L MM Negative;8 kDa M 52 155 + + D D P2 o
27 P102L MM ND F 66 81 + +++ D T, D S1, P3 ++
28 6OPRI MV Negative F 49 8 +++ + T D S1 o
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Table 2 List of all cases analysed for white matter PrP in this study (Continued)
Figure 1E-H 29 6OPRI MV Negative F 46 0 +++ +++ T T, D S2, P3, D3 o
30 6OPRI MM ND M 44 118 +++ +++ T, D D S3, GR1, P1, D1 +
Figure 3C, D,
Figure 5A, B
31 6OPRI MM ND F 45 72 +++ ++ T T, D S1, PN1 +
32 5OPRI MM ND M 57 323 + + T, D T, D S1 +
33 4OPRI MM ND F 56 7 +++ + T T, D S3, GR1 +
Figure 1A-D,
Figure 3A, B
34 4OPRI MM ND M 73 14 ++ ++ T, D T, D S1 +++
35 4OPRI MM 2 F 62 5 ++ ++ T T, D S1, GR1, PN1 ++
*Proteinase K-digested PrP fragment size according to the London classification [14,15].
ND, not done.
All case numbers (first column) are cross-referenced to Figures 1, 2, 3, 4, 5 and 6. The columns on the right describe the pattern of PrP deposition in the white matter. The semi quantitative density scores of white
matter PrP are represented in column 8. mo: months, M: male/methionine, F: female, V: valine, WM: white matter, FB = Forebrain, Cer = Cerebellum, T = Threads, D = Dots. The two columns on the right describe the
pattern and intensity of cortical PrP deposition as described in [11] and the degree of spongiform changes. S = synaptic, PN = perineuronal net, GR = Granular; P = well demarcated plaques, D = diffuse plaques; and PV =
perivascular deposits. The number indicates the semi-quantitative intensity or density of the respective feature.
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protease-resistant PrP is a relatively common feature of
some forms of inherited prion disease and in part relates
to sampling variation and in particular the region of brain
studied [15]. Typically we examined only a single sample
(~200 mg) of frontal cortex.
The white matter of brains with inherited CJD prion
disease show in the majority of cases filamentous PrP
deposition in the frontal, temporal parietal and occipital
regions of cerebral, subcortical white matter and to a
much lesser extent in the cerebellar white matter, and
the brain stem (Table 2, Figures 1, 2, 3, 4, 5, 6). Cortical
areas that contain significant amounts of abnormal
synaptic or plaque PrP, tend to show more abundant
filamentous white matter whilst a low cortical PrP load
is more often associated with very little or no filamen-
tous PrP in subjacent white matter tracts. Table 4 and
Figure 7 show the distribution of white matter filaments
in Case #17. In this case, the strongest labelling is seen
in frontal and temporal lobes, basal ganglia, followed by
parietal and occipital regions, and the least frequent
labelling in the cerebellum and pons. Occasionally we
found circular PrP deposits in cross sections (Figure 1Q),
suggestive of a localisation on myelin sheaths. In addition,
there was fine granular or dot-like positivity in almost all
cases, including sCJD of all three codon 129 genotypes
(MM, MV and VV). When the cases with filamentous
inclusions are plotted onto a diagrammatic representation
of the PRNP open reading frame, we observed that the
strongest and most consistent filamentous white matter
deposits were in cases with N-terminal mutations
(Figure 6), with octarepeat inserts, and A117V mutations,
followed by P102L mutations. These filaments were much
less frequent in brains with C terminal D178N, E200K and
V210I mutations. The intensity was unrelated to disease
duration or codon 129 genotype (Table 2) but appeared to
mirror cortical PrP load. The two groups with marked
formation of threads (4OPRI, 6OPRI and A117V) com-
prise younger patients (40-50ys); while patients with other
mutations were more than 50 years old with the exception
of two patients with an E200K mutation, of whom one
showed an unusual clinical phenotype with very long
disease duration (#5). The brain in this case showed fila-
mentous white matter PrP. One way ANOVA confirmed
that N terminal mutations are more likely to accumulate
filamentous abnormal PrP than the white matter of C
terminal mutant brains (Significance level p = 0.012). In-
stead, no filamentous, but variable granular PrP deposits
are seen in cases of sCJD, with no intensity difference
between the different polymorphisms on codon 129
(Table 5). Double labelling immunofluorescence studies
confirm the presence of PrP filamentous material in the
white matter. In keeping with light microscopy observa-
tions, the most abundant filaments are seen in 4- and
6OPRI, and A117V mutations, whilst P102L, D178N,
E200K and V210L mutations are less often associated with
filamentous PrP in the white matter. The filamentous
nature and the localisation at light microscopy level are
suggestive of axonal accumulation. To determine the pre-
cise location of the filaments in the white matter, we used
double–labelling immunofluorescence and detection by
confocal laser microscopy. There was virtually no overlap
between Alexa 488 labelled neurofilaments and Alexa 546
labelled PrP, suggesting that the filamentous deposits are
not in the axoplasm. Instead there were PrP threads that
appeared to flank and run in parallel to axons, suggesting
a localisation directly adjacent to the axoplasm of myelin-
ated fibres. Indeed further co-localisation studies with
Alexa 488 conjugated antibodies against myelin basic
protein confirmed that these filamentous PrP deposits
shows robust co-localisation of PrP threads with myelin
sheaths of all sizes. Longitudinal sections of myelinated
fibres occasionally contain PrP threads on either side of
the centrally located axons (Figure 3). Sections of dual
labelled axons show a co-localisation of PrP with MBP,
sparing the central axon (Figure 3). In contrast, samples of
sCJD contain granular deposits outside the myelin sheath
but no filamentous PrP (Figure 4), in keeping with the ob-
servations by light microscopy.
In the following paragraphs we describe PrP deposits
in cortical grey matter, followed by changes in the sub-
cortical white matter, cerebellar grey and white matter
changes and the co-localisation of abnormal PrP with
myelin and axonal structures. Finally, the results of the
dual labelling experiments are described. Type and inten-
sity of the white matter deposits (none, dot like/granular
or filamentous) with relation to the mutation are also
summarised in a graphic representation in Figure 7. This
figure also gives a reference to the cases in Table 2.
4OPRI [96 base pair insert] (1 male, 2 female); Figure 1A-D,
Figure 3A, B
The mean age for this group is 63.7 years (56–73)
(Cases #33-35). The cerebral grey matter of these cases
shows both axonal threads and granular synaptic stain
(Figure 1A). The white matter also shows threads and
dots of abnormal PrP (Figure 1B,C). The cerebellar
cortex displays the classical “striped” or “tigroid” pattern
of PrP depositions, perpendicular to the cerebellar sur-
face and the Purkinje cell layer as reported previously
Table 3 Calculation of the 1 way ANOVA
Group Number
of subjects
Mean Standard
deviation
1 (OPRI) 8 2.5 0.88
2 (P102L) 10 1.7 1.53
3 (A117V) 4 3 0
4 (E200K, D178N, V210I) 13 1.4446 0.7697
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Figure 1 Threads of PrP positive deposits in inherited prion diseases with 4 and 6 octapeptide repeat insert mutation, P102L
(Gerstmann Sträussler-Scheinker syndrome), and A117V mutation. AD, 4OPRI mutation with abundant threads, which form a dense
crisscrossing network (corresponding to myelinated fibres) in the cortex (A) and forming multiple, thin parallel threads in the subcortical white
matter, detectable with two antibodies, ICSM35 (B) and KG9 (C). Arrowheads in B and C point to accentuated threads. In the cerebellum (D), the
PrP-containing filaments are thicker, shorter, and less abundant than in the cortex. The 6OPRI mutation (E-H) is characterised by abundant
threads in the cortical grey matter I, subcortical white matter (F, ICSM35, G, KG9), and in the cerebellar granular layer (H). I-L, Both forebrain and
cerebellum with PRNP P102L mutations show white matter threads of abnormal PrP in the subcortical (J, ICSM35 and K, KG9) or cerebellar (L)
white matter. Arrows I-L show short threads of PrP deposition. Small myelinated fibres extending into the cerebral cortex also show threads of
abnormal PrP (arrowhead in I) alongside with large amyloid plaques (not shown) and synaptic PrP. M-Q, A117V mutation (Case #16 M-P and Case
#17, Q) with abundant cortical threads (M), corresponding to myelinated cortical fibres. The inset shows several parallel threads. Also the
subcortical white matter is rich in PrP positive threads (N, ICSM35 and O, KG9). The cerebellum of the same case lacks filamentous inclusions,
whilst small granular deposits are often observed (P). The brain stem of case #17 shows cross sections of myelinated fibres with occasional
circular PrP-positive structures, corresponding to PrP containing myelin sheaths. Scale bar corresponds to 20 μm in P, 40 μm in the insets of E, F,
H and M, to 80 μm in C, G, H, O and to 140 μm in all other panels.
Figure 2 Patterns of PrP deposits in brains with PRNP D178N and E200K mutations. A-C, there are small dot like inclusions in the white
matter of a case with D178N mutation (A, B, ICSM35 and KG9), no cerebellar threads (C). D-F, E200K mutation with sparse threads in the
subcortical white matter (D, ICSM35 and E, KG9) and the cerebellar white matter (F). The inset in (D) shows a rare straight PrP positive filament
and the arrowhead points at a short stub or dot of abnormal PrP. The cerebellar white matter (F) of the same case shows occasional thicker,
straight filaments of abnormal PrP (arrowheads). Scale bar corresponds to 140 μm in (D), to 80 μm in B, E and to 40 μm in all other panels.
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[11,16] and the white matter comprises rare to moder-
ately frequent dots and thread-like staining (Figure 1D).
Filamentous deposits were seen with both antibodies
(Figure 1B, ICSM35 and 1C, KG9). All three 4OPRI cases
show consistent axonal labelling in cerebral grey and
white matter as well as cerebellar white matter, in a pat-
tern and intensity similar to that observed in the 6OPRI
group [11,17]. Co-localisation studies (Figure 3A,B) with
PrP (red) and neurofilaments (green) show occasional
parallel course of PrP threads and axons (Figure 3A,A’),
Figure 3 Co-localisation studies of abnormal PrP (Alexa 546, red) with Neurofilament (A, C, E, G, I) or with myelin basic protein (B, D, F,
H, J), (green, Alexa 488) in the white matter of the frontal lobe. A, B, 4OPRI mutation shows the neurofilament signal being located beside
abnormal PrP (A, A’), whereas there is an overlap between MBP and PrP signal (B, B’). C, D; 6OPRI with filamentous PrP being localised next to
Neurofilament (C, C’) but directly congruent with MBP (D, D’). E, F there is little white matter PrP in this example of a P102L mutation, whilst a
case with an A117V mutation (G, H) shows abundant white matter PrP, which shows PrP immunoreactivity next to neurofilaments, (G, G’) and
co-localises with MBP, resulting in yellow signal (H, H’). The more C-terminal mutations, such as D178N show mostly granular PrP deposits and
no strong filamentous PrP (I, J). Scale bar 16μm for A-J and 4 μm respectively for A’-J’.
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while both longitudinal and transverse sections of myelin
sheaths confirm the presence of the threads within the
myelin structure Figure 3B,B).
5 OPRI [120 bp insert] (1 male)
The age of this patient was 57 years, with disease duration
of several years (Case #32). The onset of his illness was
difficult to determine as he gradually developed neuro-
logical symptoms in his forties which superimposed a
pre-existing personality disorder with aggressiveness and
outbursts. The brain showed PrP deposits that are similar
to sporadic sCJD and the characteristic striping pattern,
which is generally seen in the cerebellar cortex with
4OPRI and 6OPRI mutations, was absent. The cerebral
white matter showed subtle white matter threads and
there was no white matter PrP in the cerebellum.
6OPRI [144 bp insert] (1 male, 3 female); Figure 1E-H,
Figure 3C,D, Figure 5A,B
The mean age for this group is 46 years (44–49) (cases
#28-31). In all cases the cerebral grey matter contains
abundant axonal threads (Figure 1E), as well as a granu-
lar synaptic stain and scattered microplaques. These
threads are present in the myelinated fibres that radiate
from the white matter into the cortex. The subcortical
white matter contains PrP positive threads (Figure 1F,
ICSM35 and 1G, KG9) and to a lesser extent, fine gran-
ules. The cerebellar molecular layer shows the classical,
distinct “stripy” or “tigroid” pattern with an orientation
Figure 4 Co-localisation studies of abnormal PrP (Alexa 546, red) with Neurofilament (A, C, E, G) or with myelin basic protein (B, D, F,
H), (green, Alexa 488) in the C-terminal E200K mutation and in sCJD control cases (frontal cortex). A, B, E200K mutations shows rare
filamentous PrP, co-localising with the myelin sheath (B, B’) but not detectably with axonal neurofilament (A, A’). All sCJD cases (129VV, C, D;
129MV, E, F; 129MM, G, H) show variable amounts of granular PrP which does not co-localise with neurofilaments (C, E, G) or Myelin basic
protein (D, F, H). Scale bar: 16 μm for A-H and 4 μm respectively for A’-H’.
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Figure 5 Electron microscopy of two cases with abundant white matter deposition of PrP amyloid in the frontal cortex. A, B, Case #31
with 6OPRI mutation shows small granular deposits in the axoplasm of a longitudinal section of a myelinated axon, and more substantial fibrillar
electron dense deposits in a myelin sheath, that has become divided by these inclusions, raising the possibility of amyloid. C, D; Case #17 with an
A117V mutation shows a cross section of a myelinated fibre with the axon (Ax) being separated from the para-axonal inclusion that led to a
splitting of the myelin (My) sheath. The red box indicates the region shown in D with a characteristic electron dense deposition, raising the
possibility of amyloid. Scale Bars: 1 μm (A, C), 0.5 μm (B, D).
5OPRI 
6OPRI P102L A117V D178N E200K V210I 
White matter threads 
White matter dot like deposits 
No white matter deposits 
Point mutations 
OPRI (Octapeptide repeat insert) 
N Terminus C Terminus 
20 
29 
18 30 
28 
19 31 
Case number (see Table 1) 1-35 
21 
3 
23 
9 
4 
14 24 
10 
6 
12 16 34 26 
7 
13 35 17 27 
2 
22 
8 
32 5 
11 15 25 33 
4OPRI 
1 
Figure 6 Schematic representation of the deposition of white matter filamentous PrP in relation to the mutation: the horizontal bar
represents the PRNP open reading frame with the N terminus on the left and the C terminus on the right. OPRI and point mutations are
indicated with red symbols. At each mutation, the cases with white matter threads (filaments) are indicated with stars; the number of stars
indicates the abundance of deposits (corresponding to the score in Table 2). For cases where no filaments are seen, white matter dot-like
deposits are indicated by filled circles and cases with no white matter deposits are symbolised by open circles. The blue number next to the
symbols corresponds to the case numbers in Table 2, all figures and in the text). The position of the mutations on the schematic representation
is not exactly to scale.
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perpendicularly to the cerebellar surface as described
before [11,18-20]. This pattern is a hallmark of octapep-
tide insert mutations and unlikely to be related to the
filamentous deposits. Threads are also seen in the cere-
bellar granule layer (Figure 1H) and the cerebellar white
matter shows variable amounts of dot- and thread-like
staining. Case #30 shows a staining pattern that varies
from the other cases with a 6OPRI mutation, in that the
grey matter displays granular synaptic positivity without
thread labelling and the white matter shows a predomin-
ance of granular labelling and fewer threads. In conclu-
sion, this group shows consistent, strong filamentous
positivity in both, grey and white matter (Figure 3), simi-
lar to the group with 4OPRI mutation (see above). The
cerebellar white matter shows thread pathology, a fea-
ture also seen in cases with P102L and 4OPRI muta-
tions. Co-localisation studies show a striking overlap of
PrP with myelin sheaths, whilst colocalisation with axons
was below detection limits, confirming that PrP threads
are located extra-axonal, within the sheath (Figure 3C,D).
However, ultrastructural studies of case #31 show granular
protein deposits also in the axoplasm but, in keeping with
immunofluorescence studies, more substantial deposits in
the myelin sheath, which appears displaced and split by
the amyloid aggregates (Figure 5A,B).
P102L (6 male, 4 female); Figure 1I-L, Figure 3E, F
The mean age for this group is 60.8 years (53–66) (cases
#18-27). The cerebral grey matter of these cases contains
frequent core- and multicentric plaques with diffuse
granular synaptic pattern as described before [21,22] and
occasional threads composed of abnormal PrP (Figure 1I).
The subcortical white matter contains scattered plaques of
small size with variable fine granular and thread-like posi-
tivity (Figure 1J, ICLM35 and 1K, KG9). The cerebellar
cortex shows plaques and large granular aggregates. The
white matter contains variable plaques, granules and short
threads (Figure 1L). In the majority of cases with P102L
mutation, a small, and at most moderate amount of fila-
mentous labelling can be observed in the white matter
and less dense axonal positivity in the grey matter. In
more than two thirds of the cases filamentous labelling is
also present in the cerebellar white matter. In immuno-
fluorescence studies however, nearly no filamentous ma-
terial was detected (Figure 3E,F).
A117V (3 male, 1 female); Figure 1M-P, Figure 3G,H,
Figure 5C,D
The mean age for this group is 43 years (40–47) (cases #14-
17). The grey matter contains frequent granular plaques
with diffuse, moderate-to-strong granular synaptic labelling
as well as strongly labelled short (Figure 2M inset) and long
filamentous white matter deposits (Figure 2M). In all three
cases the white matter shows frequent and intense thread-
Table 4 Regional distribution of filamentous PrP in a
brain with A117V mutation (Case #17): semiquantitative
scoring of white matter PrP filaments
Case #17: areas analysed Density of filamentous PrP in
white matter tracts in the region
Anterior frontal F1-F2 +++
Posterior frontal Superior frontal
gyrus and pre motor cortex
++
Temporal T1-T2 +++
Temporal T2-T3 +++
Tip of temporal lobe +++
Parietal ++
Occipital ++
Anterior cingulate +++
Hippocampus +++
Amygdala +++
Basal ganglia, ant. +++
Basal ganglia, mid. +++
Basal ganglia, post ++
Thalamus with subthalamic
nucleus
+
Upper midbrain +/++
Lower midbrain +
Pons +
Lower medulla n.a.
Cerebellum Vermis +
Cerebellum with dentate -
Cerebellum hemisphere (+)
The graphical representation is shown in Figure 7.
Figure 7 Regional distribution of filamentous PrP in a brain
with A117V mutation. (Case #17): the intensity of the white matter
filaments is represented in shades of red, the most intense
representing a strong deposition (frontal, parietal and temporal
brain) and there is a decreasing gradient towards the posterior
lobes, the cerebellum and the brain stem, where fewer filaments
were observed. The corresponding semi-quantitative evaluation is
listed in Table 6.
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like positivity with sparse fine granules and plaques
(Figure 1N, ICLM35 and 2O, KG9). The cerebellar cortex
mainly contains patches of plaques and the white matter
shows occasional plaques with none or occasional dot-like
PrP deposits as described before [23,24]. In conclusion, this
group displays a strong, dense filamentous PrP labelling
in the cerebral white matter, similar to the 6OPRI and
4OPRI cases (see above), with significant filamentous PrP
extending to the myelinated axons in the cortical grey mat-
ter and no cerebellar threads. A cross section of the pons
(Figure 1Q) show occasional circular PrP deposits, strongly
suggestive of a localisation in the myelin sheath. Immuno-
fluorescent labelling confirms extensive co-localisation of
PrP threads in the sheaths of myelinated fibres, and no
axonal PrP. The dual labelling of PrP with neurofilaments
demonstrates no colocalisation of the signal (Figure 3G, G’),
whilst there is frequent and robust dual labelling of myelin
sheaths and filamentous PrP (Figure 3H, H’). All A117V
cases strongly accumulate filamentous PrP and it is gene-
rally very easy to detect filaments in the white matter of
A117V cases. Ultrastructural studies of case #17 show
substantial deposits of amyloid in the myelin sheath
(Figure 4C,D).
D178N (2 male, 1 female); Figure 2A-C, Figure 3I,J
The mean age for this group is 57 years (51–60); cases
#11-13. Both patients showed clinical CJD phenotype.
Here, the cortical grey matter shows diffuse, weak to mo-
derate fine granular synaptic stain with plaques of variable
size. The subcortical white matter shows a wide variability
(none to very frequent) of fine granular positivity but no
thread like labelling (Figure 2A, ICSM35 and 3B, KG9).
The cerebellar cortex shows patchy synaptic stain and granu-
lar aggregates with variable amounts of condensed granular
PrP, occasionally forming microplaques, and the subcortical
white matter has very rare or PrP dot-like positivity
(Figure 2C). Overall these cases show little PrP labelling
in the white matter and no thread-like PrP deposits. No
threads were detected by immunofluorescence, confirming
the observations by light microscopy (Figure 3I,J).
E200K (6 male, 3 female); Figure 2D-F, Figure 4A, B
The mean age for this group is 60 years (45–69) (cases #2-
10). The cortical grey matter shows diffuse, granular or
fine dot-like synaptic staining that ranges from weak to
strong intensity, similar to that in sCJD. In addition, there
was cortical perineuronal PrP deposition with variable
amounts of microplaques, and there are rare filamentous
PrP deposits. The subcortical white matter contains vari-
able amounts (sparse to very frequent) of fine granular
positivity (Figure 2D) and occasional white matter threads
(Figure 2D, inset, ICSM35, and 2E, KG9). The cerebellar
cortex shows patchy synaptic staining and granular aggre-
gates with or without microplaques. The cerebellar white
matter shows rare granular positivity and threads in some
cases (Figure 2F). In one case (case 5 in Table 2) the cere-
bellar white matter showed frequent filamentous staining
as well as dot-like positivity (Figure 2F, Figure 4A,B). This
patient displayed an unusual clinical phenotype (younger
age and significantly longer disease duration) compared to
the other patients with the same mutation, which may
explain the difference to the patients with older age and
shorter disease duration. Overall, the PrP staining patterns
in brains with the E200K mutation are similar to those
observed in sCJD [25]. Among the cases with PRNP gene
mutations, this is the only group that shows perineuronal
PrP labelling. Double labelling immunofluorescence of
one case (#5) shows filamentous PrP deposits. There is
co-localisation of PrP in MBP positive myelin sheaths
whilst PrP in axonal structures is below the detection limit
(Figure 4A,B).
V210I (1 male)
In this single case (#1) with this mutation, the findings
are very similar to those in E200K mutations. We found
only cerebral PrPSc, some of which formed fine threads
but no cerebellar PrPSc. The cortex shows synaptic label-
ling with a homogenous distribution across all cortical
layers, similar to that of sCJD.
Sporadic CJD (26 cases), Figure 4C-H
26 cases with codon 129 polymorphism MM (9), MV (10)
and VV (7) were examined. All cases showed variable
amounts of granular PrP deposits, ranging from none to
frequent, corresponding to a score from 0–3 (see Tables
5 & 6). Across all cases, no difference was seen in the in-
tensities of granular white matter PrP deposition between
codon 129 genotypes MM, MV and VV. Double labelling
Table 5 Summary of intensity scores in sporadic CJD
Scores for granular PrP (number of cases)
sCJD, codon 129 genotype Score 0 Score 1 Score2 Score 3 Significance
129MM 1 3 3 2 MM vs. MV: 0.23 (n.s.)
129MV 3 4 2 1 MV vs. VV: 0.72 (n.s.)
129VV 2 2 2 1 MM vs. VV: 0.48 (n.s.)
The left columns indicated the genotype of the codon 129 polymorphism, the subsequent columns the number of cases with the indicated scores (0–3) and the
right columns the statistical analysis of the scores between the different codon 129 genotypes. No statistically significant difference in the intensity scores are
seen between cases with codon 129 MM, MV or VV.
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immunofluorescence of PrP with axons or myelin sheaths
shows no co-localisation of granular white matter PrP
with either structure in all three codon 129 genotypes. In-
stead there is frequent granular PrP, which is immediately
adjacent to the myelinated fibres (Figure 4C-H).
Discussion
Our study shows that filamentous white matter PrP depos-
ition correlates with the localisation of the PRNP mutation
and to some extent with the age of the patients. Previous
studies have described PrP plaques in the CNS white mat-
ter in various forms of prion diseases including vCJD [6]
and some cases of 129MM sCJD [7] and in the cerebellum
of 129VV patients [26]. A study of 20 autopsy cases of CJD
(not further specified), revealed PrPSc deposition in both
cerebral and cerebellar white matter in 4 cases [8]. Immu-
nohistochemical detection of abnormal PrP showed struc-
tures described as “arrays adjacent to ‘myelinic’ fibres and
as clumps adjacent to oligodendrocyte nuclei”, and trans-
mission electron microscopy showed that they were associ-
ated with “dense lysosomes in oligodendroglial perikarya
and in their processes”. These inclusions were charac-
terized as “finely fibrillary, paracrystalline, amorphous, or
densely osmophilic material”. The authors concluded that
white matter involvement in spongiform encephalopathy
may be due to direct modifications of oligodendroglial
cells associated with abnormal metabolism of PrP [8]. In
inherited prion diseases, white matter plaques have been
described before, and typically present as small, well
circumscribed amyloid deposits [21,24].
In animals, PrP accumulation in the white matter has
been described in sheep with atypical scrapie, with two
staining patterns; a ‘globular’ type, forming ring- or oval-
shaped deposits prominent in the spinocerebellar tracts, re-
ticular formation, cerebellar and cerebral white matter, and
other white matter tract areas and a ‘punctate’ type
consisting of small circle or elongated tear-drop deposits
prominent in several grey matter areas, e.g. the reticular
formation, substantia nigra, fimbria hippocampi, and amyg-
dala [9]. Again these features are distinct from the filament-
ous immunoreactivity in human inherited prion disease.
Experimental models of prion disease have added only little
insight into the possible pathogenesis of white matter PrP
deposition. In a study of scrapie infected Syrian hamsters
[10], an intense PrPSc signal was found in the white matter,
and was thought to support the hypothesis that PrPSc is
transported along axons, but the histoblot technique had a
resolution insufficient for the subcellular localisation of the
deposits. Studies using the mouse adapted Fujisaki prion
strain reported white matter destruction and deposition of
abnormal PrP in white matter tracts [8,27], without being
more specific regarding the PrP deposition pattern. The
CJD Fujisaki strain was derived from a brain that now is
regarded as a case of P102L GSS [27].
Several transgenic mouse models of inherited prion
disease have been generated but no specific white matter
pathology has been reported. A transgenic mouse model
expressing a nine-octapeptide insertion mutant mouse
PrP (9OPRI) fused with enhanced green fluorescent
protein [28] exhibited a striking white matter accumula-
tion of abnormal PrP with intra-axonal mutant PrP as
linear filamentous aggregates in central and peripheral
axons, suggesting disruption of axonal transport [28].
Table 6 List of sporadic CJD cases included in the control
group
Codon 129 Gender Age
(years)
Disease
duration
(Months)
Frequency of granular
PrP deposits in the frontal
subcortical white matter
(intensity score)
MM M 75 2.5 0
MM M 76 3 2
MM F 66 6 3
MM M 89 13 1
MM F 81 3 1
MM M 62 3 2
MM F 74 5 2
MM F 63 3 3
MM F 74 3 1
Average
MM
M:F =
4:5
73.3 4.6 1.67
MV F 73 7 1
MV F 67 2 1
MV F 70 10 0
MV M 75 2 1
MV M 62 11 0
MV M 63 17 0
MV M 56 11 2
MV M 62 3 2
MV M 77 12 3
MV M 68 3 1
Average
MV
M:F =
7:3
67.3 7.8 1.1
VV M 69 9 0
VV F 57 3 1
VV F 72 5 1
VV F 81 9 2
VV F 81 3 0
VV M 83 3 2
VV M 61 2 3
Average
VV
M:F =
3:4
72 4.8 1.29
Cases with Codon 129MM, MV and VV alleles were used. The table also lists
the age at death, duration of illness and the density of granular PrP in the
white matter. The case numbers are cross-referenced in Figure 4.
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Several models of the human P102L feature plaques but
no white matter PrP [29-34]. Transgenic mice expressing
a murine Prnp A116V (corresponding to the human
PRNP A117V) mutation [35] on a Prnp0/0 background
displays predominantly plaque pathology, chiefly in the
cerebellum. Mice expressing the homologue of the
human D178N (129V) mutation showed motor dysfunc-
tion, alteration of spatial working memory and abnormal
EEG pattern and sleep disturbances [36], histologically
punctate, micro-plaque like deposits, and ultrastructurally a
swelling of the endoplasmic reticulum of cerebellar granule
neurons. A model of the E200K mutation [34,37] showed no
spontaneous disease even after 900 days. Inoculation with
human E200K -129VV brain yielded extensive plaques while
an E200K 129MM inoculum yielded a predominantly synap-
tic pattern, but no white matter pathology was observed [34].
Previous studies of the transport of PrP along axonal
pathways in animal models have concluded that transport
of infectious prions uses mechanisms distinct from fast
axonal transport [38], in contrast to PrPC [39]. It has been
suggested that prion spread occurs via non-canonical
mechanisms [40,41], for example in a domino-like manner
along PrPC expressing nerve membranes or Schwann cells
[42]. It is possible that an impairment of axonal transport
or clearing mechanisms leads to deposition in the myelin
sheath of N-terminal mutant PrP. Whilst no quantitative
(and comparative) data exist for the amount of PrPC in
CNS oligodendrocytes and axons, experimental data of
the peripheral nervous system suggest that Schwann cells
express negligible levels of Prnp mRNA, and that expre-
ssion of axonal PrP is required for Schwann cell myelin
maintenance [43]. It is possible but remains speculative
that a similar mechanism, involving transfer of PrP from
the axon to the myelin sheath is relevant for the main-
tenance of CNS myelin. It is possible that soluble forms or
micro-aggregates of PrP, produced in the neuronal body,
move by passive or active axonal transport. Our ultrastruc-
tural studies provide evidence of granular protein deposits
in the axoplasm, possibly representing abnormal PrP, which
may eventually accumulate in myelin sheaths. Indirect
evidence for this suggestions comes from the observation
that the most abundant filamentous white matter PrP is
localised in the vicinity of cortical areas that contain signifi-
cant amounts of abnormal synaptic or plaque PrP, whilst a
low cortical PrP load is more often associated with very little
or no filamentous PrP in subjacent white matter tracts.
Filamentous PrP deposits are not observed in sCJD. A
possible explanation is the different pathogenesis, in that
all neuronal cells express mutant PrP and that all cells car-
rying the mutation may synchronously convert mutant
PrP into the abnormally folded form of PrP. The variabil-
ity between cases with the same mutation (see [22]) may
be explained by a variable capacity to clear abnormal PrP,
or a differential propagation of disease-related isoforms, as
for example shown for the P102L mutation, where at the
molecular level three isoforms of protease-resistant PrP
with divergent physicochemical properties can be propa-
gated [22]. The difference between cases with different
mutations can be explained by different propensities to
form deposits, as well as a region-specific propensity of
cell populations to accumulate abnormal PrP even within
the same family. It could also be argued that the initiation
of the disease as well as the mechanism of cell-to-cell
transmission in sporadic prion diseases is different from
inherited forms. A remarkable observation is a very strong
bivariate correlation between age of the patient at death
and the density of threads in the white matter (p = 0.001).
A regression model even favours age over mutation type,
that is, age is a stronger determinant of the density of
threads than the mutation itself (patients with more threads
die younger). However, this correlation is explained by the
fact that age at death correlates with the mutation.
Functional studies are required to further elucidate the
mechanism of PrP deposition in the myelin sheath, and
the propensity of N-terminal mutations to form such
inclusions.
Conclusion
We report here the presence of white matter deposition of
abnormal PrP in inherited prion diseases. Strikingly, abnor-
mal PrP appears to deposit in the myelin sheath of myelin-
ated axons. The filamentous inclusions are strongest in cases
with N-terminal mutations (OPRI, A117V) and less intense
or absent in mutations toward the C-terminus (D178N,
E200K). Areas that are most affected are in the frontal, tem-
poral and parietal lobes and less filaments are seen in the
occipital lobes, the cerebellum and the brain stem.
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